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ABSTRACT 
Photochemistry and kinase inhibitor research have both independently been of major 
scientific interest in the last decades. The objective of this study was therefore to combine 
both research fields by the development of photoactivatable kinase inhibitors. Herein, the 
fascinating possibilities of photochemistry were applied on a unique group of 
pharmacological agents. 
This study reports on photoactivatable prodrugs of VEGFR inhibitors and the approved 
BRAF inhibitor vemurafenib. The latter shows impressive outcomes in the personalized 
treatment of malignant melanoma, but side effects and drug resistance limit therapeutic 
results. In order to conquer these limitations and to create powerful biological tools for kinase 
and cancer research, so-called caged prodrugs were developed. Photoremovable protecting 
groups (PPGs) were thus implemented at crucial pharmacophoric functionalities of the 
inhibitors in order to diminish their biological effects. This approach provides control over the 
activation of molecules triggered by ultraviolet light. First, the hinge binder moiety of 
vemurafenib, a 7-azaindole, was investigated concerning its properties as a leaving group in 
the photolysis reaction. Several PPGs were then examined with regard to chemical 
accessibility and release characteristics. Next, photoactivatable prodrugs of vemurafenib and 
VEGFR inhibitors, a diarylmaleimide and a carbazole, were designed and synthesized. Their 
photochemical features were subsequently investigated. In vitro evaluation proved the loss-of-
function of the prodrugs and the light-dependent recovery of efficacy in kinase and cellular 
assays. 
The approved VEGFR inhibitor axitinib was furthermore investigated as a photoswitchable 
kinase inhibitor. Based on molecular modeling, the (Z)-isomer should be significantly less 
active toward the targets of (E)-axitinib. It was therefore explored if the inhibitory effect of 
axitinib could be turned on and off triggered by irradiation. The switching properties of the 
photoinduced E-Z isomerization were thus examined. Interestingly, the formation of a 
(Z)-axitinib tautomer was observed. In vitro analyses demonstrated the decreased efficacy of 
the (Z)-isomer at an enzymatic level. These results, however, did not translate into cell 
proliferation assays leaving the paradoxically more active (Z)-isomer for future investigation. 
In conclusion, the first photoactivatable vemurafenib and VEGFR inhibitor prodrugs have 
been synthesized and characterized in the course of this study. A decreased potency of the 
(Z)-stereoisomer of axitinib has been demonstrated in enzymatic assays. The applicability of 
axitinib as a photoswitch remains to be confirmed in further biological assays.  
  
 
  
  
KURZZUSAMMENFASSUNG 
Photochemie und die Entwicklung von Kinaseinhibitoren stehen seit Jahrzehnten unabhängig 
voneinander im Fokus der Wissenschaft. Das Ziel dieser Arbeit war daher, beide 
Forschungsgebiete durch die Entwicklung photoaktivierbarer Kinaseinhibitoren miteinander 
zu verknüpfen. Die faszinierenden Möglichkeiten der Photochemie wurden dabei auf eine 
einzigartige Gruppe pharmakologischer Substanzen angewendet. 
Diese Arbeit berichtet über photoaktivierbare Prodrugs von VEGFR-Inhibitoren sowie des 
zugelassenen BRAF-Inhibitors Vemurafenib. Dieser zeigt beeindruckende Erfolge in der 
personalisierten Behandlung des malignen Melanoms, jedoch limitiert durch Nebenwirkungen 
und Resistenzen. Um diesen Limitierungen zu begegnen und um leistungsfähige Werkzeuge 
für die Kinase- und Krebsforschung bereitzustellen, wurden sogenannte caged prodrugs 
entwickelt. Dazu wurden photoabspaltbare Schutzgruppen (PPGs) an zentralen 
pharmakophoren Gruppen der Inhibitoren angebracht, um diese biologisch zu inaktivieren. 
Dies erlaubt die Kontrolle über die Aktivierung von Molekülen durch ultraviolettes Licht. 
Zunächst wurde der hinge-binder des Vemurafenibs, das 7-Azaindol, hinsichtlich seiner 
Eigenschaft als Abgangsgruppe in der Photolyse-Reaktion näher untersucht. Verschiedene 
PPGs wurden bezüglich chemischer Zugänglichkeit und Freisetzung gegenübergestellt. 
Anschließend wurden caged prodrugs des Vemurafenibs sowie Inhibitoren aus der Klasse der 
Diarylmaleimide bzw. Carbazole designt und synthetisiert. Ihre photochemischen 
Eigenschaften wurden untersucht. In vitro-Experimente bestätigten den Wirkungsverlust der 
Prodrugs sowie die lichtabhängige Wiederherstellung der Wirkung in Kinase- und Zellassays. 
Ferner wurde der zugelassene VEGFR-Inhibitor Axitinib als photoschaltbarer Kinaseinhibitor 
untersucht. Molecular modeling legte nahe, dass das (Z)-Stereoisomer schwächer wirksam sei 
als das (E)-Isomer. Daher wurde untersucht, ob die Wirkung von Axitinib durch Bestrahlung 
reversibel geschaltet werden kann. Interessanterweise konnte dabei die Bildung eines 
Tautomers des (Z)-Isomers beobachtet werden. In vitro-Studien zeigten eine Verringerung des 
hemmenden Effekts des (Z)-Isomers auf enzymatischer Ebene. Diese Ergebnisse übertrugen 
sich allerdings nicht auf Zell-Proliferations-Assays. Die hierin paradoxerweise gesteigerte 
Wirkung des (Z)-Isomers sollte daher noch eingehender untersucht werden. 
Im Rahmen dieser Arbeit wurden die ersten photoaktivierbaren Vemurafenib- und VEGFR-
Inhibitor-Prodrugs synthetisiert und charakterisiert. Die verringerte Wirkung des Axitinib-
(Z)-Stereoisomers wurde in enzymatischen Assays nachgewiesen. Die Anwendbarkeit als 
Photoschalter muss jedoch noch in weiteren biologischen Testsystemen bestätigt werden. 
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1. INTRODUCTION 
Photochemistry and the development of kinase inhibitors are both disciplines that have 
independently received much attention by the research community over the last decades. It is 
therefore rather surprising that the combination of both fields has been neglected so far. 
Activation by light provides precise spatial and temporal control of biological processes.1–5 
This offers unparalleled opportunities to understand and influence complex biochemical 
mechanisms, even in living cells.2 The introduction of kinase inhibitors was a milestone in 
modern drug discovery and revolutionized targeted cancer therapy.6,7 However, lack of 
efficacy, limited selectivity, the occurrence of therapy-limiting side effects, and the emergence 
of tumor resistances illustrate the urgent need for novel drug candidates as well as innovative 
therapeutic approaches.6,8 New concepts that are able to reduce adverse events and overcome 
tumor resistance would be of significant benefit.6,8  
The objective of this study, therefore, was to combine both research fields by the development 
of photoactivatable kinase inhibitors. The fascinating possibilities of photochemistry were 
herein applied on a unique group of pharmacological substances. 
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1.1 ACTIVATION BY LIGHT 
Spatial and temporal control of biological processes is a fascinating challenge.5 Light seems 
to be an ideal trigger for an external control of biochemical mechanisms due to its high 
spatiotemporal resolution as well as non-invasive and orthogonal character.5 Furthermore, it 
does not cause contamination of the sample; wavelength and intensity can be regulated with 
high precision, e.g. with lasers or microscopes.5 Rapid concentration jumps of the active form 
of a light-responsive molecule can be achieved providing precise control of area, time, and 
dosage.2  
The photocontrol of biologically active compounds offers outstanding experimental 
possibilities.9 Photoactivatable ligands have become important tools in drug discovery and 
drug development.9 They are used for a wide range of applications including target 
identification, determination of ligand affinity resp. selectivity, and detection of binding sites.9 
The selectivity of drugs can furthermore be increased by controlling their activity with light.5 
This might be beneficial with regard to the occurrence of side effects or the emergence of 
resistances.5 Not only small molecules have nowadays undergone this strategy, but also 
nucleic acids, peptides, and even large proteins.4 
In general, there are different strategies to control the activity of molecules by irradiation. 
They can either be irreversibly activated by light (so-called caged compounds) or reversibly 
switched between an active and an inactive form (photoswitches).3,4,10 
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1.1.1 Caging Concept 
Caged compounds can be activated by irradiation with light.10,11 The implementation of 
photoremovable protection groups (PPGs) provides control over the release of bioactive 
molecules triggered by ultraviolet (UV) light (Figure 1).1,2 Higher drug concentrations can 
therefore be reached in the area of interest, sparing other compartments.2 The photo prodrug 
concept is essentially based on the blockade of a pharmacophoric group. The PPG is thus 
attached to the drug molecule by a covalent bond.2 This bond has then to be cleaved by 
radiant energy, releasing the parent bioactive compound.2  
 
target  
caged 
inhibitor 
 
inhibited 
target 
 
cleaved 
protection group 
Figure 1. Schematic representation of the caging principle. An inhibitor is covalently linked to a PPG and 
thus biologically inactive (“caged”). Irradiation with UV light cleaves this bond and the bioactive compound is 
released. 
The first and most prominent example is certainly the photorelease of caged adenosine 
triphosphate (ATP) by Kaplan and co-workers in 1978.12 Intensive research has since then 
been carried out in the field of photochemistry concerning various classes of protecting 
groups and evaluation of their photocharacteristics.4,9–11,13–15. Klán et al.10 defined six main 
categories of PPGs with more than twenty subcategories (Figure 2). Hundreds of derivatives 
have been specified within these classes, attachable to a variety of leaving groups and offering 
a wide range of absorption maxima and release characteristics. 
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Figure 2. Chemical structures of diverse PPGs classes.10 LG = leaving group. 
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Nevertheless, none of these PPGs can be considered to provide perfect characteristics in all 
criteria.10,13 An individual selection has therefore to be made depending on the intended 
application. This choice is based on the following parameters and requirements: 
- low intrinsic activity of the caged compound and good stability under assay conditions 
prior to photolysis; good solubility and permeability; 
- high absorption coefficients at a nonhazardous wavelength > 300 nm, high quantum 
yield (efficiency for release), clean and quantitative photoreaction; 
- biocompatible photochemical by-products with low absorption at the irradiation 
wavelength; and 
- for time-resolved work, the release rate of the bioagent must exceed that of the 
response investigated.
10,13
 
o-Nitrobenzyl derivatives have by far been the most commonly used PPGs.1 A broad 
spectrum of derivatives has been established with different absorption wavelengths and the 
ability to be attached to a variety of leaving groups.10,16–19 Photolysis of these prodrugs forms 
potentially toxic by-products, though, containing a reactive nitroso function (e.g. 
o-nitrosobenzaldehyde) with strong innate absorption.1 To conquer these disadvantages a high 
number of alternative PPGs has been developed.  
While the caging concept has been successfully applied on various bioagents, there are only a 
few reports on photoactivatable kinase inhibitors. Morckel et al. for instance created a 
photoactivatable small-molecule Rho kinase inhibitor.20 This tool compound was used to 
uncover molecular mechanisms of embryonic development in Xenopus laevis by targeting 
specific regions of the living embryo.20 In addition, small molecular equivalents of Src kinase 
have been caged21 as well as peptidic PKA inhibitors22. Light-regulated protein kinase C 
peptide-based sensors23 and tyrosine kinase reporters24 have furthermore been described. In 
our group, Zindler et al. recently reported about the design, synthesis, and characterization of 
a photoactivatable caged prodrug of imatinib.25 
Activation of caged compounds remains irreversible though. But for many pharmacological 
applications a reversible activation and deactivation of kinase inhibitors would be of high 
value for an improved control over the effects of active molecules. 
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1.1.2 Ph toswitches 
Important biological processes are regulated by light in a reversible manner e.g. vision26 and 
photosynthesis3,27. Photons are absorbed by a chromophore leading to a conformational 
transformation. The term photoswitch is therefore used for molecules which switch reversibly 
between two or more isomeric forms induced by light.3 
A broad range of synthetic photoswitches has been designed.3 These molecular switches 
undergo conformational changes in their structure depending on the wavelength of the 
irradiated light.3 They can be characterized by the absorption maxima of their isoforms and by 
their photostationary state (PPS). This term is defined as a steady state reached by a reacting 
chemical system when light has been absorbed.28 Szymański et al.3 list six categories of 
molecular photoswitches (Table 1). They differentiate between chromophores that switch 
between E and Z configuration (azobenzenes, stilbenes, and hemithioindigos) and 
chromophores that interconvert between closed and open forms (spiropyrans, diarylethenes, 
and fulgides). The change in the three-dimensional (3D) geometry then modifies the 
biological effect. The most studied synthetic photoswitches are azobenzenes.29 A 
photoswitchable RET kinase inhibitor bearing an azobenzene group has recently been 
described.30  
The approved kinase inhibitors axitinib (19) and sunitinib (20) exhibit photosensitivity.31,32 
Both inhibitors are diarylethenes (Figure 3), but do not convert to a closed form upon 
irradiation. Instead an E-Z isomerization can be observed. They might, therefore, also be 
described as stilbene-like. 
 
Figure 3. Chemical structures of the light-sensitive approved kinase inhibitors axitinib (19) and sunitinib 
(20). The diarylethene structural element is highlighted in grey. 
This light-dependent isomerization offers an interesting starting point for the development of 
innovative photoswitchable kinase inhibitors. 
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Table 1. Groups of molecular photoswitches.3  
Photoswitches Light-induced Isomerization 
Azobenzenes 
 
Stilbenes 
 
Hemithioindigos 
 
Spiropyrans 
 
Diarylethenes 
 
Thiophenefulgides 
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1.1.3 Ultraviolet Light 
Sunlight is composed of a continuous spectrum of electromagnetic radiation and can be 
divided into three sections: 
- ultraviolet  (UV, wavelength range 100-400 nm) 
- visible  (vis, 400-750 nm), and 
- infrared  (IR, 750 nm-500 µm) light.33,34 
UV radiation can further be subdivided into UVA, UVB, and UVC (Table 2).34 It interacts 
with chemical molecules, particularly organic compounds, and thus causes e.g. fluorescence 
excitation or initiates chemical reactions. UV light shows distinct biological effects and has 
been used for many scientific applications, for instance in the field of photochemistry.14,33 
Table 2. Classification of UV light wavelength ranges and corresponding biological effects.33,34 
Name Abbreviation Wavelength Biological Effects 
Ultraviolet A 
(near UV) 
UVA 315-400 nm 
Skin tanning  
Photoaging 
Carcinogenic effects 
Ultraviolet B UVB 280-315 nm 
Photosynthesis of vitamin D 
Erythema  
Carcinogenic effects 
DNA damage 
Photokeratitis  
Ultraviolet C UVC 100-280 nm 
Photokeratitis 
Microbiocidal effects 
 
UV light sources 
The spectrum of the sunlight contains only a small amount of UV radiation.35 Artificial light 
sources like mercury or xenon arcs, often in combination with optical filters, are mostly used 
in photochemistry.2,35 Lasers emit precisely focused monochromatic light with high power 
and have been used for multiple applications.2,35 
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In this work, light-emitting diodes (LEDs) have been used which have undergone a rapid 
development in the past years. They are semiconductors and emit light over a narrow 
wavelength range (±10 nm).35 A large type variety with emission between the near UV and the 
IR light range are commercially available.1 The development of models with an emission 
below 365 nm, however, is in early stages and intensities are still very low.35 LEDs are small 
devices with high intensity, do not need a warm-up period and can be flexibly assembled. 
They are therefore convenient for chemical and biochemical applications. 
Medicinal applications 
Besides the various damaging effects of UV irradiation on biological systems, it has also been 
utilized as a therapeutic agent for various dermatological diseases.33 Plant extracts that 
contain the natural photosensitizer psoralen (27, Figure 4), a coumarin derivative, have been 
topically applied followed by sunlight exposure in Egypt thousands of years ago.33 This 
remedy was used as a treatment for vitiligo (leucoderma), a chronic skin disease which is 
characterized by the loss of pigmentation.33,34 The first modern clinical studies with topical 
and oral psoralens were reported in 1948.36,37 Orally administration of 8-methoxypsoralen 
(8-MOP, 28, Figure 4) and subsequent irradiation with UVA light proved to be effective 
against psoriasis, mycosis, vitiligo, and atopic dermatitis.38 This type of photochemotherapy is 
also called PUVA (psoralen plus UVA) therapy.33 Psoralens herein act as DNA intercalators 
and form, upon UVA irradiation, monoadducts as well as covalent interstrand cross-links with 
thymine residues which induces apoptosis.39 UVB radiation has also been successfully 
applied for clearing psoriasis.40 However, these phototherapies are associated with acute and 
chronic side effects of UV light on human skin.33,41 
 
 
Figure 4. Chemical structures of the furocoumarins psoralen (27) and 8-methoxy-psoralen (8-MOP, 28). 
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1.2 KINASE INHIBITORS 
Protein kinases have become one of the most pursued targets in pharmacological research in 
the last decades.42 Due to their key role in cellular signaling, the misregulation of kinase 
activity is the cause for many diseases. Besides various forms of cancer, their regulation is 
e.g. critical for the development of inflammatory diseases, Alzheimer’s, and Parkinson’s 
disease.43–45 
Kinase inhibitors have been successfully established over the past 15 years, especially in 
cancer treatment. To date, there are 28 FDA (Food and Drug Administration) approved small-
molecule kinase inhibitors (smKI); half of which have been approved in the past three 
years.42,46 For an overview of these drugs, their targets, and indications as well as dates of 
approval, see Table 3. The corresponding chemical structures are shown in Figures 5, 6, and 7. 
The approval of imatinib (31, Figure 5) in 2001 was a milestone in modern drug discovery 
and revolutionized targeted cancer therapy.47 An unparalleled development of innovative 
drugs was set in motion. Further eight protein kinase inhibitors were introduced into therapy 
until 2009. Meanwhile, the knowledge about kinase signaling networks and associated 
pathology steadily grew.42 Since 2011 a tremendous number of 19 new inhibitors has been 
approved and numerous candidates are currently in the pipeline.42  
Even though these molecules are structurally very homogeneous and many chemical features 
have been recycled for the development of the successors, innovations are yet achieved. New 
targets have been addressed; accomplishments with regard to potency and selectivity have 
been made.42 The first lipid kinase inhibitor, namely idelalisib48,49 (51, Figure 7), was 
approved in 2014; all other compounds represent protein kinase inhibitors. With respect to 
afatinib50 and ibrutinib51 (52 and 53, Figure 7), the first two covalent binding, thus irreversible 
inhibitors were introduced in 2013.52 The first allosteric inhibitor, trametinib (54, Figure 7), 
was also launched in 2013.53  
However, despite the progress already being made in the field of kinase inhibitor research, the 
current treatments concentrate on a very limited number of target proteins. In addition, severe 
side effects and rapidly emerging resistances often limit the therapeutic prospects. But more 
than one million publications on kinases in the past years, over 5000 crystal structures, and 
current achievements in the development of kinase assays allow looking into the future 
optimistically.42 
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Table 3. Currently FDA approved small-molecule kinase inhibitors.42,45,46,54–56 INN, international 
nonproprietary name; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic 
myeloid leukemia; CRC, colorectal cancer; FL, follicular lymphoma; GIST, gastrointestinal stromal tumor; 
HCC, hepatocellular cancer; MCL, mantle cell lymphoma; NSCLC, non-small cell lung cancer; RCC, renal cell 
carcinoma; SLL, small lymphocytic leukemia. 
INN Trade Name 
Binding Mode, 
Type 
Main Target(s) Indication(s) 
First FDA 
Approval 
Afatinib Gilotrif I, covalent EGFR, HER2/4 NSCLC 2013 
Axitinib Inlyta I VEGFR, PDGFR, cKIT RCC 2012 
Bosutinib Bosulif I ABL, SRC CML 2012 
Cabozantinib Cometriq II VEGFR, PDGFR, KIT, MET thyroid cancer 2012 
Ceritinib Zykadia I ALK, IGF-1R, InsR, ROS1 NSCLC 2014 
Crizotinib Xalcori/Xalkori I ALK, MET NSCLC 2011 
Dabrafenib Tafinlar I BRAF melanoma 2013 
Dasatinib Sprycel I ABL, PDGFR, KIT, SRC CML, ALL 2006 
Erlotinib Tarceva I EGFR 
NSCLC, 
pancreatic cancer 
2004 
Gefitinib Iressa I EGFR NSCLC 2003 
Ibrutinib Imbruvica I, covalent BTK MCL, CLL 2013 
Idelalisib Zydelig I PI3K CLL, FL, SLL 2014 
Imatinib Gleevec/Glivec II ABL, PDGFR, KIT CML, GIST 2001 
Lapatinib Tykerb/Tyverb I
56
, II
57
 HER2, EGFR breast cancer 2007 
Lenvatinib Lenvima I
55
, II
42
 VEGFR, FGFR, PDGFR, KIT thyroid cancer 2015 
Nilotinib Tasigna II ABL, PDGFR, KIT CML 2007 
Nintedanib Ofev II FGFR, PDGFR, VEGFR 
idiopathic pulmonary 
fibrosis 
2014 
Palbociclib Ibrance I CDK4/6 breast cancer 2015 
Pazopanib Votrient I
56
, II
42
 VEGFR, PDGFR, KIT RCC 2009 
Ponatinib Iclusig II ABL, VEGFR, PDGFR, FGFR CML, ALL 2012 
Regorafenib Stivarga II 
VEGFR, ABL, BRAF, KIT, 
PDGFR 
CRC, GIST 2012 
Ruxolitinib Jakafi/Jakavi I JAK myelofibrosis 2011 
Sorafenib Nexavar II VEGFR, PDGFR, KIT, BRAF 
RCC, HCC, 
thyroid cancer 
2005 
Sunitinib Sutent I VEGFR, KIT, PDGFR, FLT3 RCC, GIST 2006 
Tofacitinib Xeljanz I JAK rheumatoid arthritis 2012 
Trametinib Mekinist III MEK melanoma 2013 
Vandetanib Caprelsa I EGFR, VEGFR, RET, FGFR thyroid cancer 2011 
Vemurafenib Zelboraf I BRAF melanoma 2011 
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ABL inhibitors 
 
EGFR inhibitors 
 
 
Figure 5. Chemical structures of FDA approved small molecule ABL and EGFR inhibitors.42 Structural 
elements that bind in the adenine pocket are highlighted in grey. Dashed arrows indicate hydrogen bonds toward 
the backbone of the hinge region.  
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VEGFR inhibitors 
 
BRAF inhibitors 
 
Figure 6. Chemical structures of FDA approved small molecule VEGFR and BRAF inhibitors.42 Structural 
elements that bind in the adenine pocket are highlighted in grey. Dashed arrows indicate hydrogen bonds toward 
the backbone of the hinge region.  
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JAK inhibitors 
 
ALK inhibitors MET inhibitors 
 
CDK inhibitor PI3K inhibitor 
  
Irreversible inhibitors MEK inhibitor 
  
Figure 7. Chemical structures of further FDA approved small-molecule kinase inhibitors.42 Structural 
elements that bind in the adenine pocket are highlighted in grey. Dashed arrows indicate hydrogen bonds toward 
the backbone of the hinge region. Solid arrows show where reactive nucleophilic cysteine residues of the target 
protein attack Michael acceptor groups of the two irreversible inhibitors. 
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1.2.1 Protein Kinases 
Function and signal transduction 
Protein kinases are phosphotransferases; in other words, enzymes that catalyze the transfer of 
the γ-phosphate group of ATP onto a substrate.58 Signal proteins are thus phosphorylated at 
the hydroxyl group of specific amino acid residues, in the majority of cases serine/threonine 
or tyrosine residues. 58 Signal transduction cascades are mediated in this way regulating many 
cellular activities including proliferation, survival, apoptosis, metabolism, transcription, and 
differentiation.59 Because of their versatile role in cellular processes, misregulation of kinases 
like overexpression or hyperactivity due to mutations is the cause for many diseases. Kinases 
have therefore become important targets in drug discovery.7,60 
Kinase structure 
Although human kinases are quite diverse in their primary amino acid sequences, their 3D 
structures show a high degree of similarity.42 The structure of the kinase domain is highly 
conserved since most of them use ATP as a common cofactor.61 As Figure 8 illustrates, protein 
kinases consist of an N-terminal lobe (N-lobe) which is linked via a so-called hinge region to 
a C-terminal lobe (C-lobe).7 The otherwise β-sheet dominated N-lobe also contains an αC-
helix whose conformation plays a key role in the regulation of the kinase function. The 
C-lobe, on the other hand, contains mostly α-helices.7 The ATP binding pocket is located in 
the cleft between both lobes, where the backbone of the hinge region is addressed by the 
adenosine moiety of ATP by two hydrogen bonds.7 Most kinase inhibitors bind in the adenine 
pocket of the active site and also form hydrogen bonds toward the hinge-region (Figures 5, 6, 
and 7).7,45 
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Figure 8. General structure of protein kinases.7 The structure of kinases is exemplified on the serine/threonine 
protein kinase BRAFV600E (pdb 3OG762). The hinge region connects the N-terminal and the C-terminal lobe. The 
cofactor ATP and most kinase inhibitors bind in the cleft between both lobes, the ATP binding pocket, interacting 
with the hinge region. In this example, the A-loop is in the active conformation and the ATP pocket is occupied 
by vemurafenib (44, Figure 6). 
The access to the active site is controlled by a flexible activation loop (A-loop), which starts 
with the conserved amino acid sequence Asp-Phe-Gly (DFG motif).42 The aspartate residue of 
this motif further complexes a magnesium ion (Mg2+) which is crucial for the phosphate 
transfer from ATP to the substrate.58 The A-loop contains several activation sites itself whose 
phosphorylation induces conformational changes regulating the activity of the kinase.63 In the 
inactive conformation, the A-loop blocks the active site (DFGout conformation) and prevents 
ATP from binding.8 Upon phosphorylation of the A-loop, the DFG motif flaps deeper into the 
binding pocket (DFGin conformation) permitting ATP access to its binding pocket.
42,45
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According to the pharmacophore model of Traxler and Furet64, the ATP binding site itself 
consists of the highly conserved adenine-binding region, ribose pocket (sugar pocket), and 
phosphate-binding region (Figure 9).61 Adjacent to these, a hydrophobic pocket (hydrophobic 
pocket I, HP I), an allosteric hydrophobic back pocket (deep pocket) and a surface-exposed 
hydrophobic region (HP II) are located.45,61 The latter three are non-conserved pockets 
because they are not occupied by ATP. Addressing these regions therefore allows the design of 
selective ATP competitive kinase inhibitors (Figures 10 and 11).45,60,61 The access to the HP I 
is partially hindered by the gatekeeper, an amino acid residue that varies between individual 
kinases.65 Gatekeeper mutations are often the cause of acquired kinase inhibitor resistances.66 
 
 
Figure 9. Model of the ATP binding pocket.45,58,61,64 Interactions of ATP with important structural elements and 
pharmacophore regions are shown.  
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Figure 10. Pharmacophore model of a type I inhibitor in the ATP binding site (DFGin conformation).
45,64 
Addressed binding pockets of a type I inhibitor are exemplified on vemurafenib (44, Figure 6) interacting with 
the ATP pocket of BRAFV600E (pdb 3OG762) in the active conformation. The entrance to the deep pocket is 
blocked by the phenylalanine residue of the DFG motif.  
 
 Figure 11. Pharmacophore model of a type II inhibitor in the ATP binding site (DFGout conformation).
45,64 
Addressed binding pockets of a type II inhibitor are exemplified on sorafenib (42, Figure 6) interacting with the 
ATP pocket of VEGFR2 (pdb 4ASD67) in the inactive conformation. The phenylalanine residue of the DFG 
motif is flapped toward the ATP binding site so that the entrance to the deep pocket is unblocked and can thus be 
addressed by the inhibitor.  
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Binding modes of kinase inhibitors 
Kinase inhibitors can be categorized by binding modes (Table 4).7,8,42,45,56 Most compounds 
represent reversible inhibitors binding into the ATP site. Four types can be differentiated with 
regard to the addressed binding pockets and the adopted kinase conformation upon binding. 
Type I inhibitors bind to the active form of the kinase (DFGin inhibitors).
45 The access to the 
deep pocket is thus blocked by the DFG motif.8 Hydrogen bonds are formed by heterocycles 
of the inhibitor toward the backbone of the protein’s hinge region.45,56 Addressing the 
neighboring hydrophobic pockets can improve selectivity, since the ATP pocket itself is 
highly conserved throughout all kinase families.8 
Type II inhibitors, on the other hand, bind to and thus stabilize the enzymatically inactive 
kinase configuration (DFGout inhibitors).
8 The DFG motif is herein flapped outward from the 
ATP binding site permitting access to the deep pocket.42 The A-loop adopts the inactive 
conformation blocking the access of ATP to the adenine pocket.8 Besides the hinge region, the 
allosteric back pocket is addressed by type II inhibitors which are therefore also called deep 
pocket binders.68 This approach offers better chances for selectivity since this region is less 
conserved.8 Slow on/off binding kinetics and stabilization of the inactive kinase state explain 
why relatively weak type II inhibitors can show very potent cellular efficacy.69 
Type III inhibitors exclusively bind in allosteric regions adjacent to the active site without 
making any contact with the ATP pocket itself.42 In the type IV binding mode an allosteric site 
remote from the ATP pocket is addressed.42 In both cases, the DFGout conformation is 
stabilized hindering ATP to access to the active site and thus inhibiting the enzyme’s 
function.8 
Irreversible kinase inhibitors covalently bind to a reactive nucleophilic residue of the 
protein.42 The two approved representatives, afatinib and ibrutinib (52 resp. 53, Figure 7), 
bear a Michael acceptor functionality which is attacked by a nucleophilic cysteine residue 
proximal to the ATP binding site.42 Both drugs are initial type I binders before becoming 
actually covalently bond, but irreversible inhibitors of the other types are likewise feasible. 
The covalent approach aims to increase specificity and potency, although toxicity concerns 
have been raised.42,52 
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Table 4. Binding mode classification of kinase inhibitors.7,42,45,56 Small-molecule kinase inhibitors can be 
divided into reversible and irreversible inhibitors. Types I to IV additionally differentiate regarding the addressed 
binding pockets of the target protein and the stabilized kinase conformation. 
Type Binding Kinetics Addressed Pockets Kinase Conformation Examples 
I 
ATP competitive, 
reversible (fast) 
adenine pocket, 
HP I / HP II 
active (DFGin) gefitinib 
I 
(covalent) 
initially ATP 
competitive, 
irreversible 
adenine pocket, 
HP I / HP II 
active (DFGin) afatinib, ibrutinib 
II 
ATP competitive with 
allosteric component, 
reversible (slow) 
adenine pocket, 
deep pocket, 
HP I / HP II 
inactive (DFGout) imatinib, sorafenib 
III 
(allosteric) 
non-ATP competitive, 
reversible 
deep pocket, 
HP I / HP II 
inactive (DFGout) trametinib 
IV 
(allosteric) 
non-ATP competitive, 
reversible 
allosteric pocket 
(remote from ATP pocket, 
e.g. substrate binding domain
70
) 
inactive (DFGout) 
only experimental 
compounds 
(e.g. GNF-2)
56
 
 
Alternative and revised classifications have further been suggested. Irreversible inhibitors, for 
instance, have also been declared as the fifth class of inhibitors.70 Some inhibitors, e.g. 
dasatinib (30, Figure 5), have been observed to bind to conformations that are intermediate 
between DFGin and DFGout.
56 A hybrid binding mode (classified by type I I/II or type V) with 
mixed characteristics of types I and II has therefore been discussed.56,58 
McTigue et al. have intensively studied the binding modes of VEGFR inhibitors.67 They 
argued that declared type I inhibitors like axitinib and sunitinib (19 resp. 20, Figure 6) bind to 
the DFGout conformation without interaction with the deep pocket and categorize them as a 
new type IV. The difference to type II inhibitors like sorafenib (42, Figure 6) lies, according to 
them, in the conformation of the juxtamembrane domain.67 New pharmacophore models have 
been designed based on these results.71 
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According to Okamoto et al. sunitinib as a type I inhibitor shows fast binding kinetics and 
binds to the DFGin conformation, whereas sorafenib as a type II inhibitor shows slow binding 
kinetics and binds to DFGout.
55 They demonstrated that lenvatinib (38, Figure 6) exhibits a 
prolonged residence time; it binds to the DFGin conformation but additionally addresses the 
neighboring allosteric pocket. They therefore suggest calling these types of inhibitors type V. 
Bivalent kinase inhibitors have additionally been reported and classified as type V 
inhibitors.72 They consist of an ATP competitive small molecule that is linked to a peptide 
ligand. The latter binds to a signaling interaction site of the targeted kinase in order to 
improve selectivity and potency.73  
Another model by Kornev et al. uses a nonlinear motif, the so-called regulatory or 
hydrophobic spine, for the explanation of the active and inactive conformation.74 According 
to the model, a spine comprised of four hydrophobic residues is dynamically formed upon 
activation. Inhibitors can bind in the ATP pocket depending on the conformation of this spine 
and can thus be classified. 
The traditional classification system cannot express all the subtleties and nuances of kinase 
inhibitor binding modes. The active and inactive conformation of the DFG motif are only two 
extremes between various possible kinase configurations due to the flexibility of the protein 
chain. New types of kinase inhibitors with novel binding modes are furthermore emerging. 
Zhao et al. therefore stated that classification should be made according to how inhibitors 
affect kinetic parameters of the kinase and whether they display competitive, non-competitive 
or mixed inhibition profiles.56 But they also discussed the practical difficulties of this 
approach: this kind of enzymological data is rarely available for new kinase inhibitors; and 
the intracellular state of a kinase can hardly be reproduced in a test system due to complex 
post-translational and regulatory interactions in the cell. Crystallographic structures therefore 
provide an invaluable guide at the molecular level for medicinal chemists.56  
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1.2.2 BRAFV600E Inhibitor Vemurafenib 
The RAS/RAF/MEK/ERK signal transduction cascade is an essential signaling network that 
governs proliferation, differentiation and cell survival (Figure 12).75 Cellular responses to 
growth signals are mediated by this mitogen-activated protein kinase (MAPK) pathway, 
which is frequently deregulated in cancer.76 The three isoforms ARAF, BRAF and CRAF are 
cytoplasmic serine/threonine kinases that are regulated by binding RAS.76 Mutations in the 
BRAF gene occur in more than half of malignant melanomas and in a variety of other 
cancers.62 Whereat, a single substitution of glutamic acid for valine at position 600 (V600E, 
previously misnamed 59977) is accounting for the majority of cases.62 BRAFV600E thus 
becomes constitutively activated independent from RAS regulation.78 When the oncogenic 
potential of the BRAF gene was recognized, multiple drug discovery approaches were 
launched.75,79 
 
Figure 12. RAS/RAF/MEK/ERK signal transduction cascade.80 On the left, the physiological pathway in 
melanocytes after binding of a growth factor (GF) is illustrated. The cascade leads to subsequent 
phosphorylation of RAS, BRAF, MEK, and ERK and therefore to a signal enhancement. Gene transcription is 
hence regulated resulting in physiological cell proliferation and cell survival. In certain melanoma cancer cells, 
as shown on the right, a gain-of-function mutation of BRAF leads to an up-regulation of this pathway and 
consequently to an uncontrolled cell proliferation. 
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Sorafenib (42, Figure 6) was initially developed as an anti-melanoma agent targeting RAF, 
but failed in clinical studies due to inefficacy.78 However, further investigations revealed its 
anti-angiogenetic effects by multi-target inhibition including VEGFR and PDGFR.78 
Sorafenib has thus been used since 2005 as an orphan drug (Nexavar, Bayer) for the treatment 
of renal cell and hepatocellular carcinoma.81–83 
A structure-guided approach subsequently led to the development of vemurafenib (44, Figure 
6) with improved BRAF selectivity and efficacy.62,78 Vemurafenib was the first approved drug 
for the personalized treatment of BRAF-mutant cancer.62,78 The kinase inhibitor was 
discovered in 2005 and further developed under the research code PLX4032 by Plexxikon and 
Roche.62,78 It received approval under the trade name Zelboraf for the treatment of metastatic 
melanoma with BRAFV600 mutation in the United States and Europe in 2011 and 2012, 
respectively.62,78  
The introduction of vemurafenib into melanoma therapy showed impressive results. 
Remarkable response rates of 81% (phase I clinical trial80) resp. over 50% (phase II and III 
clinical trials84,85) were reached. The advantage over the comparative treatment with 
dacarbazine, an alkylating agent, was so evident that the FDA recommended a revision of the 
analysis plan so that patients in the control arm were permitted to receive vemurafenib as 
well.78 But despite outstanding tumor regressions and distinctive improvements in survival, 
vemurafenib cannot cure metastatic melanoma. Moreover, a massive dosage of 960 mg twice 
daily is required for an optimal therapeutic effect.78 An unacceptable toxicity was already 
documented at 1,120 mg twice a day.86 This leads to a high incidence of severe adverse events 
such as arthralgia (joint pain), skin rash, and the development of squamous cell carcinoma in 
26% of patients.84 Most patients furthermore suffer from lethal relapse due to drug-resistance 
after only a few months of therapy. Investigations on mechanisms revealed that drug 
resistance is selected by continuous vemurafenib administration.87 It could be demonstrated 
that resistant melanomas become drug dependent for their continued proliferation.87 A 
discontinuous dosing strategy was therefore suggested.87 
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In May resp. August 2013 dabrafenib (43, Figure 6), another mutant BRAF selective anti-
melanoma agent, was approved by the FDA and the European Medicine Agency (EMA).42 
Several other small molecules targeting BRAF are currently evaluated in clinical trials.88  
In order to reduce side effects and delay the formation of resistances, a light-mediated spatial 
and temporal control of BRAF inhibitors would be of great benefit. The development of photo 
prodrugs by introduction of PPGs might create novel therapeutic options and could enhance 
basic research by innovative tool compounds. Caged vemurafenib prodrugs are one of the 
main topics in this work. Von Drathen focused in his bachelor thesis on approaches for 
photoactivatable dabrafenib prodrugs.89 
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1.2.3 VEGFR Inhibitors Diarylmaleimide and Carbazole 
The vascular endothelian growth factor (VEGF) is an important mitogen in the physiological 
regulation of angiogenesis.90,91 Formation and growth of new blood vessels is a key process 
during embryogenesis and skeletal growth.92 In adult individuals, however, angiogenesis 
activities are rare with the exception of reproductive functions and wound healing.93 
Pathophysiological angiogenesis is beyond that associated with tumor growth and intraocular 
neovascular diseases.91 The first anti-angiogenetic drug was bevacizumab (trade name 
Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.94  
There are five different VEGF ligands which represent homodimeric glycoproteins.95 These 
growth factors bind to three receptor tyrosine kinase (RTK) isoforms, namely VEGFR1, 
VEGFR2, and VEGFR3.95 The related receptors consist of seven extracellular 
immunoglobulin-like domains, a single transmembrane region, and an intracellular split 
tyrosine-kinase domain.91 VEGFR1 is responsible for hematopoietic cell development, 
VEGFR2 is critical for vascular endothelial function, and VEGFR3 regulates lymphatic 
endothelial cell function.95 VEGF-A (also VEGF) is the most important stimulus for most 
physiological and pathological angiogenetic effects mediated by VEGFR2.95 These effects on 
endothelial cells include proliferation, migration, survival, and permeability.95 
Upon binding of a growth factor two receptor proteins dimerize.96 This induces 
autophosphorylation of the intracellular kinase domains triggering diverse signal transduction 
cascades.97 Important signaling pathways and their respective cellular responses are shown in 
Figure 13. 
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Figure 13. VEGF and VEGFR2 mediated signal transduction cascades.97 The growth factor VEGF binds to 
the extracellular domain of the receptor tyrosine kinase VEGFR2. This is followed by the dimerization of two 
receptor monomers and autophosphorylation of the intracellular domains. This leads to the activation of a 
cascade of downstream protein pathways and to the indicated biological effects. Only crucial proteins of each 
pathway are shown. 
Besides therapeutic antibodies, small molecule tyrosine kinase inhibitors (TKIs) targeting 
VEGFR have been developed.67 Seven small molecule VEGFR inhibitors have been approved 
until today (Table 3).42 One of them, axitinib, is discussed in more detail in the next chapter. 
These agents are usually not highly specific for VEGFR and thus also hit other related 
tyrosine kinases e.g. platelet-derived growth factor receptor (PDFGR).97 A high number of 
further VEGFR inhibitors are currently in the clinical development or have been developed as 
experimental substances.88 Peifer et al. reported in 2006 about a novel class of potent VEGFR 
inhibitors, namely 3,4-diarylmaleimides, as anti-angiogenesis agents.98,99 Within this series 
compound 55 (Figure 14) showed the highest potency with a VEGFR2 IC50 of 2.5 nM.
99
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Figure 14. Light-induced 1,6-π-electrocyclization of diarylmaleimide 55 and subsequent oxidation of the 
intermediate 56 to the carbazole 57.98  
Diarylmaleimide 55 seemed to be particularly interesting with regard to the photo project. Not 
only the high in vivo efficacy but also its light sensitivity made this compound an interesting 
candidate for a photoactivatable kinase inhibitor. Figure 14 shows that a cyclization reaction 
is taking place upon light exposure.98 A non-planar intermediate (56) is formed at first which 
could not be isolated.98 The latter is then oxidized to a planar carbazole structure in the next 
step. The carbazole represents a potent VEGFR inhibitor as well.99 It furthermore shows 
strong fluorescence which additionally seemed to be advantageous for microscopic 
investigations regarding e.g. its distribution in cellular compartments. 
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1.2.4 VEGFR Inhibitor Axitinib 
Targeted therapeutics addressing the VEGFR have revolutionized the treatment of metastatic 
renal cell carcinoma (RCC).100 90% of RCC patients show a mutation in the Von Hippel-
Lindau (VHL) gene with an overproduction of the angiogenic factor VEGF.67 The inhibition 
of VEGFR thus suppresses angiogenesis, cellular adhesion, and migration.67 
Since the introduction of the multi-kinase inhibitor sorafenib in 2005, the disease 
management of RCC has evolved rapidly.101 Second-generation VEGFR inhibitors such as 
axitinib (Inlyta, Pfizer) offer optimized potency and selectivity.101 Axitinib (19, Figure 6) is an 
indazole-derived, small molecule tyrosine kinase inhibitor.92 It has been approved for the 
therapy of advanced RCC in 2012.101 Its antiangiogenic effect is based on the inhibition of 
VEGFR1-3 at nanomolar concentrations.101 Other targets of axitinib are the highly related 
receptor tyrosine kinases PDGFR and cKIT.101 Their inhibition is, however, about eight-times 
weaker compared to VEGFR.101 
Beyond the indication for kidney cancer, angiogenesis plays an important role in the genesis 
of many tumors. An expansion of the indication is therefore conceivable and several clinical 
trials are currently performed e.g. for the treatment of melanoma, hepatic, or prostate cancer.88 
Furthermore, axitinib was recently discovered to effectively inhibit a mutant of BCR-ABL1 
that is often responsible for acquired drug resistance in the therapy of chronic myeloid 
leukemia (CML) with kinase inhibitors.102 In addition to its decisive role in cancer therapy, 
axitinib has been used in numerous in vitro and in vivo experiments.67,103,104 
 
Figure 15. Light-induced E-Z isomerization of axitinib. 
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The structure of axitinib offers an interesting E-Z photoswitching option based on the 
diarylethene resp. stilbene-like moiety (Figure 15).3 It was hypothesized that the 
stereoisomers would thus exhibit different biological activities. The possibility to control the 
efficacy of axitinib by switching it on and off through irradiation would be of great benefit in 
various experimental settings.  
 
 
 
  
  
 
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Caged Vemurafenib 30 
2. AIMS AND OBJECTIVES 
2.1 CAGED VEMURAFENIB 
The goal of this project was the development of novel photoactivatable prodrugs of 
vemurafenib. The occurrence of therapy-limiting side effects as well as only temporarily 
efficacy illustrates the urgent need for new therapeutic approaches with kinase inhibitors.84–86 
The caging approach might enable higher drug concentrations specifically generated by 
irradiation in cancer-afflicted tissues, resulting in a faster, more efficient regression with 
fewer side effects.4,10,14,30 Beyond novel therapeutic applications, these photo prodrugs could 
serve as experimental tools e.g. for kinetic or mechanistic studies.105 
 
Figure 16. Workflow of the caged vemurafenib project. The presented strategy involves (1) selection of an 
appropriate candidate for the caging concept, (2) determination of suitable pharmacophore moieties, (3) 
demonstration of adequate UV stability of the active inhibitor, (4) synthesis of caged photo prodrugs, (5) 
photochemical characterization and photoactivation, and (6) in vitro evaluation of photoactivation. The long-
term objective is (7) the proof of concept in animal studies. 
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The objective of this study was the design, synthesis, and biological evaluation of 
photoactivatable prodrugs of vemurafenib following the workflow illustrated in Figure 16. 
First, molecular modeling was to reveal promising pharmacophoric groups to be protected by 
PPGs (chapter 3.1.1). Afterwards an adequate UV stability at 365 nm of vemurafenib was to 
be verified in order to ensure that it is not degraded upon irradiation (chapter 3.1.2). 
Diverse classes of PPGs were to be assessed regarding their chemical accessibility (chapter 
3.1.3) and their photochemical characteristics (chapter 3.1.4), respectively. For the PPG 
assessment, a dummy compound was to be used in order to simplify the reactions conditions. 
The hinge binder scaffold of vemurafenib (44, Figure 17), represented by a 7-azaindole, was 
thus to be investigated concerning its intended role as a leaving group in a photoreaction. 
Despite the enormous amount of data about PPGs, information on the photoprotection of 
N-heterocycles is rarely available.18–20 This is presumably due to the fact that nitrogen 
compounds represent poor leaving groups in the photolysis reaction.10,19 Type I and II kinase 
inhibitors typically address the hinge region by nitrogen functions (Figures 5, 6, and 7).7 This 
interaction is essential for the binding mode and its blockade is therefore especially 
interesting regarding the caging concept.  
 
 
Figure 17. Chemical structure of vemurafenib (44). The hinge binder (7-azaindole) is highlighted in grey. 
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The question was if 7-azaindole could be released by the PPG at sufficient reaction rates or if 
further substituents would be necessary to stabilize transition states of the complex photolysis 
reaction (chapter 3.1.4). The objective was therefore to find the minimal structural 
requirement for the photoreaction. This identified fragment was consequently to be used as a 
dummy compound. Representatives from the following PPG classes were to be linked to this 
structure in order to compare their photochemical characteristics: o-nitrobenzyl, phenacyl, 
desyl, and coumarin moieties (Figure 18). 
o-Nitrobenzyl groups 
 
 
Phenacyl groups Desyl group Coumarin groups 
 
Figure 18. Selection of PPGs to be assessed in the vemurafenib project. LG = leaving group. 
Based on these findings, PPGs with optimized photolysis characteristics were to be selected 
for the synthesis of vemurafenib prodrugs (chapter 3.1.3). These were next to be 
photochemically characterized (chapter 3.1.4). This included assignment of an optimal 
wavelength for deprotection and investigation of photoinduced release of vemurafenib. 
Determination of BRAFV600E Kd values and a broad kinase selectivity profile for these 
compounds had subsequently to be performed to prove the intended loss-of-function by 
photoprotection. Finally, recovery of vemurafenib’s efficacy by UV irradiation had to be 
demonstrated in enzymatic resp. cellular assays and the biological impact of the released 
protecting group biologically evaluated (chapter 3.1.5).   
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2.2 CAGED DIARYLMALEIMIDES AND CARBAZOLE 
Besides the approved kinase inhibitor vemurafenib, the caging project included two 
experimental compounds: the diarylmaleimide 55 and the carbazole 57.98 An interesting 
aspect about these compounds is the light-induced conversion from the diarylmaleimide to the 
planar carbazole (Figure 14).98 Both compounds represent potent VEGFR inhibitors. By this 
reaction, a 1,6-π-electrocyclization with subsequent oxidation, the non-planar intermediate 56 
is formed.98 This intermediate cannot be isolated. An in situ formation of 56 was therefore to 
be examined in photochemical and biological assays. 
Additionally, both inhibitors were selected to be caged according to the strategy presented in 
chapter 2.1 (Figure 16). The objective of this approach was to develop photoactivatable 
VEGFR inhibitors as powerful pharmacological tools. Further focus was set on the 
exploration of another N-heterocycle, namely the maleimide moiety, as a leaving group for 
photolysis reactions. 
The set-up of this project included the following steps: 
(1) determination of a suitable pharmacophore moiety by molecular modeling 
(chapter 3.2.1), 
(2) investigation of UV stability and light-induced conversion from 55 to 57 
(chapter 3.2.3), 
(3) synthesis of caged photo prodrugs (chapter 3.2.2), 
(4) their photochemical characterization (chapter 3.2.3), 
(5) in vitro evaluation of the in situ formed 56, and 
(6) in vitro evaluation of the photoactivated caged prodrugs (chapter 3.2.4).   
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2.3 PHOTOSWITCHABLE AXITINIB 
The goal of this project was to investigate if axitinib can be used as a photoswitchable kinase 
inhibitor. The approved VEGFR inhibitor has shown excellent therapeutic results and has 
been used in a variety of biochemical assays.101 Based on the light-induced E-Z isomerization 
(Figure 15), the stilbene-like structure of axitinib offers an interesting photoswitching option 
which had not been reported in the academic field so far. As a photoswitch the biological 
effects of axitinib could be precisely turned on and off with high spatial and temporal control. 
This would offer opportunities both from a therapeutic point but also in basic kinase research. 
The strategy involved the following steps: 
(1) molecular modeling and docking studies in order to predict the binding affinity of both 
stereoisomers 19 and 19a (chapter 3.3.1), 
(2) isolation of axitinib’s (Z)-stereoisomer (19a) (chapter 3.3.2), 
(3) photochemical characterization of the (E)- and the (Z)-stereoisomer (chapter 3.3.3), 
(4) exploration of the photoinduced E-Z isomerization depending on the irradiated 
wavelength (chapter 3.3.3), and 
(5) biological evaluation comparing the inhibitory efficiency of both stereoisomers, 
including enzymatic and cellular in vitro assays (chapter 3.3.4). 
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3. RESULTS AND DISCUSSION 
3.1 CAGED VEMURAFENIB 
3.1.1 Molecular Modeling 
The ligand-protein interactions of vemurafenib (44, Figure 6) in the ATP pocket of BRAFV600E 
(pdb 3OG762) were examined by molecular modeling (chapter 5.1). In order to design 
effectless vemurafenib prodrugs, it was necessary to define key pharmacophoric moieties of 
this kinase inhibitor to be subsequently blocked by PPGs.  
In Figure 20 (A) and (B) the binding mode of vemurafenib in the ATP pocket of BRAFV600E is 
shown (pdb 3OG7).62 Figure 19 shows the corresponding two-dimensional (2D) ligand-
interaction diagram for clarity. The type I inhibitor vemurafenib is addressing two key 
H-bonds by its 7-azaindole moiety toward the hinge region.7 The sulfonamide NH residue of 
vemurafenib furthermore interacts with backbone amides of the DFG motif. Both the 
7-azaindole and sulfonamide were hence considered to be suitable pharmacophoric moieties 
for photoprotection. 
 
Figure 19. 2D ligand-interaction diagram of vemurafenib in BRAFV600E (pdb 3OG762). H-bond interactions 
of the ligand toward the protein backbone are shown. 
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Figure 20. X-ray defined binding mode of vemurafenib in the ATP pocket of BRAFV600E (pdb 3OG762) and 
determination of photoprotection sites. Arrows indicate the perspective of the enlarged views in (B), (C), and 
(D). Hydrogen bonds between the ligand and the protein backbone are indicated by black dotted lines. Red 
dashed lines represent sterical clashes between the PPG and the target protein. 
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In line with this notion, superposition of modeled photoprotected vemurafenib derivatives 58 
and 60 (Figure 21) in the active site of BRAFV600E resulted in significant sterical clashes 
(Figure 20 (C) and (D)), indicating nonplausible binding modes. It was however assumed that 
blocking the azaindole NH moiety of vemurafenib’s hinge binder would be more promising to 
demolish any affinity of the photoprotected prodrugs to other kinases since all type I and II 
inhibitors use this interaction.106 On the other hand, prodrugs with a PPG attached to the 
sulfonamide residue might still show some affinity to kinases featuring a larger or more 
flexible binding pocket in this peripheral area.6,107  
  
 58   (R = H) 60 
  59   (R = CH3) 
Figure 21. Chemical structures of caged vemurafenib prodrugs. The PPGs are highlighted in grey. 
Motivated by the modeling data, both NH photoprotected vemurafenib analogs were 
synthesized as described in chapter 3.1.3. This allowed a comparison of their anticipated in 
vitro non-efficacy against the target enzyme BRAFV600E and within a broad kinase panel to 
assess their specificity. 
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3.1.2 UV Stability 
Reactivation of photoprotected prodrugs requires the parent compound’s stability at the used 
wavelength of irradiated light. The drug molecule would otherwise be degraded immediately 
after its release or even before the covalent bond to the PPG is cleaved. The UV stability of 
vemurafenib was hence examined at 365 nm (chapter 5.2.2). As shown in chapter 3.1.4, this 
wavelength is suitable for the cleavage of the introduced PPGs. 10 mM (DMSO) and 0.01 mM 
(PBS buffer containing 10% DMSO) solutions of vemurafenib were irradiated for 20 min. 
HPLC analysis was used for content determination (chapter 5.3.4). Under these conditions, 
vemurafenib showed good stability over a period of 20 min (Figure 22). 
 
A 10 mM  
DMSO 
B 0.01 mM 
PBS buffer with 10% DMSO 
 
 
 
 
Figure 22. UV stability of vemurafenib. Stability of compound solutions in DMSO (A) resp. PBS buffer with 
10% DMSO (B) against irradiation at 365 nm (LED source, 5.4 W) analyzed by HPLC. 
  
0.0
0.5
1.0
1.5
2.0
2.5
0
20
40
60
80
100
120
0 10 20
A
b
s
o
lu
te
 i
n
je
c
ti
o
n
 
(µ
g
/5
 μ
L
) 
V
e
m
u
ra
fe
n
ib
 c
o
n
te
n
t 
(%
) 
Irradiation time (min) 
0
10
20
30
40
50
0
20
40
60
80
100
120
0 5 10 15 20
A
b
s
o
lu
te
 i
n
je
c
ti
o
n
  
(n
g
/2
0
 μ
L
) 
V
e
m
u
ra
fe
n
ib
 c
o
n
te
n
t 
(%
) 
Irradiation time (min) 
  
39  
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Results and Discussion 
3.1.3 Synthesis 
DMNB protected azaindole derivatives 
The hinge binder scaffold of vemurafenib was investigated in more detail to identify the 
essential core structure required for the PPG photoreaction. Since nitrogen compounds and 
particularly N-heterocycles represent poor leaving groups in photocleavage reactions, it was 
assumed that stabilization of transition states of the photolysis reaction would be critical. The 
deprotection mechanism is shown for o-nitrobenzyl caged compounds in Figure 23. 
Mesomeric and inductive effects by substituents of the leaving group play a key role for its 
release.19 Starting with 7-azaindole as a dummy compound, this moiety was expanded based 
on the structure of vemurafenib. An acetyl and a benzoyl substituent were further introduced 
as described below. Three caged azaindole analogs were thus synthesized (chapter 5.3.10) and 
their photochemical characteristics subsequently analyzed (chapter 3.1.4). 
 
Figure 23. Release mechanism of o-nitrobenzyl caged compounds.19,108 A photoinduced H-atom transfer leads 
to the formation of a primary aci-nitro intermediate (62). The latter is consecutively cyclized to give a 
benzisoxazolol (63). After deprotonation, the leaving group is irreversibly cleaved and an o-nitrosobenzaldehyde 
(65) is formed. LG = leaving group. 
7-Azaindole (66) and 3-acetyl-7-azaindole were commercially available. 3-benzoyl-7-
azaindole (67) was prepared by a Friedel-Crafts acylation according to Zhang et al. (Figure 
24, chapter 5.3.10)109. The 7-azaindole was thus benzylated in 3-position using aluminium 
chloride as a Lewis acid catalyst. 
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Figure 24. Preparation of 3-benzoyl-7-azaindole (67). 
These three azaindoles were subsequently caged with the 4,5-dimethoxy-2-nitrobenzyl 
(DMNB) group110 as illustrated in Figure 25. This straightforward synthesis proceeds by a 
base catalyzed substitution reaction (SN1/2). After deprotonation, the nitrogen anion acts as a 
nucleophile replacing the halogen atom in 4,5-dimethoxy-2-nitrobenzyl bromide (DMNB-Br). 
 
 
Figure 25. Synthesis of photoprotected azaindole derivatives 69, 70, and 71. 
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The three caged azaindole derivatives 69, 70, and 71 were then analyzed regarding their 
photocleavage characteristics; results and discussion are presented in chapter 3.1.4. 
3-Benzoyl-7-azaindole (67) was thus identified to be crucial for photocleavage of the 
protection group. It was consequently utilized as a dummy compound for the comparison of 
different classes of PPGs in terms of chemical accessibility and uncaging characteristics. 
Introduction of diverse PPG classes 
A broad range of PPGs with different characteristics regarding e.g. attachable leaving groups, 
absorption maxima, release rates, and photochemical by-products are available. The 
designated dummy compound, 3-benzoyl-7-azaindole, was to be linked to a variety of PPGs 
in order to make a selection for caging of the kinase inhibitors.  
First, three variations of the o-nitrobenzyl PPGs were to be introduced. The 1-(4,5-dimethoxy-
2-nitrophenyl)ethyl (DMNPE) group bears a methyl function at the benzylic position in 
comparison to the DMNB group. In consequence of this, a less toxic ketone is released 
instead of a nitrosoaldehyde (Figure 23) which was interesting for the biological evaluation. 
The 6-nitroveratryloxymethyl (NVOM) and 6-nitroveratryloxycarbonyl (NVOC) group 
promised faster release rates due to the hemiaminal ether resp. carbamate structure in the 
caged nitrogen compounds. 
The first two mentioned PPGs were prepared and linked to the dummy compound according 
to Figure 26 (chapter 5.3.10). Both synthetic strategies started with the nitration of 1-(3,4-
dimethoxyphenyl)ethanone (72).111 The obtained 1-(4,5-dimethoxy-2-nitrophenyl)-ethanone 
(73) was subsequently reduced to the corresponding alcohol 74 by reaction with sodium 
borohydride.112 
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Figure 26. Protection of 3-benzoyl-7-azaindole (67) with o-nitrobenzyl derivatives affording caged 
prodrugs 76 and 79.  
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For the introduction of the DMNPE group into the 3-benzoyl-7-azaindole molecule, the 
hydroxyl moiety had first to be substituted by a bromine atom serving as an improved leaving 
group in compound 75. This synthesis was performed by addition of phosphorus 
tribromide.113 Caging of the azaindole derivative was again a base catalyzed SN reaction 
yielding the DMNPE caged 76.110 
For the preparation of the NVOM group, 1-(4,5-dimethoxy-2-nitrophenyl)ethanol (74) was 
treated with dimethyl sulfide and benzoyl peroxide as a radical initiator yielding 77. To 
replace the methyl sulfide moiety by a chloride atom, sulfuryl chloride was used to produce 
78.18 Caging of 3-benzoyl-7-azaindole was once more achieved by a nucleophilic substitution 
to obtain NVOM caged 79.110 
Caging of 3-benzoyl-7-azaindole with the NVOC group was not successful (Figure 27). 
Apparently, DMNB caged 71 was formed after decarboxylation of 6-nitroveratryloxycarbonyl 
chloride (NVOC-Cl). Variation of the base (K2CO3), temperature (0 °C) and reaction under 
CO2 atmosphere did not succeed either. The reagent might therefore be too instable due to 
ambient light exposure and a dark laboratory might be required. 
 
Figure 27. Failed protection of 3-benzoyl-7-azaindole (67) with NVOC-Cl. 
In Figure 28 several one-step caging reactions are shown (chapter 5.3.10). Via the established 
route110 following PPGs were linked to 3-benzoyl-7-azaindole: 4-hydroxy-phenacyl (pHP, 
82), 4-(dimethylamino)phenacyl (83), 4-methyl-7-methoxycoumarin (84), 4-methyl-6,7-
dimethoxycoumarin (85), and desyl (1,2-diphenylethanone, 86). 
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Figure 28. Protection of 3-benzoyl-7-azaindole (67) with diverse PPGs. 
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Vemurafenib prodrugs 
Investigation of the binding mode revealed that both NH moieties within the vemurafenib 
structure should be appropriate for the caging concept (chapter 3.1.1). The azaindole and the 
sulfonamide function were therefore protected by PPGs as described in the following. This 
allowed a comparison of both protection sites regarding the kinetics of the photolysis reaction 
(chapter 3.1.4) and the influence on the biological activity (chapter 3.1.5). 
Two o-nitrobenzylic PPGs were selected to be introduced into the vemurafenib molecule, 
namely the DMNB and the DMNPE moiety. Both PPGs had proven to be chemical accessible 
(see above) and to show fast and clean photolysis reactions when attached to 3-benzoyl-7-
azaindole (chapter 3.1.4). The DMNB group produces a nitrosobenzaldehyde as a photo 
leaving group which is reported to be more toxic than the ketone formed by the DMNPE 
group.10 The biological effects of the released PPGs were thus to be investigated (chapter 
3.1.5). 
The use of DMNB-Br afforded the caged prodrugs 57, 59, and 87 (Figure 29). These 
compounds could be isolated by flash chromatography and were fully characterized. A 
comparable reaction was performed using DMNPE-Br (Figure 30). It is noteworthy that in 
this reaction, due to sterical hindrance at the sulfonamide, only the azaindole DMNPE 
protected derivative 59 was obtained and fully characterized. By-products were formed to 
small quantities and could not be isolated. LC-MS analysis indicated that the sulfonamide and 
the doubly protected derivatives 88 and 89 were formed analogously to the reaction above. In 
preliminary NMR analysis two sets of signals were identifiable for compound 88 which 
presumably belong to conformers as discussed in Figure 31. In case of the DMNPE doubly 
protected derivative 89, a diastereomer pair (89a/b) was presumably formed due to the 
presence of two chiral centers. This hypothesis was supported by preliminary NMR studies 
and different chromatographical behavior of the compounds (Figure 32). 
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44 
vemurafenib 
 58 
DMNB-azaindole 
11% 
 60 
DMNB-sulfonamide 
20% 
 87 
DMNB-doubly protected 
23% 
Figure 29. Synthesis of DMNB caged vemurafenib prodrugs 58 and 60. The doubly protected 87 was formed 
as a by-product. 
 
44 
vemurafenib 
 59 
DMNPE-azaindole 
23% 
 88 
DMNPE-sulfonamide 
not isolated 
 89 
DMNPE-doubly protected 
not isolated 
Figure 30. Synthesis of DMNPE caged vemurafenib prodrug 59. According to preliminary NMR and LC-MS 
studies the sulfonamide protected 88 and the doubly protected 89 were formed as by-products in small quantities 
but could not be isolated. 
A  B  C 
 
 
 
 
 
Figure 31. Modeled structures of proposed conformers of sulfonamide DMNPE protected vemurafenib 
(88). Due to sterical hindrance, DMNPE protection of vemurafenib’s sulfonamide supposedly resulted in the 
formation of two conformers with separate NMR signal sets, shown in (A) and (C). Sterical clashes in the 
theoretical transition structure were calculated (B), which would hinder the rotation of the aromatic ring of the 
PPG.  
 
  
47  
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Results and Discussion 
 
 PPG and 
side products 
44  88 59  89a/b  
Figure 32. Chromatographic separation of DMNPE protected vemurafenib derivatives. In the SN reaction 
of vemurafenib with DMNPE bromide a complex product mixture was formed. This figure shows the 
chromatographic separation of these products on a C18 reversed phase column. Non-reacted starting material can 
be assigned in the chromatogram. The DMNPE azaindole prodrug 59 was formed as the main product. Small 
quantities of the sulfonamide protected 88 and the doubly protected 89 were formed. The double peak (same m/z 
ratio) and preliminary NMR studies suggest that the latter represents a diastereomer pair (89a/b). 
The azaindole and the sulfonamide DMNB photoprotected prodrugs 58 and 60 enabled a 
comparison between these two protection sites concerning their photorelease characteristics 
and their biological activities, respectively. Through irradiation, the DMNB group produces a 
nitrosobenzaldehyde, whereas a less toxic ketone is released by the DMNPE moiety.10 
Compounds 58 and 59 hence allowed a comparison of these two PPGs regarding 
photokinetics and toxicity in cellular assays.  
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3.1.4 Ph tochemical Characterization 
DMNB protected azaindole derivatives 
In the first step, UV/vis absorption spectra of the caged compounds 69, 70, and 71 as well as 
their corresponding unprotected azaindole analogs were recorded to reveal an optimal 
wavelength for deprotection (chapter 5.2.1). Figure 33 demonstrates that there were only 
marginal differences between the spectra recorded in DMSO compared to those measured in 
an aqueous solvent. In all cases the unprotected azaindole derivatives did not absorb light 
with a wavelength above 350 nm; whereas the caged compounds showed an absorption peak 
between 350 and 360 nm. LEDs with emission wavelength of 365 nm were thus chosen for 
our irradiation experiments because of their high intensity and easy handling.  
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Figure 33. UV/vis absorption spectra of azaindole derivatives. UV/vis absorption spectra of photoprotected 
azaindole derivatives (solid lines) in comparison to their corresponding unprotected analogs (dashed lines) in (A) 
DMSO resp. (B) PBS buffer with 10% DMSO are shown.  
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Next, photocleavage upon UV irradiation of the caged azaindole derivatives 69, 70, and 71 
was examined (chapter 5.2.3). The prodrugs were therefore dissolved in DMSO (1 mM) resp. 
buffer solution (0.01 mM) and irradiated by LEDs (365 nm, 5.4 W) for up to ten minutes. The 
ratio between caged and uncaged probe was analyzed time dependently by HPLC illustrated 
as peak area in % (Figure 34, chapter 5.3.4). Besides retention time, LC-MS analysis of the 
DMSO probes was used for proof of identity (chapter 5.3.7). 
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Figure 34. Photoactivation of the DMNB protected azaindole derivatives 69, 70, and 71. (A) 1 mM (DMSO) 
resp. (B) 0.01 mM (PBS buffer with 10% DMSO) compound solutions were irradiated at 365 nm (5.4 W) for up 
to 10 min and analyzed time dependently by HPLC and LC-MS. The amount of caged probe (diamonds) is 
plotted against the released azaindole analog (triangles). 
  
0
20
40
60
80
100
0 2 4 6 8 10
0
20
40
60
80
100
0 2 4 6 8 10
0
20
40
60
80
100
0 2 4 6 8 10
0
20
40
60
80
100
0 2 4 6 8 10
0
20
40
60
80
100
0 2 4 6 8 10
0
20
40
60
80
100
0 2 4 6 8 10
  
 
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Caged Vemurafenib 50 
Caged 7-azaindole 69 was perfectly stable against UV irradiation under these conditions and 
did not show any conversion. Apparently, the transitions states of the release mechanism 
shown in chapter 3.1.3 (Figure 23) could not be stabilized by this leaving group. 
Photoprotected 3-acetyl-7-azaindole 70 could be uncaged but at a very slow reaction rate. 
However, the 3-benzoyl-7-azaindole prodrug 71 showed good photorelease characteristics. 
Concentration and solvent did not have a significant impact on the uncaging process. 
The 3-benzoyl-7-azaindole motif can therefore be considered to be the essential vemurafenib 
fragment for a suitable photorelease of the N-heterocycle. The transition states of the 
photolysis reaction seem to be stabilized by an extended mesomeric system. Further 
investigations e.g. molecular calculations of binding energies have to clarify the details of the 
mechanisms of these findings. 
Comparison of diverse PPG classes 
Since 3-benzoyl-7-azaindole (67) was easily cleaved from the DMNB protection group, it had 
proven to be applicable as an N-heterocycle photo leaving group. 67 was therefore used as a 
dummy compound for further photoexperiments to compare different PPGs. Diverse 
representatives were thus synthetically linked to this molecule as described in chapter 3.1.3. 
In this section, Figure 35 gives a compact overview over the photocharacteristics of these 
diversely caged 3-benzoyl-7-azaindole prodrugs (chapters 5.2.1 and 5.2.3).  
As expected, DMNPE protected 76 and NVOM caged 79 (both belonging to the o-nitrobenzyl 
PPG family) also showed a peak absorbance around 360 nm. Their photorelease upon 
irradiation at 365 nm was in fact very similar to that of DMNB protected 71. The introduction 
of a methyl group resp. an ether bridge, thus, did not result in an accelerated reaction rate 
which is in contrast to the results reported in the literature10. The cleaved protection group of 
these two compounds however contains a ketone function instead of an aldehyde, which 
might be less toxic in biological experiments.10 Hence, they are potentially interesting for the 
photoprotection of N-heterocycles and for the following caging projects. As seen before for 
the DMNB derivatives, concentration and solvent did not have a significant impact on the 
uncaging process. 
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Figure 35. Photoactivation and UV/vis absorption spectra of differently caged 3-benzoyl-7-azaindole 
derivatives. (A) 1 mM (DMSO) resp. (B) 0.01 mM (PBS buffer with 10% DMSO) compound solutions were 
irradiated at 365 nm (5.4 W) for 10 min and analyzed time dependently by HPLC and LC-MS. The amount of 
caged probe (diamonds) is plotted against the released 3-benzoyl-7-azaindole (67, triangles). (C) UV/vis 
absorption spectra in DMSO resp. PBS buffer with 10% DMSO at pH 7.2. 
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Figure 36. pH-Dependent photoactivation and UV/vis absorption spectra of 4-hydroxy-phenacyl (pHP) 
caged 3-benzoyl-7-azaindole (82). (A) 1 mM (DMSO) resp. (B) 0.01 mM (PBS buffer with 10% DMSO, pH 
6.2, 7.2, and 8.2) compound solutions were irradiated at 365 nm (5.4 W) for 10 min and analyzed time 
dependently by HPLC and LC-MS. The amount of caged probe (diamonds) is plotted against the released 
3-benzoyl-7-azaindole (67, triangles). (C) UV/vis absorption spectra in DMSO resp. PBS buffer with 10% 
DMSO at pH 6.2, 7.2, and 8.2.  
The photocharacteristics of 4-hydroxy-phenacyl (pHP) caged 82 are presented separately in 
Figure 36. In DMSO 82 did not show absorption at 365 nm. It is therefore not surprising that 
only a small percentage of the prodrug was deprotected after ten minute irradiation. Notably, 
in an aqueous solvent the spectra showed a distinct pH dependency due to deprotonation of 
the acidic phenol group. The increase of the pH value (6.2, 7.2, and 8.2) caused a 
bathochromic shift leading to an ascending absorption at 365 nm. Nevertheless, this did not 
have an influence on the insufficient deprotection reaction. Lower wavelengths might 
improve the photolysis reaction but should be avoided for the irradiation of biological probes. 
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Results and Discussion 
The related 4-(dimethylamino)phenacyl caged 83 showed an adequate absorption value at 
365 nm in DMSO and even higher, pH-independent (in the range between pH 6.2 and 8.2) 
values in an aqueous solvent (Figure 35). Irradiation of 83 at 365 nm however led to rapid 
unspecific degradation (products not characterized). Only traces of deprotected 3-benzoyl-7-
azaindole could be detected. This PPG was thus considered to be unsuitable for the purpose of 
N-heterocycle photoprotection. 
4-Methyl-7-methoxycoumarin caged 84 did not absorb light at a wavelength of 365 nm. More 
than 10% 3-benzoyl-7-azaindole could surprisingly be released after ten minutes of 
irradiation. This slow conversion is not convenient for biological applications though. The 
absorption band of another coumarin derivative, the 4-methyl-6,7-dimethoxycoumarin caged 
85, was shifted bathochromically. Irradiation however led to unspecific degradation (products 
not characterized) and only traces of 3-benzoyl-7-azaindole (67) were cleaved after ten 
minutes time. 
The last investigated PPG was the desyl group. Both in DMSO and in buffer solution, caged 
compound 86 showed little absorption. After ten minutes only small quantities of 3-benzoyl-
7-azaindole (67) were released by irradiation which was not sufficient enough for the caging 
project. 
In conclusion, suitable PPGs for the dummy compound, 3-benzoyl-azaindole (67), could be 
defined by the presented systematic approach. The o-nitrobenzyl groups DMNB, DMNPE, 
and NVOM revealed clean photocleavage with comparable, rapid reaction rates. All other 
investigated PPGs did not provide satisfactory results. DMNB and DMNPE were thus 
selected as PPGs for the vemurafenib project in order to compare the impact of the different 
cleaved protection groups (aldehyde vs. ketone) in biological assays.  
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Vemurafenib prodrugs 
For the prodrug concept, it is essential that the parent compound is released rapidly and 
quantitatively upon irradiation. UV/vis absorption spectra were recorded in order to find the 
optimal irradiation wavelength for deprotection of the vemurafenib prodrugs (Figure 37, 
chapter 5.2.1). Shortwave UV irradiation underneath 300 nm (UVB and UVC) might damage 
tissues or proteins because of their high energy. Vemurafenib itself furthermore showed 
absorption up to 350 nm. Irradiation with light below that wavelength might hence lead to 
instability of the parent compound. The prodrugs showed an additional absorption peak 
around 365 nm due to the introduced PPG. LEDs are advantageously available for this 
wavelength, show a high intensity and were therefore chosen for the photochemical and 
subsequent biological evaluation. 
 
A Methanol resp. DMSO B PBS buffer with 10% DMSO 
 
 
 
 
Figure 37. UV/vis absorption spectra of vemurafenib prodrugs in MeOH/DMSO (A) resp. PBS buffer with 
10% DMSO (B).  
In the following step, photorelease kinetics of the different vemurafenib prodrugs were 
studied (chapter 5.2.3). An LED reactor with an emission at 365 nm (5.4 W) was utilized to 
irradiate 1 mM (DMSO) and 0.01 mM (PBS buffer containing 10% DMSO) solutions of the 
compounds (Figure 38).  
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Results and Discussion 
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Figure 38. Photoactivation of the vemurafenib prodrugs 58, 59, and 60 in DMSO (A) resp. PBS buffer with 
10% DMSO (B). The compound solutions were irradiated at 365 nm (5.4 W) for 10 min and analyzed by HPLC 
and LC-MS. The amount of caged probe (diamonds) is plotted against released vemurafenib (triangles). The 
formation of a cyclic benzisoxazolidine intermediate was observed (crosses); for further details, see Figure 39. 
Upon irradiation in aqueous media, the sulfonamide protected derivative 60 showed fastest 
cleavage of the PPG. After 30 s, more than 90% of vemurafenib was released. Azaindole 
protected 58 and 59 were comparable to each other in their photocharacteristics. More than 
90% of vemurafenib was released within 1 min. Similar results were obtained in pure DMSO; 
however, the slightly slower reaction rate is presumably based on higher compound 
concentration in this setting. In the literature, DMNPE is reported to have a higher quantum 
yield compared to that of DMNB.10 The assumption that 59 would show faster releasing 
characteristics than 58 could not be confirmed in our study. According to LC-MS and NMR 
studies, the formation of a cyclic benzisoxazolidine intermediate (93) could be observed; for a 
detailed discussion, see Figure 39. 
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Figure 39. Photorelease of vemurafenib and cyclic benzisoxazolidine intermediate formation. (A) A 1 mM 
solution of compound 59 in DMSO was irradiated at 365 nm (5.4 W) for 10 min and analyzed by HPLC (chapter 
5.2.3). The amount of caged probe (diamonds) and released vemurafenib (triangles) was analyzed time 
dependently. Additionally, the formation of an intermediate was observed (crosses). After 1 min its content 
reached up to 13% of the peak area as a maximum, before it was slowly degraded again. (B) The proposed 
cleavage mechanism of the DMNPE protecting group is presented.114 The cyclic benzisoxazolidine intermediate 
(93) was presumably detected by HPLC analysis of the irradiated solution (chapter 5.3.4). In the dark, the 
intermediate was stable in DMSO solution for several hours, which allowed further analysis. (C) In the mixed 
NMR spectrum of a 90 s irradiated probe the datasets of caged/uncaged vemurafenib and the cleaved PPG can be 
recognized (chapter 5.3.6). Besides, there are additional peaks (integral 0.1) that presumably belong to the 
intermediate (arrows). The sharp singlet of an exchangeable proton with a significant downfield shift of 
11.6 ppm supposedly belongs to the N-OH group. (D, left) In the chromatogram of the LC-MS analysis the 
caged prodrug 59, uncaged vemurafenib (44) and the cleaved PPG (95) can be identified (chapter 5.3.7). The 
intermediate shows a shorter retention time compared to 59 indicating a more polar molecule which supports the 
structure of 93. (D, right) The MS spectrum revealed a signal of m/z 681 for the intermediate. A hydroxide ion is 
presumably eliminated by the cyclic benzisoxazolidine 93 during electrospray ionization. The ring opening of 
the benzisoxazolidine is furthermore reported to be the rate-determining step of this reaction, which would 
explain an accumulation of this intermediate. 
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Results and Discussion 
In conclusion, both NH photoprotection sites proved to be suitable for rapid and quantitative 
photorelease of vemurafenib. The next question to be addressed was whether the protection of 
these moieties would actually diminish the effect on BRAFV600E and also suppress the 
antiproliferative effect in cells. 
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3.1.5 Biological Evaluation 
The major part of this chapter has been drafted by Boris Pinchuk in course of preparing the 
manuscript Horbert and Pinchuk et al.115. Minor modifications e.g. embedding of 
complementary data have been implemented in order to improve readability. 
Kinase assays 
Binding affinities of vemurafenib and caged compounds toward BRAFV600E were determined 
(Table 5, chapter 5.4.1). In line with the modeling data, the caged compounds exhibited a 
lower binding affinity toward BRAFV600E in comparison to that of vemurafenib. 
Table 5. Kd values of vemurafenib (44) and the caged prodrugs 58, 59, and 60 toward BRAFV600E. 
Compound 44 58 59 60 
Kd values 10 nM 440 nM 77 nM 79 nM 
The lowest binding affinity was found for azaindole protected 58. This is strong evidence that 
protection of the azaindole moiety forestalls the inhibitor-enzyme interaction. Surprisingly, 59 
and 60 still show unexpected binding toward BRAFV600E although their affinities are 
significantly less than that of vemurafenib (44). The determined affinities can be explained by 
minute quantities of unprotected active compound in the samples and/or instability of caged 
compounds resulting in the release of vemurafenib under the assay conditions. For 
investigations on the stability of the prodrugs in cellular growth medium (chapter 5.4.6), also 
see Figure 40. 
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Figure 40. Stability of the vemurafenib prodrugs 58, 59, and 60 in cellular growth medium. 0.01 mM 
compound solutions (DMEM medium with 2 mM L-glutamine, 1 mM sodium pyruvate and 10% DMSO) were 
incubated in a 5% CO2 humidified atmosphere at 37 °C for 48 h and analyzed by HPLC. The amount of caged 
probe (diamonds) is plotted against released vemurafenib (triangles). All three prodrugs showed a good stability 
under the described conditions. 
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Results and Discussion 
A selectivity profile over 140 kinases for vemurafenib (44), 58, and 60 at a concentration of 
10 µM was subsequently performed (chapter 5.4.3). The results are presented as a heat map in 
Figure 41. Apparently, vemurafenib potently inhibited several other kinases besides 
BRAFV600E. There are altogether 32 kinases whose activity was reduced to less than 30% 
under these test conditions. The most affected kinases were BRK, MAP4K5, and DDR2. This 
data indicates that vemurafenib is not highly selective at the tested concentration in 
biochemical assays. Sulfonamide caged compound 60 reduced the activity of 13 kinases to 
less than 30%. Its inhibitory potency against non-target kinases was diminished in comparison 
to that of vemurafenib. Some non-specific interactions were, however, still observable. 
Regarding this data, it can be assumed that protection of the sulfonamide residue prevents 
binding to BRAFV600E but was still not sufficient enough to completely suppress inhibition of 
other kinases. In contrast, azaindole protected compound 58 inhibited only two kinases: 
MAP4K5 (7% residual activity) and RIPK2 (26% residual activity). These findings are in line 
with the initial assumption that blockade of the hinge binder, the azaindole moiety, would 
annihilate the affinity to kinases in general more effectively than the protection of the 
sulfonamide residue. 
 
44 
 
58 
60 
Figure 41. Kinase selectivity profiling of vemurafenib and caged prodrugs. The inhibitory effect of 
vemurafenib (44) and the caged derivatives 58 and 60, respectively, was tested in a panel of 140 kinases. The 
residual activity of kinases was measured after incubation with 10 µM of each compound. The data is portrayed 
as a heat map of the mean activity of assay duplicates. The color code refers to the residual kinase activity 
ranging from red (low residual activity) to blue (high residual activity). Apparently, 58 inhibited significantly 
less kinases than vemurafenib and 60. Details are shown in Supplementary Table 1 (Appendix). 
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Cellular assays 
On the basis of the enzymatic data, it was supposed that the caged derivatives would show 
considerably less activity in cellular assays compared to that of vemurafenib. To prove this 
hypothesis, the anti-proliferative activity was investigated in cellular growth assays using the 
melanoma cell line SKMel13 which carries the BRAFV600E mutation (chapters 5.4.4 and 
5.4.5).116 Dose-response curves for the non-irradiated compounds were measured (Figure 42 
(A)). 
A   B   
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44 + UV 
58 + UV 
59 + UV 
60 + UV 
w/o UV irradiation  with UV irradiation  
Figure 42. Activation of caged vemurafenib prodrugs in cell proliferation assays. The recovery of 
vemurafenib’s efficacy by UV irradiation was demonstrated using SKMel13 cells. (A) Dose-response curves of 
vemurafenib (44) and the caged prodrugs 58, 59, and 60 were determined without UV irradiation. Cell growth 
was measured 48 h after incubation with the compounds. Vemurafenib clearly showed cytotoxic effects at 
concentrations above 1 µM. The caged derivatives did not exhibit cytotoxic activity: the TGI-mark was not 
reached even at high concentrations. (B) Cells were incubated for 1 h with the compounds and then irradiated at 
365 nm (1.8 W) for 5 min. Cell growth was determined 48 h after incubation with the compounds. After 
irradiation the caged derivatives showed similar dose-response curves in comparison to active vemurafenib. 
GI50 = 50% growth inhibition; TGI = total growth inhibition; LC50 = 50% lethal concentration. (±SD, n=4) 
Vemurafenib showed potent cytotoxic activity (GI50 value 0.17 μM). This finding corresponds 
with previous studies that revealed a strong inhibition of V600E-positive melanoma cells by 
vemurafenib.117–119 In contrast, the caged compounds exhibited no cell toxicity toward the 
melanoma cells in the nanomolar range. Cytostatic effects occurred at considerably higher 
concentrations (GI50 values: 4.3 μM for 59 and 2.6 μM for 60). Compound 58 did not show 
significant cell growth inhibition at all. The marginal cytostatic effects of the caged probes at 
higher concentrations could again be caused by minute impurities of unprotected vemurafenib 
or by off-target effects of the compounds. 
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Results and Discussion 
It was next examined whether the inhibitory potency of the photoprotected compounds in 
cells could be restored upon UV irradiation. The cell growth assays described above were 
performed by irradiating the cells with UV light at 365 nm (1.8 W, 5 min) with and without 
compound incubation. The dose-response curves are presented in Figure 42 (B). In this assay, 
the UV irradiation at the applied dosage was well-tolerated by the cells. After UV irradiation, 
the prodrugs showed antiproliferative activity comparable to that of unprotected vemurafenib 
(GI50 values: 0.19 μM for vemurafenib, 1.5 μM for 58, 0.46 μM for 59, and 0.35 μM for 60). 
The slightly reduced activity in comparison to that of vemurafenib might be explained by 
incomplete photorelease under the described conditions. Summarizing the results of the 
proliferative cell assays, it can be postulated that the irradiation of the caged compounds 
restores the potent activity of vemurafenib. 
Having demonstrated the photoactivation of vemurafenib from its caged prodrugs, the effect 
of the cleaved PPG on cellular growth was investigated (chapters 5.4.4 and 5.4.5). The caged 
vemurafenib prodrugs were not suitable to answer this question because of the intrinsic 
toxicity of uncaged vemurafenib after irradiation. Two model compounds were therefore used 
(Figure 43): the presumably nontoxic tert-butyloxycarbonyl (BOC) protected L-alanine (68) 
and its DMNB photoprotected derivative (69). 
  
 
96 
 
97 
Figure 43. Chemical structures of BOC protected L-alanine (96) and its DMNB photoprotected derivative 
(97). 
The effect of both compounds on the proliferation of SKMel13 cells was measured at first 
(Figure 44). Both protected amino acid derivatives did not show any antiproliferative effects 
even at high concentrations. The same experiment was repeated with UV irradiation (365 nm, 
1.8 W). Irradiated 96 was still neither cytotoxic nor cytostatic. In contrast, 97 exhibited 
distinct antiproliferative activity after irradiation at concentrations above 10 μM (GI50 value 
34.4 μM). It can therefore be assumed that the measured cell toxicity was caused by the 
cleaved DMNB. The toxic concentration (10 μM) however was approximately 100-fold higher 
than the efficacious concentration of the released vemurafenib (0.17 μM). 
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Figure 44. Effect of the photo released PPG on cell proliferation. (A) Dose-response curves of L-alanine 
derivative 96 and its photoprotected analog 97 in cell viability assays (SKMel13 cells) without UV irradiation. 
Cell growth was determined after 48 h incubation with compound solutions. Both compounds did not show anti-
proliferative effects. (B) Dose-response curves of 96 and 97 in the same assay with UV irradiation. After 1 h 
incubation with compound solutions, cells were irradiated at 365 nm (1.8 W) for 5 min. Cell growth was again 
determined after 48 h. Herein, 97 showed anti-proliferative efficacy in concentrations above 10 μM providing 
evidence for the cytotoxicity of the cleaved PPG at higher concentrations. GI50 = 50% growth inhibition; TGI = 
total growth inhibition; LC50 = 50% lethal concentration. (±SD, n=2) 
 
Western blots 
In order to study the impact of vemurafenib and its caged derivatives on BRAFV600E signaling, 
western blot analysis was performed on downstream Erk phosphorylation (Figure 45, chapter 
5.4.7). 
Erk phosphorylation in SKMel13 cells was investigated after incubation with compound 
solutions without irradiation. Total Erk was used as a loading control. As reported for a BRAF 
inhibitor, vemurafenib (44) displayed dose-dependent pErk inhibition at concentrations higher 
than 0.01 μM.62,117–119 The phosphorylation of Erk was completely blocked at concentrations 
above 0.1 μM. According to the biochemical data, the caged compounds 58 and 60 revealed 
significantly less inhibition of Erk phosphorylation. Even at a concentration of 10 μM, there 
were detectable signals of pErk. 
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Results and Discussion 
Erk phosphorylation in cells was consecutively surveyed after incubation with compound 
solutions and subsequent UV irradiation. No alteration in pErk inhibition by vemurafenib (44) 
could be determined with or without irradiation. This demonstrates that the amount of 
phosphorylated Erk is not dependent on UV irradiation under the described conditions. After 
UV irradiation, 58 and 60 exhibited the same inhibitory potency on pErk as that of 
vemurafenib. A complete suppression of Erk phosphorylation was demonstrated for 
concentrations above 0.1 μM. Dose dependency correlated with that of vemurafenib. This 
indicates that the inhibitory efficacy of vemurafenib on BRAFV600E signaling can be 
completely reactivated upon irradiation of the caged derivatives with UV light. 
 
A  B  
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w/o UV irradiation  with UV irradiation 
Figure 45. Activation of inhibitory effect of the caged prodrugs 58 and 60 on BRAFV600E signaling in vitro. 
SKMel13 cells were treated for 1 h at 37 °C with solutions of vemurafenib (44) and caged prodrugs 58 resp. 60. 
Subsequently, cells were lysed and immunoblotted. (A) Cells were not irradiated. (B) Cells were incubated for 
1 h, irradiated at 365 nm (1.8 W) for 5 min and after further 1 h incubation lysed and immunoblotted. The 
experiments were carried out in duplicates. t-Erk = total Erk; p-Erk = phosphorylated Erk. 
  
  
 
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Caged Diarylmaleimides and Carbazole 64 
3.2 CAGED DIARYLMALEIMIDES AND CARBAZOLE 
3.2.1 Molecular Modeling 
The ligand-protein interactions of diarylmaleimide 55 and carbazole 57 in the ATP pocket of 
VEGFR2 were examined by molecular modeling (chapter 5.1). In order to design 
pharmacologically inactive photo prodrugs, key pharmacophoric moieties were defined within 
these kinase inhibitor structures to be subsequently blocked by PPGs. 
  
Figure 46. Binding mode of diarylmaleimide 55. Modeled 3D binding mode (left) and 2D ligand-interaction 
diagram (right) of 55 in the ATP pocket of VEGFR2 (pdb 3CJF120). Black dotted lines resp. magenta arrows 
represent hydrogen bonds between the ligand and the backbone of the protein. 
  
Figure 47. Binding mode of carbazole 57. Modeled 3D binding mode (left) and 2D ligand-interaction diagram 
(right) of 57 in the ATP pocket of VEGFR2 (pdb 3CJF120). Black dotted lines resp. magenta arrows represent 
hydrogen bonds between the ligand and the backbone of the protein. 
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Results and Discussion 
In Figure 46 the calculated 3D binding mode of 55 in the ATP pocket of VEGFR2 
(pdb 3CJF120) and the corresponding 2D ligand-interaction diagram are shown. Analogously, 
the calculated 3D binding mode and the corresponding 2D ligand-interaction diagram of 57, 
docked in the same protein structure, are shown in Figure 47. The type I inhibitors form two 
key H-bonds with their imide moiety toward the hinge region. The indole NH moiety does not 
show a direct hydrogen bond toward the protein, but a water mediated interaction has been 
discussed by Peifer et al.99 
The imide function was however considered to be the most promising pharmacophoric moiety 
for photoprotection due to the central importance of the hinge region in the interaction with 
all type I and II inhibitors. In line with this notion, superposition of the modeled 
photoprotected derivatives 98, 99, and 100 (Figure 48) in the active site of VEGFR2 resulted 
in significant sterical clashes (exemplified with compound 100 in Figure 49). Likewise, 
docking of these caged compounds did not yield plausible binding modes (data not shown). 
 
 
 
 
  
98 99 100 
Figure 48. Chemical structures of NB/DMNB photoprotected diarylmaleimides 98 resp. 99 and 
photoprotected carbazole 100. The PPGs are highlighted in grey. 
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Figure 49. The DMNB caged carbazole 100 was positioned in the binding pocket of VEGFR2 (pdb 
3CJF120) imitating the core binding mode of its unprotected analog 57. Red dashed lines represent sterical 
clashes between the PPG and the hinge region of the protein. 
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Results and Discussion 
3.2.2 Synthesis 
The diarylmaleimide 55 was synthesized according to the procedure reported by Peifer et al.98 
(Figure 50, chapter 5.3.10). 3,4,5-Trimethoxyphenylacetamide (102) was synthesized by 
activation of the corresponding carboxylic acid (101) with thionyl chloride and subsequent 
treatment with aqueous ammonia solution. The indole-3-ethylglyoxylate (104) was 
subsequently obtained via Friedel-Crafts-type acylation of indole (66) with ethyl oxalyl 
chloride (103). A Knoevenagel condensation121 finally afforded the asymmetrically 
substituted 3,4-diarylmaleimide by ring closure. 
 
Figure 50. Synthesis of the diarylmaleimide 55. 
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Due to light and atmospheric oxygen exposure during the synthesis of 55 its carbazole 
derivative 57 was formed by a 1,6-π-electrocyclization reaction and subsequent oxidation as 
illustrated in Figure 14 and discussed by Peifer et al.98. Since 57 is a potent VEGFR inhibitor 
as well, this compound has also been incorporated in the caging project. 
The o-nitrobenzyl (NB) PPG was introduced into 55 by a base catalyzed SN reaction using 
1-(bromomethyl)-2-nitrobenzene (NB-Br) as a reactant. Apart from the protected maleimide 
98, the doubly protected derivative 105 was obtained as a by-product (Figure 51). 
 
 
Figure 51. Synthesis of the NB protected diarylmaleimide (98) and formation of the doubly protected 
by-product (105). 
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Results and Discussion 
The DMNB protected maleimide 99 was synthesized in an analog manner using DMNB-Br as 
PPG. The doubly protected derivative 106 was again formed as a by-product (Figure 52). 
 
Figure 52. Synthesis of the DMNB protected diarylmaleimide (99) and formation of the doubly protected 
by-product (106). 
The corresponding synthesis of the DMNB protected carbazole 100 is shown in Figure 53. 
Due to sterical hindrance of the carbazole nitrogen atom 100 was formed as the single product 
of this reaction. 
 
 
Figure 53. Synthesis of the DMNB protected carbazole (100). 
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3.2.3 Ph tochemical Characterization 
UV/vis absorption spectra of the unprotected compounds were first recorded (chapter 5.2.1) 
and UV stability of compound solutions was examined (Figure 54, chapter 5.2.2). The 
diarylmaleimide 55 showed two absorption peaks around 350 and 440 nm. Irradiation at 
365 nm presumably initiated the cyclization reaction presented in Figure 14. Based on LC-MS 
analysis, only the intermediate 56 was quantitatively formed after 10 min of irradiation 
(chapter 5.3.7). Under these experimental conditions the subsequent oxidative reaction step to 
the carbazole 57 apparently did not take place. The carbazole itself, on the other hand, showed 
only marginal light absorbance at 365 nm and was stable against irradiation at this wavelength 
over a period of 10 min. 
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Figure 54. UV stability and UV/vis absorption spectra of the unprotected diarylmaleimide 55 and 
carbazole 57. (A) 1 mM (DMSO) compound solutions of 55 (triangles) and 57 (squares) were irradiated at 
365 nm (5.4 W) for up to 10 min and analyzed time dependently by HPLC. Based on LC-MS analysis, 
irradiation of 55 afforded the intermediate product 56 (dotted line) by an electrocyclization reaction (Figure 14). 
The carbazole 57 was stable at the described conditions. (B) UV/vis absorption spectra of 0.1 mM (DMSO) 
compound solutions of 55 and 57 are shown. 
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Results and Discussion 
In the next step, the photocharacteristics of the caged compounds were investigated (Figure 
55, chapters 5.2.1 and 5.2.3). In the area of interest the UV/vis absorption spectrum of the NB 
caged diarylmaleimide 98 was similar to that of its unprotected derivative. DMNB protected 
compounds 99 and 100, on the other hand, showed an increased absorption around 350 nm in 
comparison to their unprotected derivatives.  
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Figure 55. UV stability and UV/vis absorption spectra of caged 98, 99, and 100. Photoactivation of 
NB/DMNB caged diarylmaleimide 98 resp. 99 and DMNB caged carbazole 100. 1 mM (DMSO) compound 
solutions were irradiated at 365 nm (5.4 W) for up to 10 min and analyzed time dependently by HPLC. Symbols 
are used as follows: caged compounds (grey diamonds), released diarylmaleimide 55 (black triangles), 
electrocyclization intermediate 56 (dotted line), and released carbazole 57 (black squares). (B) UV/vis absorption 
spectra of 0.1 mM (DMSO) compound solutions are shown.  
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Although the NB protecting group itself shows very low quantum yields at the utilized 
wavelength of 365 nm10, irradiation of 98 led to the cleavage of this PPG and a comparably 
slow release of the parent compound 55. The reason for this might be the extended mesomeric 
system of the leaving group. The maximum detected concentration of 55 was 27% after 
5 min. The cyclization intermediate 56 was again formed to a large extend and increased with 
the duration of light exposure (more than 50% after 10 min). Irradiation of the related DMNB 
protected derivative 99 yielded comparable results. The cleavage proceeded more rapidly and 
a concentration of 43% of the parent compound could be achieved after 3 min of irradiation. 
Continuing light exposure led to a conversion from 55 to 56. Irradiation of the DMNB 
protected 100 led to a tolerably clean cleavage reaction and a nearly quantitative release of 57 
(more than 80%) within a few minutes. Small quantities of several not specified by-products 
were formed upon irradiation (not shown in the diagrams). 
In conclusion, irradiation of the protected diarylmaleimide prodrugs 98 and 99 did not provide 
clean cleavage reactions. A mixture of the parent compound and the cyclized 56 was formed. 
The influence of medium and concentration should be further studied to enable a final 
assessment. An in situ formation of 56 could however have an additional effect in biological 
assays and was therefore evaluated in the following chapter 3.2.4. Uncaging of 100 proceeded 
straightforwardly within several minutes of irradiation and the carbazole 57 was released to a 
high extend. 
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3.2.4 Biological Evaluation 
The next question to be addressed was whether caging of the imide function in the DMNB 
protected diarylmaleimide 99 resp. carbazole 100 would actually diminish the effect on 
VEGFR2 as well as the antiproliferative effect in cells. 99 was chosen disfavoring its NB 
caged derivative 98 because of the faster cleaving kinetics and higher release of the parent 
compound. It had furthermore to be investigated if irradiation could restore the inhibitory 
activity of both prodrugs 99 and 100, respectively. In kinase assays the inhibitory effect of the 
prodrugs were compared with their parent compounds on an enzymatic level. Cell 
proliferation assays were performed in order to assess the biological effects of the prodrugs 99 
and 100 before and after irradiation. 
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Kinase assays 
Inhibition curves and IC50 values were determined in a radiometric and a non-radiometric 
enzymatic VEGFR2 assay (see Table 6, chapter 5.4.2).122 
Table 6. Inhibitory effect of caged and uncaged inhibitors in VEGFR2 kinase assays.122 Inhibition curves 
and IC50 values of diarylmaleimide 55 resp. carbazole 57 and their DMNB caged prodrugs 99 resp. 100 in 
radiometric and non-radiometric enzymatic VEGFR2 assays are shown (ProQinase, Freiburg).  
Compound 
VEGFR2 IC50  
radiometric 
VEGFR2 IC50  
non-radiometric 
 
55 
 
0.005 µM 
 
0.068 µM 
 
99 
 
4.6 µM 
 
87 µM 
 
57 
 
0.15 µM 
 
15 µM 
 
100 
 
45 µM 
 
> 100 µM 
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The diarylmaleimide 55 proved to be highly potent with an IC50 value of 0.005 µM in the 
radiometric and 0.068 µM in the non-radiometric VEGFR2 kinase assay. The less potent 
carbazole 57 showed IC50 values of 0.15 µM and 15 µM, respectively. The variation of the 
results between the two test systems is probably due to the different experimental settings. 
Besides the differences in the detection method, the complete VEGFR enzyme is utilized in 
the radiometric assay. In the non-radiometric assay, on the other hand, only the purified kinase 
domain is used. The differences of the IC50 values between 55 and its prodrug 99 were 
particularly profound, both in the radiometric and in the non-radiometric assay. The DMNB 
protected 99 showed a by a factor of 1000 diminished potency compared to the unprotected 
diarylmaleimide 55. The caged carbazole 100 was 300-fold less active than 57 in the 
radiometric assay and not active in the non-radiometric assay. 
Moreover, a selectivity profile over 79 kinases was recorded (chapter 5.4.3). The results are 
presented as a heatmap in Figure 56. The graphic shows that the diarylmaleimide 55 is more 
selective than its carbazole derivative 57. The most inhibited kinases of 55 were PIM3 (5% 
residual activity) resp. VEGFR (10%) and of 57 PIM3/1 (4% resp. 5%), GSK3b (5%), and 
HIPK2 (7%). VEGFR showed a residual activity of 37% when treated with 57. 
  
55 57 
Figure 56. Selectivity profile of diarylmaleimide 55 and carbazole 57 in a panel over 79 kinases. The 
inhibitory effect was tested at a concentration of 0.1 µM by determination of the residual kinase activity. In the 
presented heatmap the columns have been individually ranked from low (red) to high (blue) residual activity 
values. Details are shown in Supplementary Table 2 (Appendix). 
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Cellular assays 
The antiproliferative effects of the compounds were tested in cellular assays and it was 
explored if irradiation with UV light could restore the efficacy of the photo prodrugs (chapters 
5.4.4 and 5.4.5).123 
Due to the results of the enzymatic data, it was supposed that the caged prodrugs would be 
considerably less active in cellular assays compared to their parent compounds. To prove this 
hypothesis, the antiproliferative activities in cellular growth assays were examined using the 
VEGFR dependent PC3 cell line.124,125 Dose-response curves for the non-irradiated 
compounds are presented in Figure 57 (A). The diarylmaleimide 55 showed potent cytotoxic 
activity with a GI50 value of 6.4 μM. In contrast, its caged derivative 99 exhibited only low 
cell toxicity (GI50 not reached). The antiproliferative activity of the carbazole 57 was 
measured with a GI50 value of 0.24 μM, the considerably less active 100 with 35 μM. The 
marginal cytostatic effects of the caged probes at higher concentrations might again be caused 
by minor impurities of the unprotected derivatives in the samples or by off-target effects of 
the caged prodrugs. 
 
A   B   
 
 
 
  55 
  57 
  99 
100 
 
 
  55 + UV 
  57 + UV 
  99 + UV 
100 + UV 
w/o UV irradiation  with UV irradiation  
Figure 57. Activation of caged prodrugs in cell proliferation assays.123 (A) Dose-response curves of 
diarylmaleimide 55 resp. carbazole 57 and their corresponding DMNB caged prodrugs 99 resp. 100 were 
determined without UV irradiation. (B) Cells with the compounds were irradiated at 365 nm (1.8 W) for 5 min. 
After irradiation the caged derivatives showed similar dose-response curves or even increased effects in 
comparison to the parent compounds. GI50 = 50% growth inhibition; TGI = total growth inhibition; LC50 = 50% 
lethal concentration. (±SD, n=3) 
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The next question addressed was whether the antiproliferative activity of the caged inhibitors 
could be recovered by UV irradiation. The cell growth assays were repeated with irradiation 
of the compound treated cells at 365 nm (1.8 W, 5 min). The dose-response curves are 
presented in Figure 57 (B). In control experiments was shown that the used dosage of UV 
irradiation was well-tolerated by the cells. After irradiation, the prodrugs showed comparable 
or even increased efficacy compared to that of the unprotected compounds. The GI50 value of 
the diarylmaleimide 55 (2.9 μM) was very similar to that without irradiation (6.4 μM). A 
strongly increased antiproliferative effect could be recognized for its prodrug 99 (GI50 value 
0.39 μM). Surprisingly, the prodrug was even 10-fold more active after irradiation than its 
parent drug. Synergistic effects of the released inhibitor, the irradiation and the cleaved 
protecting group can be discussed. The carbazole 57 and its prodrug 100 showed similar 
results after irradiation (GI50 values 0.13 μM resp. 0.22 μM). In conclusion, irradiation of the 
prodrugs 99 and 100 restored the activity of the corresponding diarylmaleimide (55) and 
carbazole (57), respectively. 
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3.3 PHOTOSWITCHABLE AXITINIB 
3.3.1 Molecular Modeling 
The impact of the E-Z isomerization of axitinib on its molecular binding mode was 
investigated by molecular modeling (chapter 5.1). In Figure 58 (left) the ligand-protein 
interactions of the crystallized complex of (E)-axitinib (19) in the ATP pocket of VEGFR2 
(pdb 4AG8)67 are presented. Figure 59 shows the corresponding 2D ligand-interaction 
diagram. Superposition of (Z)-axitinib (19a) on (E)-axitinib resulted in significant sterical 
clashes with the backbone of the protein (Figure 58, right). Similarly, when (Z)-axitinib was 
docked in the active site of VEGFR2 no plausible binding mode could be found (data not 
shown).89 
 
Figure 58. Molecular binding mode of (E)-axitinib (19) in the active site of VEGFR2 and superposition of 
(Z)-axitinib (19a). Left: Binding mode of (E)-axitinib in VEGFR2 determined by X-ray analysis (pdb 4AG8).67 
Black dotted lines represent H-bonds between the ligand and the backbone of the protein. Right: (Z)-Axitinib 
modeled in the binding pocket maintaining the core binding mode of (E)-axitinib. Red dotted lines indicate 
predicted sterical clashes between the pyridine moiety of the (Z)-isomer and the protein backbone of the hinge 
loop in the target kinase. 
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Figure 59. Ligand-interaction diagram of (E)-axitinib (19) in the active site of VEGFR2 (pdb 4AG867). Key 
ligand-protein interactions are shown. 
The interactions were additionally modeled between both axitinib stereoisomers and VEGFR1 
(pdb 3HNG)126, PDGFRβ (DFG in/out, homology model)127 resp. cKIT (pdb 3G0E, 
4HVS)128,129. No plausible docking modes could again be found for the (Z)-isomer in contrast 
to the (E)-isomer.89 It was thus postulated that (Z)-axitinib should not be able to inhibit these 
kinases. 
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3.3.2 Synthesis and Tautomerism 
Encouraged by the molecular modeling data, a DMSO solution of commercially available 
(E)-axitinib was irradiated at 365 nm (10 min, 5.4 W) to produce the (Z)-isomer (chapter 
5.3.10). The resulting mixture of both isomers could then be separated by flash 
chromatography (chapter 5.3.2). NMR analysis of the separated (Z)-isomer surprisingly 
revealed a mixed spectrum (see Figure 60 and 61, chapter 5.3.6), indicating the existence of 
two different (Z)-axitinib species (19a and 19b) at a ratio of 7:3. Both spectra sets showed the 
characteristic smaller H-C=C-H coupling constant (12.8 Hz) of a (Z)-isomer compared to the 
(E)-isomer (16.4 Hz). Since indazoles are known to show annular NH-tautomerism130,131, it 
was hypothesized that two (Z)-axitinib tautomers were formed, namely the indazole 1H- and 
the 2H-tautomer (Figure 62).89 
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Figure 60. 1H NMR spectrum (300 MHz, DMSO-d6, 294 K) and detailed view of the aromatic region of 
(Z)-axitinib (7:3 mixture of 1H- and 2H-tautomer).89 
~ 70% (Z)-axitinib (1H-tautomer)
 
~ 30% (Z)-axitinib (2H-tautomer)
 
Figure 61. Signals of aromatic hydrocarbons in a 1H-1H COSY spectrum and signal assignment to the 
1H-and 2H-tautomer of (Z)-axitinib.89 
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Figure 62. Photoinduced E-Z isomerization of axitinib and formation of 1H- and 2H-indazole annular 
tautomers.89 
 
X-ray crystallography (chapter 5.3.9) indeed proved the existence of the 2H-tautomer (Figure 
63) which is stabilized by an intramolecular hydrogen bond between the indazole 2N-H and 
the pyridine nitrogen.89 In solution, however, two tautomers were existent. The term (Z)-
axitinib describes in the following the mixture of both tautomers 19a and 19b. 
 
 
Figure 63. X-ray crystal structure of the 2H-tautomer of (Z)-axitinib (19b, CCDC 1419085).89 In the solid 
state only the 2H-tautomer was detected by X-ray analysis, which is stabilized by an intramolecular H-bond 
between the indazole 2N-H and the pyridine nitrogen. In DMSO solution, a 7:3 ratio of the 1H- to the 2H-
tautomer was contrarily observed (based on NMR analysis). 
  
  
83  
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Results and Discussion 
3.3.3 Photochemical Characterization 
With both the separated (E)- and the (Z)-isomer in hand, the light induced E-Z isomerization 
was further examined depending on the irradiated wavelength. According to the respective 
UV/vis spectra (Figure 64, chapter 5.2.1), (E)-axitinib possessed an absorption maximum at 
330 nm. In the range between 380 and 410 nm only (Z)-axitinib showed light absorbance.89 
 
 
Figure 64. UV/vis absorption spectra of (E)-axitinib (solid line) and (Z)-axitinib (dashed line) solutions 
(0.02 mM in methanol).89 Wavelengths of the used LED sources (365 resp. 385 nm) are illustrated as grey bars. 
 
LEDs with emission wavelengths of 365 resp. 385 nm were chosen for the irradiation 
experiments because of their high intensity and commercial availability. Figure 65 shows the 
photoisomerization of (E)-axitinib resp. (Z)-axitinib solutions after irradiation with these two 
wavelengths (chapter 5.2.4). The conversion was monitored by HPLC analysis (chapter 
5.3.4). LC-MS was used besides retention time for proof of identity (chapter 5.3.7). Within a 
few minutes, irradiation at 365 nm resulted in a photostationary state (PSS) of 35-45% 
(E)-axitinib and 55-65% (Z)-axitinib. On the other hand, irradiation at 385 nm afforded 85% 
(E)-axitinib and 15% (Z)-axitinib.89 
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Figure 65. Photoisomerization of (E)-axitinib and (Z)-axitinib.89 Irradiation of an (E)-axitinib solution (5 mM 
in DMSO) at (A) 365 nm resp. (B) 385 nm led to photoisomerization resulting in different photostationary states 
of (E)-axitinib (black squares) to its (Z)-isomer (grey diamonds) quantified time dependently by HPLC analysis. 
Irradiation of an equally concentrated (Z)-axitinib solution at (C) 365 nm resp. (D) 385 nm evolved similar 
ratios. 
 
Summing up, the PSS of both isomers could be shifted to either side depending on the 
irradiated wavelength, but a total conversion could not be achieved. In biological settings, 
however, there are typically much lower compound concentration levels compared to the 
analytical situation described above. After UV triggered activation of the (Z)-isomer, 
(E)-axitinib might thus be tightly bound by the target and therefore withdrawn from the 
chemical balance, enabling a more quantitative shift to the bioactive (E)-configuration. 
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3.3.4 Biological Evaluation 
To provide evidence for the hypothesis regarding different affinities of (E)-axitinib and 
(Z)-axitinib towards relevant kinases, the biological activities of both isomers were compared 
using in vitro assays. Inhibition curves were therefore determined in both a radiometric and a 
non-radiometric enzymatic VEGFR2 assay (Figure 66, chapter 5.4.2). The inhibitory effect of 
(E)-axitinib and (Z)-axitinib was additionally tested in a photometric PDGFRβ assay (Figure 
67).132 The IC50 values of both stereoisomers toward these target kinases are shown in Table 
7. In conclusion, (E)-axitinib was at least 30-fold more potent toward VEGFR2 than 
(Z)-axitinib in the radiometric 33PanQinase® assay and 2 to 3-fold more active in the non-
radiometric ADP-Glo™ assay. Regarding PDGFRβ, (E)-axitinib was about 20-fold more 
potent than its (Z)-isomer. In line with the modeling data it could hence be demonstrated by 
these enzymatic test systems that (Z)-axitinib is biologically less active than (E)-axitinib. 
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Figure 66. Inhibition curves of (E)-axitinib and (Z)-axitinib for VEGFR2 kinase.122 (E)-Axitinib was at least 
30-fold more potent toward VEGFR2 than (Z)-axitinib in the radiometric 33PanQinase® assay and 2 to 3-fold 
more active in the non-radiometric ADP-Glo™ assay (ProQinase, Freiburg). 
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Figure 67. Inhibition curves of (E)-axitinib, (Z)-axitinib and the reference inhibitor CP-673451 for 
PDGFRβ kinase.132 (E)-Axitinib was about 20-fold more potent (IC50 30 nM) than (Z)-axitinib (IC50 600 nM). 
The experimental compound CP-673451 was used as a control and showed an IC50 of 1 nM which is in good 
accordance with the literature.133 (±SD, n=3) 
 
Table 7. Inhibitory effect of (E)-axitinib and (Z)-axitinib in enzymatic assays.122,132 
Inhibitor 
VEGFR2 IC50  
(radiometric) 
VEGFR2 IC50 
 (non-radiometric) 
PDGFRβ IC50 
 
(E)-axitinib < 1 nM 25 nM 30 nM 
(Z)-axitinib 29 nM 65 nM 600 nM 
 
Since the biological activities were significantly different regarding PDGFRβ the compounds 
were furthermore tested on PDGFRβ dependent NIH/3T3 cells (chapters 5.4.4 and 
5.4.5).124,125 In non-irradiated cells all three compounds herein showed cytotoxic effects above 
concentrations of 10 µM. (E)-Axitinib appeared to be slightly more potent compared to 
(Z)-axitinib (Figure 68). The control data using only UV irradiation demonstrated, however, 
that the NIH/3T3 cells did not tolerate UV irradiation.123 In order to examine if (Z)-axitinib 
was converted to (E)-axitinib in the aqueous environment of the cellular assays, the stability 
of the (Z)-stereoisomer was tested under similar conditions (chapter 5.4.6). Herein, no 
significant conversion could be detected (Figure 69). 
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Figure 68. Anti-proliferative effect of (E)-axitinib, (Z)-axitinib and the reference inhibitor imatinib on 
PDGFR dependent NIH/3T3 cells.123 Dose-response curves of (E)-axitinib, (Z)-axitinib and imatinib in 
NIH/3T3 cell proliferative assays (without irradiation) measured via the resazurin assay. Imatinib was used as a 
control. NIH/3T3 cells did not tolerate UV irradiation (data not shown). (±SD, n=3) 
 
A  MEM  B MEM with 10% FBS  
  
Figure 69. Stability of (Z)-axitinib under assay conditions.132 Stability of (Z)-axitinib in minimum essential 
medium (MEM) at 37 °C without (A) and with (B) fetal bovine serum (FBS). Concentrations were monitored 
time dependently by HPLC analysis. 
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The impact of both isomers on PDGFRβ signaling in vitro was consequently studied in 
greater detail using NIH/3T3 cells without UV irradiation. Western blot analyses herein 
showed the inhibition of the phosphorylation of PDGFRβ and its downstream kinases AKT 
and ERK, respectively (Figure 70, chapter 5.4.7). The comparison between the impact of both 
axitinib stereoisomers illustrates that the phosphorylation of PDGFRβ was slightly less 
inhibited by (Z)-axitinib compared to (E)-axitinib at 0.01 µM. More clearly, AKT and ERK 
phosphorylation was effectively blocked by (E)-axitinib at 0.01 µM whereas these kinases 
were still phosphorylated at (Z)-axitinib concentrations of 0.01 µM (p-PDGFRβ) and 0.1 µM 
(p-AKT, p-ERK).132 These results were thus in line with the enzymatic data. 
  
Figure 70. Inhibitory effect of (E)-axitinib and (Z)-axitinib on PDGFRβ signaling in western blot 
analyses.132 Concentrations are indicated in µM. t = total; p = phosphorylated. 
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It was next investigated if these findings could be transferred to cellular settings using 
VEGFR dependent PC3 cells134 (chapters 5.4.4 and 5.4.5). Dose-response curves were 
measured without and with UV irradiation (Figure 71). As expected, the reference inhibitor 
imatinib showed cytostatic effects above 10 µM and cytotoxic effects above 100 µM, 
respectively. At concentrations above 10 µM without irradiation, (Z)-axitinib appeared to be as 
cytostatic as (E)-axitinib. After irradiation of the cells at 365 nm (5 min, 1.8 W) both axitinib 
isomers appeared to have gained potency. Surprisingly, (Z)-axitinib was even more cytotoxic 
than its (E)-isomer. UV irradiation showed a smaller effect on the dose-response curve of 
imatinib.123 Although the PC3 cells seemed to tolerate the irradiation well, cell stress based on 
the UV application might have had an effect on their viability resp. the permeability of 
membranes and therefore modulating the bioavailability of the tested compounds. 
 
A
     
w/o irradiation B with irradiation 
 
 
Figure 71. Anti-proliferative effect of (E)-axitinib, (Z)-axitinib and the reference inhibitor imatinib on 
VEGFR dependent PC3 cells.123 The anti-proliferative effect of (E)-axitinib and (Z)-axitinib on VEGFR 
dependent PC3 cells was demonstrated via resazurin assay. Imatinib was used as a control. (A) Cells were not 
irradiated. (B) Cells were irradiated at 365 nm (1.8 W) for 5 min. (±SD, n=3) 
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It was thus hypothesized that, in these cells, (Z)-axitinib might hit a target different from the 
kinases that had been investigated so far. To address this question, a selectivity profile in a 
panel of 300 kinases was determined for both axitinib stereoisomers at a concentration of 
1 µM (chapter 5.4.3). The results are presented as a heat map in Figure 72. Both (E)-axitinib 
and (Z)-axitinib showed a quite similar profile and no additional kinase target(s) could be 
identified for (Z)-axitinib.  
 
Figure 72. Selectivity profiles of (E)- and (Z)-axitinib. The assay concentration was 1 µM in a panel of 300 
kinases. The inhibitory effect of (E)-axitinib and (Z)-axitinib was tested by determination of the residual kinase 
activity. In the presented heatmap the color code is ranging from grey (low residual activity) to white (high 
residual activity. Details are shown in Supplementary Table 3 (Appendix). 
Residual activity values of exemplary target receptor tyrosine kinases of (E)-axitinib are 
shown in Table 1. (E)-Axitinib seems again to block these kinases more effectively than (Z)-
axitinib even though the differences are not significant. 
Table 8. Inhibitory effect of (E)-axitinib and (Z)-axitinib toward selected receptor tyrosine kinases. The 
residual kinase activity was measured at a compound concentration of 1 µM. 
Residual activity (%) VEGFR1 VEGFR2 PDGFRα PDGFRβ cKIT 
(E)-axitinib 4 0 -4 1 6 
(Z)-axitinib 8 1 2 4 9 
 
Due to the high potency of axitinib, the lack of differentiation might be caused by a saturation 
of the system. With regard to the western blot analysis (Figure 70) a concentration of 0.01 µM 
might allow an enhanced distinction between the effects of both isomers und should therefore 
be considered for further testing. 
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4. CONCLUSION 
4.1 CAGED VEMURAFENIB 
This project included the successful design, synthesis, photochemical, and in vitro 
characterization of novel caged prodrugs of the kinase inhibitor vemurafenib (44). Molecular 
modeling studies predicted the loss of inhibitory potency by blocking a pharmacophore 
moiety with a PPG. UV stability of the kinase inhibitor was subsequently confirmed. The next 
goal of this study was to identify the minimal structural requirement for light-induced 
deprotection of vemurafenib’s hinge binder. In conclusion, DMNB protected 7-azaindole (69) 
could not be cleaved and DMNB protected 3-acetyl-7azaindole (70) only at slow reaction 
rates. 3-Benzoyl-7-azaindole (67) was therefore considered to be the crucial fragment for 
deprotection of azaindole derivatives and was consequently used as a dummy compound for 
the following experiments.  
The subsequent goal was to compare various classes of PPGs with regard to chemical 
accessibility and photochemical release rates. Among the tested classes only o-nitrobenzyl 
protection groups released the utilized N-heterocycle at applicable reaction rates and with few 
side products. The phenacyl, coumarin, and desyl group did in contrast not produce 
acceptable results. These groups were thus not further investigated. No significant differences 
regarding photocharacteristics could be detected between the different tested o-nitrobenzyl 
derivatives. DMNB and DMNPE were therefore chosen for photoprotection of vemurafenib 
and the corresponding prodrugs were synthesized. 
After photoactivation of the caged inhibitors had been confirmed, the compounds were tested 
in different in vitro assays. It was demonstrated that caging significantly diminishes the 
inhibitory efficacy and promiscuity of vemurafenib. In particular, azaindole protected 
compound 58 revealed hardly measurable activity even at high concentrations, both in 
biochemical and cellular assays. The nonspecific interactions toward off-target kinases could 
be drastically reduced by protecting the hinge binder, the azaindole moiety. It was finally 
demonstrated that UV irradiation at 365 nm restored the inhibitory potency in proliferative 
and signal transduction assays. Cellular growth assays verified that the applied UV dosage 
was well-tolerated by the melanoma cells. 
  
 
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Caged Vemurafenib 92 
The herein presented caged compounds are the first photoactivatable derivatives of an 
approved small-molecule kinase inhibitor providing an exciting option for novel therapeutic 
applications. Targeted irradiation might allow a controlled, high-concentrated release of active 
compound selectively in disease-afflicted tissues. With this approach, systemic side effects 
might be prevented and acquired resistances reduced.  
The implementation of light for the release of therapeutically active substances may be 
restricted due to low tissue penetration. Several solutions for this problem are conceivable: the 
required light could be transmitted via optical fibers or endoscopic probes. Tissues could 
moreover be irradiated during surgery. By variation of the PPG the required wavelength can 
be adjusted. The deepest permeation into biological tissue can be achieved by wavelengths 
around 800 nm (biological optical window). Hence, two-photon excitation might be an 
interesting approach.10 
For future therapeutic applications, biological effects of the cleaved PPG and the cyclic 
benzisoxazolidine intermediate should be thoroughly explored. UV irradiation of the herein 
utilized o-nitrobenzylic PPGs generates potentially toxic nitroso compounds. In the presented 
cellular proliferation assays, the released 4,5-dimethoxy-2-nitroso-benzaldehyde (the cleaved 
DMNB) showed intrinsic toxicity only at concentrations above 10 μM. This might not be 
critical because the caged compounds could be applied at much lower concentrations. The 
caged vemurafenib derivatives exhibit antiproliferative effects already at concentrations 
around 0.1 μM. Therefore, there might still be a wide therapeutic window for possible 
applications. Due to its short half-life, the biological effect of the cyclic intermediate 93 could 
not be explored in the described assays. Further investigations in cellular assays and animal 
studies could reveal the effects of cleaved PPGs on biological tissue more thoroughly. 
In conclusion, novel caged derivatives of the approved kinase inhibitor vemurafenib were 
created and it was demonstrated that these prodrugs can be photoactivated in vitro. The 
presented strategy involved (1) the determination of suitable pharmacophore moieties, (2) UV 
stability testing of the active inhibitor, (3) synthesis of caged prodrugs, (4) characterization of 
photoactivation, and (5) evaluation of the photoactivation in vitro. 
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This approach can also be transferred to other (kinase) inhibitors and PPGs. Caged kinase 
inhibitors represent a powerful biochemical tool for studying the kinetics and regulation of 
phosphorylation processes in signal transduction cascades. On the other hand, caged kinase 
inhibitors create new possibilities for therapeutic applications. Profound research regarding 
the stability, bioavailability, metabolism, and toxicity of the caged kinase inhibitors is required 
to promote their medical applicability. 
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4.2 CAGED DIARYLMALEIMIDES AND CARBAZOLE 
In this study, the design, synthesis, photochemical, and biochemical evaluation of caged 
prodrugs of two potent, experimental VEGFR kinase inhibitors was demonstrated. Molecular 
modeling studies revealed that the imide function of the presented diarylmaleimide resp. 
carbazole acts as the hinge binding moiety. Protection with a PPG was therefore a promising 
caging approach in order to diminish the inhibitors’ efficacies. 
Examination of the UV stability indicated that irradiation of the diarylmaleimide 55 triggered 
the formation of a photocyclized product, namely the intermediate 56 of the reaction from the 
diarylmaleimide to the carbazole (57). Since this compound could not be isolated, an in situ 
formation was an interesting approach. 
The compounds were tested in a VEGFR2 kinase assay. It could be demonstrated that DMNB 
caging significantly diminished the inhibitory efficacy of both inhibitors. In cell proliferation 
assays it was further proved that UV irradiation at 365 nm restored the inhibitory activity of 
both prodrugs 99 and 100, respectively. In the case of the caged diarylmaleimide (99), the 
antiproliferative effect of the irradiated prodrug was interestingly even increased by a factor 
of 10 compared to the parent compound. A synergistic effect of the released inhibitor, the 
cleaved protecting group, formation of the intermediate, and influence of the irradiation on the 
cells can therefore be discussed. 
Notably, irradiation of the unprotected diarylmaleimide did not have an impact on the dose-
response curve. Thus, the anticipated formation of the intermediate did not lead to an 
increased biological effect. 
In conclusion, the herein presented VEGFR inhibitor prodrugs can serve as novel 
pharmacological tools in a variety of experiments. Is has to be mentioned though that 
irradiation of the diarylmaleimide prodrugs does not provide a clean photoreaction. The 
formation of the cyclized 56 has to be considered. Its biological effect should therefore be 
investigated in further detail. 
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4.3 PHOTOSWITCHABLE AXITINIB 
The aim of this study was to examine axitinib’s applicability as a photoswitchable kinase 
inhibitor. 
According to the molecular modeling studies, the (Z)-stereoisomer should significantly less 
inhibit target kinases of (E)-axitinib because of sterical hindrance. The (Z)-isomer was then 
afforded by irradiation of a DMSO solution of the (E)-isomer and subsequent separation by 
flash chromatography. NMR studies and X-ray crystallography proved that due to annular 
NH-tautomerism of the indazole two tautomers were formed. Photochemical characterization 
revealed that both stereoisomers showed quite divergent UV/vis absorption spectra and that 
the PSS of both isomers could be shifted to either side depending on the irradiated 
wavelength. Photoswitching from one stereoisomer to the other by irradiation with UV light 
(365 and 385 nm) was thus possible in solution although no complete conversion could be 
achieved. 
Enzymatic in vitro VEGFR2 and PDGFRβ assays using the isolated stereoisomers actually 
proved that the potency of (Z)-axitinib could be diminished up to 30-fold compared to 
(E)-axitinib. These results also translated into cellular settings as demonstrated by western 
blot based signal transduction analysis using PDGFRβ dependent NIH/3T3 cells. Herein, the 
respective inhibitory effects of both axitinib stereoisomers were in a similar range as 
compared to the enzymatic level. 
Cell proliferation assays using VEGFR2 dependent PC3 cells, however, demonstrated similar 
inhibitory effects for both axitinib stereoisomers. Further investigations, therefore, have to be 
made to understand the biological activities of (E)- and (Z)-axitinib in more detail. 
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5. EXPERIMENTAL 
5.1 MOLECULAR MODELING 
Molecular modeling was performed on a DELL 8 core system. For visualization Maestro, 
version 9.7, Schrödinger, LLC, New York, NY, 2014 was used. Protein crystal structures were 
prepared prior to docking by the Protein Preparation Wizard135 utilizing the following 
programs: Epik136, version 2.7, 2013; Impact, version 6.2, 2014; Prime137,138, version 3.4, 
2014. Thus, the X-ray crystal structure refinement process included addition of hydrogen 
atoms, optimization of hydrogen bonds, and removal of atomic clashes. Default settings were 
used. Missing side chains and loops were filled in with Prime. Furthermore, 
selenomethionines were converted to methionines and water molecules were deleted. 
Additionally, ligands were prepared in order to create energetically minimized 3D geometries 
and assign proper bond orders (MacroModel, version 10.3, 2014). Accessible tautomer and 
ionization states were calculated prior to screening (LigPrep, version 2.9, 2014). To generate 
bioactive conformers a conformational search method was used (ConfGen139, version 2.7, 
2014). Receptor grid generation was performed by Glide140,141, version 6.2, 2014. For ligand 
docking and screening the Glide SP workflow was used. Energetically minimized ligand 
conformations were docked into the active site of the protein; possible binding poses were 
determined and subsequently ranked based on their calculated binding affinities. 
Furthermore, caged ligands were investigated regarding their interactions within the ATP 
binding pocket. The structures were therefore superimposed with crystallized or modeled 
inhibitors by the flexible ligand alignment function. Afterwards, steric hindrance was 
determined by calculation of ligand-protein contacts. Ugly contacts with a contact cutoff ratio 
< 0.5 were indicated by red dashed lines. The cutoff ratio was calculated by Maestro based on 
the following formula: C = D1,2 / (R1+R2) where D1,2 is the distance between the two atomic 
centers and where R1 resp. R2 are the radii of the atomic centers. C increases monotonically 
for each contact type, that is C(ugly) < C(bad) < C(good). 
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5.2 PHOTOEXPERIMENTS 
5.2.1 UV/vis Absorption Spectra 
Spectra were recorded on UV/vis spectrophotometer Varian Cary® 50 Scan, Agilent 
Technologies. UV/vis absorbance was measured in methanol, DMSO or PBS buffer with 10% 
DMSO. Concentration is either indicated or compounds were solved and diluted until peak 
absorbance was in a range of 0.6 to 0.8. Subsequently, graphs were normalized on basis of 
area under the curve between 260 and 320 nm. 
5.2.2 UV Stability 
Vemurafenib 
Vemurafenib (44) was dissolved in DMSO (10 mM) resp. in PBS buffer with 10% DMSO at 
0.01 mM and irradiated at 365 nm (LED source: 12 x Nichia NCSU033B, Sahlmann 
Photochemical Solutions, 100%, 5.4 W) up to 20 min. Aliquots were diluted 1:10 resp. 1:1 
with methanol and analyzed by HPLC. Additional to HPLC analysis LC-MS was used to 
confirm compound identity. 
Diarylmaleimide and carbazole 
Compounds 55 and 57 were dissolved in DMSO (1 mM) and irradiated at 365 nm (LED 
source: 12 x Nichia NCSU033B, Sahlmann Photochemical Solutions, 100%, 5.4 W) up to 
10 min. Aliquots were diluted 1:10 with methanol and analyzed by HPLC. Additional to 
HPLC analysis LC-MS was used to confirm compound identity. 
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5.2.3 Ph toactivation 
Caged vemurafenib 
Compounds 58, 59, and 60 were dissolved in DMSO (1 mM) resp. in PBS buffer with 10% 
DMSO (0.01 mM). The solutions were irradiated at 365 nm (LED source: 12 x Nichia 
NCSU033B, Sahlmann Photochemical Solutions, 100%, 5.4 W) up to 10 min. After 0.25, 0.5, 
0.75, 1, 2, 3, 5 and 10 min of irradiation samples were taken. Aliquots were diluted 1:5 resp. 
1:1 with methanol and subsequently analyzed by HPLC. Additional to retention time LC-MS 
was used to proof identity. 
Caged diarylmaleimides and carbazole 
Compounds 98, 99, and 100 were dissolved in DMSO (1 mM) and the solutions were 
irradiated at 365 nm (LED source: 12 x Nichia NCSU033B, Sahlmann Photochemical 
Solutions, 100%, 5.4 W) up to 10 min. After 0.25, 0.5, 0.75, 1, 2, 3, 5 and 10 min of 
irradiation samples were taken. Aliquots were diluted 1:5 resp. 1:1 with methanol and 
subsequently analyzed by HPLC. Additional to retention time LC-MS was used to proof 
identity. 
5.2.4 Photoswitching Experiments 
Photoswitchable axitinib 
Compounds 19 and 19a/b were dissolved in DMSO (5 mM) and irradiated either at 365 nm 
(LED source: 12 x Nichia NCSU033B, Sahlmann Photochemical Solutions, 100%, 5.4 W) or 
at 385 nm (LED source: 3 x Nichia NCSU034A, Sahlmann Photochemical Solutions, 1.2 W) 
up to 15 min. After 0, 1, 2, 3, 4, 5, 7.5, 10, 12.5 and 15 min aliquots were 1:5 diluted with 
methanol and subsequently analyzed by HPLC. Additional to retention time LC-MS was used 
to proof identity. 
Experiments have been carried out by Jantje Weber.89 
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5.3 CHEMICAL SYNTHESIS AND CHARACTERIZATION 
5.3.1 Reagents and Solvents 
All reagents and solvents were obtained from the following commercial sources: abcr GmbH, 
Fisher Scientific GmbH/Acros, Sigma-Aldrich Chemie or VWR International GmbH. 
5.3.2 Flash Chromatography 
Column chromatography was performed on a LaFlash system (VWR) using silica gel 
columns (PF-30SIHP, 30 µm, 40 g, puriFlash) or RP18 columns (PF-15C18HP, 15 µm, 55 g, 
puriFlash). The crude product was loaded on Merck silica gel 60 (15-40 µm). 
5.3.3 TLC 
The progress of reactions was monitored by thin-layer chromatography (TLC) utilizing silica 
gel polyester sheets (SIL G/UV254, 0.2 mm, Polygram®, Macherey-Nagel). 
5.3.4 HPLC 
High-performance liquid chromatography (HPLC) analyses were performed on a Hewlett 
Packard 1050 Series. As column either a Phenomenex Kinetex™ C8, 5 µm (4.6 mm × 
150 mm) or an Agilent ZORBAX® Eclipse XDB-C8, 5 μm (4.6 mm × 150 mm) was used. 
Injection volume of the compound solutions was 20 µL resp. 30 µL. As mobile phase (flow 
rate 1.5 mL/min) served a gradient of KH2PO4 buffer (10 mM, pH 2.3) and methanol over 
14 min resp. 16 min. The detection wavelength was adapted to the according UV/vis 
absorption spectra. All key compounds submitted to biological assays were proven by this 
method to show ≥ 98% purity. 
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5.3.5 Melting Point 
Melting points were determined on a Stuart Scientific SMP3 apparatus and are uncorrected. 
5.3.6 NMR 
1H, 13C, 15N, and 19F NMR spectra were recorded on a Bruker Avance III 300 instrument at 
294 K resp. 300 K with a multinuclear probe head using the manufacturer’s pulse programs. 
Spectra were referenced to internal DMSO-d5/CHCl3 (
1H NMR: δ 2.50/7.26 ppm), internal 
DMSO-d6/CDCl3 (
13C NMR: δ 39.5/77.2 ppm), external CFCl3 (
19F NMR: δ 0.0 ppm) resp. 
external nitromethane (15N NMR: δ 0.0 ppm) which was corrected to ammonia scale by 
addition of 381.6 ppm. The following NMR abbreviations are used: b (broad), s (singlet), d 
(doublet), t (triplet), m (unresolved multiplet). NMR assignments were determined by analysis 
of multidimensional spectra (H,H COSY, HSQC, HMBC). 
NMR spectroscopy was performed by Dr. Ulrich Girreser and his NMR team. 
5.3.7 LC-MS 
LC-MS samples were chromatographically separated utilizing an Agilent 1100 HPLC system 
consisting of a thermostated autosampler, diode array detection, and an Agilent ZORBAX® 
Eclipse XDB-C8, 5 μm (4.6 mm × 150 mm). Elution was achieved with a solvent gradient 
system of water and acetonitrile, with 0.1% of acetic acid and a flow rate of 1 mL/min. The 
eluent flow was splitted to the mass spectrometer. Mass spectrometry was carried out using a 
Bruker Esquire ~LC instrument with electrospray ionization (ESI) operating in the positive 
ion mode. Following parameters were used: drying gas nitrogen 8 L/min, nebulizer 35 psi, dry 
gas heating 350 °C, HV capillary 4000 V, HV EndPlate offset -500 V. 
LC-MS analyses were performed by Dr. Ulrich Girreser and Sven Wichmann. 
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5.3.8 HRMS 
High resolution mass spectra (HRMS) were recorded on a Finnigan MAT 8200 mass 
spectrometer with electron ionization (EI). 
HRMS analyses were performed at the Institute of Organic Chemistry, Christian Albrechts 
University (Kiel, Germany). 
5.3.9 X-ray Crystallography 
X-ray crystal structure analysis was performed on a Stoe IPDS 2T with Cu / Mo-X ray tubes 
and Oxford Cryostream. 
X-ray analyses were performed by Dr. Dieter Schollmeyer at the Institute of Organic 
Chemistry, Johannes Gutenberg University (Mainz, Germany). 
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5.3.10   Chemical Synthesis 
Caged vemurafenib 
Chemical synthesis and characterization of the following compounds has also been described 
in 115. 
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Phenyl-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (67) 
RH_038 
C14H10N2O (Mr 222.24) 
Synthesis was performed by Martin Schütt. 
AlCl3 (42 mmol, 5.6 g) was suspended in DCM (150 mL) and 7-azaindole (8.4 mmol, 1.0 g) 
was added portionwise. Subsequently, the reaction mixture was stirred for 1 h at room 
temperature. Benzoyl chloride (42 mmol, 4.9 mL) was added dropwise and the solution was 
stirred for another 8 h at room temperature. Afterwards, methanol (20 mL) was used to 
quench the reaction. After evaporation of the solvent, the crude product was purified by flash 
silica gel chromatography with a gradient of petroleum ether and ethyl acetate to afford light 
pink crystals (6.7 mmol, 1.5 g, 80%). Purity (HPLC) 95%; m.p. 189 °C; 1H NMR (300 MHz, 
CDCl3): δ 7.30 (dd, 
3J = 7.9 Hz, 3J = 4.7 Hz, 1H), 7.52-7.61 (m, 2H), 7.60-7.65 (m, 1H), 7.81-
7.84 (m, 2H), 8.09 (s, 1H), 8.34 (dd, 3J = 4.7 Hz, 4J = 1.7 Hz, 1H), 8.54 (dd, 3J = 7.9 Hz, 4J = 
1.7 Hz, 1H), 12.65 (bs, 1H); 13C NMR (75 MHz, CDCl3): δ 113.6, 118.2, 118.7, 128.5, 129.8, 
131.4, 135.8, 139.6, 144.6, 149.1, 189.8. 
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1-(4,5-Dimethoxy-2-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridine (69) 
RH_035 
C16H15N3O4 (Mr 313.31) 
Synthesis was performed by Martin Schütt. 
7-Azaindole (0.5 mmol, 60 mg), 4,5-dimethoxy-2-nitrobenzyl bromide (0.75 mmol, 207 mg) 
and Li2CO3 (2.0 mmol, 150 mg) were dissolved in DMF (20 mL) and the reaction mixture 
stirred for 18 h at room temperature. After evaporation of the solvent, the syrup-like crude 
product was washed with ice water. This procedure was repeated twice. The residue was 
dissolved in ethyl acetate, dried over Na2SO4, filtered and concentrated to give a bright yellow 
solid (0.32 mmol, 100 mg, 64%). Purity (HPLC) > 98%; m.p. 121 °C; 1H NMR (300 MHz, 
CDCl3): δ 3.64 (s, 3H), 3.93 (s, 3H), 6.34 (s, 2H), 6.72 (d, 
3J = 2.7 Hz, 1 H), 6.84 (bs, 1H), 
6.92 (t, 3J = 6.8 Hz, 1H), 7.71 (s, 1H), 7.80 (d, 3J = 6.3 Hz, 1H), 7.90 (d, 3J = 2.7 Hz, 1H), 
8.17 (d, 3J = 7.3 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 52.9, 56.5, 56.6, 102.0, 108.4, 109.9, 
112.5, 125.3, 129.6, 130.8, 131.5, 140.7, 144.9, 148.5, 148.9, 153.9; LC-MS (ESI): 
m/z 314 [MH]+. 
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1-(1-(4,5-Dimethoxy-2-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)ethanone (70) 
RH_036 
C18H17N3O5 (Mr 355.34) 
Synthesis was performed by Martin Schütt. 
3-Acetyl-7-azaindole (1.0 mmol, 160 mg), 4,5-dimethoxy-2-nitrobenzyl bromide (1.5 mmol, 
414 mg) and Li2CO3 (4.0 mmol, 300 mg) were dissolved in DMF (40 mL) and the reaction 
mixture was stirred for 18 h at room temperature. After evaporation of the solvent, the crude 
product was washed with ice water (20 mL). The residue was dissolved in DCM, dried over 
Na2SO4, filtered and concentrated to give a pale yellow solid (0.47 mmol, 167 mg, 47%). 
Purity (HPLC) > 98%; m.p. 202 °C; 1H NMR (300 MHz, CDCl3): δ 2.56 (s, 3H), 3.69 (s, 3H), 
3.94 (s, 3H), 6.35 (s, 2H), 6.84 (s, 1H), 7.18 (dd, 3J = 7.5 Hz, 3J = 6.3 Hz, 1H), 7.72 (s, 1H), 
7.96 (dd, 3J = 6.3 Hz, 4J = 1.1 Hz, 1H), 8.43 (s, 1H), 8.96 (dd, 3J = 7.5 Hz, 4J = 1.1 Hz, 1H); 
13C NMR (75 MHz, CDCl3): δ 27.3, 53.1, 56.6, 56.6, 108.5, 112.6, 114.0, 118.7, 124.3, 128.4, 
131.5, 135.7, 140.8, 149.3, 150.8, 151.8, 153.9, 193.4; LC-MS (ESI): m/z 356 [MH]+. 
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 (1-(4,5-Dimethoxy-2-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(phenyl)methanone 
(71) 
RH_037 
C23H19N3O5 (Mr 417.41) 
Synthesis was performed by Martin Schütt. 
3-Benzoyl-7-azaindole (0.5 mmol, 111 mg), 4,5-dimethoxy-2-nitrobenzyl bromide 
(0.75 mmol, 207 mg) and Li2CO3 (2.0 mmol, 150 mg) were dissolved in DMF (15 mL) and 
stirred for 72 h at room temperature. After evaporation of the solvent, the crude product was 
washed with ice water (20 mL). The residue was dissolved in DCM, dried over Na2SO4, 
filtered and concentrated to give a pale yellow solid (0.21 mmol, 171 mg, 41%). Purity 
(HPLC) > 98%; m.p. 162 °C; 1H NMR (300 MHz, CDCl3): δ 3.67 (s, 3H), 3.92 (s, 3H), 5.93 
(s, 2H), 6.69 (s, 1H), 7.32 (dd, 3J = 7.9 Hz, 3J = 4.8 Hz, 1H), 7.46-7.52 (m, 2H), 7.53-7.60 (m, 
1H), 7.68 (s, 1H), 7.80-7.83 (m, 2H), 7.92 (s, 1H), 8.43 (dd, 3J = 4.7 Hz, 4J = 1.6 Hz, 1H), 
8.71 (dd, 3J = 7.9 Hz, 4J = 1.6 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 46.3, 56.4, 56.5, 108.4, 
112.1, 114.9, 119.2, 119.9, 127.0, 128.7, 128.8, 131.8, 131.9, 137.0, 139.8, 140.3, 144.9, 
148.3, 148.6, 153.8, 190.7; LC-MS (ESI): m/z 418 [MH]+. 
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1-(4,5-Dimethoxy-2-nitrophenyl)ethanone (73) 
RH_021 
C10H11NO5 (Mr 225.20) 
1-(3,4-Dimethoxyphenyl)ethanone (28 mmol, 5.0 g) was added portionwise to a cooled 
mixture of 65% nitric acid (230 mmol, 15.6 mL) and concentrated sulfuric acid (140 mmol, 
7.5 mL) at -5 °C. Afterwards, the reaction mixture was stirred for further 30 min at -5 °C. 
Next, the solution was poured onto ice, the precipitate was filtered off and washed with water. 
Recrystallization from methanol yielded yellow crystals (13 mmol, 3.0 g, 48%). Purity 
(HPLC) 86%; m.p. 137 °C; 1H NMR (300 MHz, DMSO-d6): δ 2.52 (s, 3H), 3.90 (s, 3H), 3.92 
(s, 3H), 7.21 (s, 1H), 7.63 (s, 1H); LC-MS (ESI): m/z 226 [MH]+. 
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1-(4,5-Dimethoxy-2-nitrophenyl)ethanol (74) 
RH_022 
C10H13NO5 (Mr 227.21) 
1-(4,5-Dimethoxy-2-nitrophenyl)ethanone (5.0 mmol, 1.13 g) was dissolved in boiling 
ethanol (15 mL) and NaBH4 (2.4 mmol, 0.09 g) was then added portionwise. After stirring 
under reflux for 1 h the reaction mixture was poured into ice water (50 mL) and acidified with 
hydrochloric acid (20%) to pH 6. The product was filtered off and dried in vacuo. 
Recrystallization from a mixture of cyclohexane and ethanol afforded red crystals (2.8 mmol, 
636 mg, 56%). Purity (HPLC) 94%; m.p. 124 °C; 1H NMR (300 MHz, CDCl3): δ 1.55 (d, 
3J = 
6.3 Hz, 3H), 2.15 (bs, 1H), 3.93 (s, 3H), 3.99 (s, 3H), 5.56 (q, 3J = 6.3 Hz, 1H), 7.30 (s, 1H), 
7.56 (s, 1H); LC-MS (ESI): m/z 210 [M-OH]+. 
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1-(1-Bromoethyl)-4,5-dimethoxy-2-nitrobenzene (75) 
RH_029 
C10H12BrNO4 (Mr 290.11) 
1-(4,5-Dimethoxy-2-nitrophenyl)ethanol (0.5 mmol, 114 mg) was dissolved in DCM (3 mL). 
Subsequently, PBr3 (1.5 mmol, 0.14 mL) was diluted with DCM (1 mL) and added dropwise 
under stirring at room temperature. The organic phase was washed with brine, dried over 
Na2SO4 and concentrated. Flash silica gel chromatography with a gradient of petroleum ether 
and ethyl acetate quantitatively afforded a brown-yellowish oil which was directly used for 
further synthesis. Purity (HPLC) > 98%; 1H NMR (300 MHz, CDCl3): δ 2.27 (d, 
3J = 6.8 Hz, 
3H), 3.94 (s, 3H), 4.01 (s, 3H), 6.81 (q, 3J = 6.8 Hz, 1H), 7.27 (s, 1H), 7.46 (s, 1H). 
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(1-(1-(4,5-Dimethoxy-2-nitrophenyl)ethyl)-1H-pyrrolo[2,3-b]pyridin-3-
yl)(phenyl)methanone (76) 
RH_044 
C24H21N3O5 (Mr 431.44) 
1-(4,5-Dimethoxy-2-nitrophenyl)ethanol (0.45 mmol, 102 mg) was dissolved in DCM (5 mL) 
and PBr3 (1.35 mmol, 0.13 mL), diluted with DCM (1 mL), was added dropwise at 0 °C. 
After stirring 15 min at room temperature the reaction mixture was washed with brine, dried 
over Na2SO4, filtered and used after evaporation of the solvent without further purification. 
The residue was dissolved in DMF (5 mL). 3-Benzoyl-7-azaindole (0.40 mmol, 89 mg) as 
well as K2CO3 (1.2 mmol, 166 mg) were added. The reaction mixture was stirred for 18 h at 
room temperature. After evaporation of the solvent, the yellowish oil was redissolved in ethyl 
acetate, washed with brine and dried over Na2SO4. The crude product was purified by flash 
silica gel chromatography with a gradient of petroleum ether and ethyl acetate to give a 
yellowish solid (0.07 mmol, 32 mg, 19%). Purity (HPLC) > 98%; m.p. 157 °C; 1H NMR 
(300 MHz, DMSO-d6): δ 2.07 (d, 
3J = 7.1 Hz, 3H), 3.77 (s, 3H), 3.82 (s, 3H), 6.71 (q, 3J = 
7.1 Hz, 1H), 7.05 (s, 1H), 7.30 (dd, 3J = 7.9 Hz, 3J = 4.7 Hz, 1H), 7.54 (s, 1H), 7.55-7.61 (m, 
2H), 7.64-7.69 (m, 1H), 7.86-7.89 (m, 2H), 8.30 (dd, 3J = 4.7 Hz, 4J = 1.6 Hz, 1H), 8.48 (dd, 
3J = 7.9 Hz, 4J = 1.6 Hz, 1H), 8.54 (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 19.6, 49.2, 56.1, 
56.2, 107.7, 109. 7, 113.1, 119.0, 119.3, 128.6, 128.8, 130.2, 130.5, 131.8, 135.3, 139.4, 
140.7, 144.6, 147.5, 147.8, 152.9, 189.6; LC-MS (ESI): m/z 432 [MH]+. 
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(1-(4,5-Dimethoxy-2-nitrophenyl)ethoxy)methyl)(methyl)sulfane (77) 
RH_023 
C12H17NO5S (Mr 287.33) 
1-(4,5-Dimethoxy-2-nitrophenyl)ethanol (2.2 mmol, 0.5 g) was dissolved in acetonitrile 
(15 mL). Dimethyl sulfide (19.3 mmol, 1.2 g) was added at 0 °C. Over a period of 20 min 
benzoyl peroxide (12.4 mmol, 6.0 g, stabilized with dicyclohexyl phthalate at a ratio of 1:1) 
was slowly added. Subsequently, the reaction mixture was stirred for 2 h. Purification by flash 
silica gel chromatography with a gradient of petroleum ether and ethyl acetate afforded a 
yellow solid (1.1 mmol, 330 mg, 52%). Purity (HPLC) 94%; m.p. 70 °C; 1H NMR (300 MHz, 
CDCl3): δ 1.55 (d, 
3J = 6.3 Hz, 3H), 2.15 (s, 3H), 3.93 (s, 3H), 3.99 (s, 3H), 4.33 (d, 2J = 
11.3 Hz, 1H), 4.60 (d, 2J = 11.3 Hz, 1H), 5.56 (q, 3J = 6.3 Hz, 1H), 7.30 (s, 1H), 7.56 (s, 1H); 
13C NMR (75 MHz, CDCl3): δ 14.36, 23.50, 56.49, 56.59, 70.48, 73.40, 107.76, 108.74, 
134.84, 140.67, 148.01, 153.98; LC-MS (ESI): m/z 210 [M-OCH2SCH3]
+. 
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1-(1-(Chloromethoxy)ethyl)-4,5-dimethoxy-2-nitrobenzene (78) 
RH_024 
C11H14ClNO5 (Mr 275.69) 
(1-(4,5-Dimethoxy-2-nitrophenyl)ethoxy)methyl)(methyl)sulfane (0.3 mmol, 100 mg) was 
dissolved in DCM (5 mL). Subsequently, sulfuryl chloride (1.2 mmol, 0.1 mL) was diluted 
with DCM (1 mL) and added dropwise at 0 °C to the reaction mixture. After stirring for 4 h at 
room temperature the reaction was completed. The solvent was removed under reduced 
pressure to give a yellow oil. The product was used without further purification. 1H NMR 
(300 MHz, CDCl3): δ 1.51 (d, 
3J = 6.3 Hz, 3H), 3.88 (s, 3H), 3.92 (s, 3H), 5.22 (d, 2J = 
5.9 Hz, 1H), 5.46 (d, 2J = 5.9 Hz, 1H), 5.59 (q, 3J = 6.3 Hz, 1H), 7.03 (s, 1H), 7.52 (s, 1H); 
13C NMR (75 MHz, CDCl3): δ 23.17, 56.50, 56.60, 73.46, 80.59, 107.77, 108.80, 133.44, 
140.31, 148.26, 153.91. 
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(1-((1-(4,5-Dimethoxy-2-nitrophenyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-
yl)(phenyl)methanone (79) 
RH_043 
C25H23N3O6 (Mr 461.47) 
(1-(4,5-Dimethoxy-2-nitrophenyl)ethoxy)methyl)(methyl)sulfane (0.44 mmol, 127 mg) was 
dissolved in DCM (5 mL). Subsequently, sulfuryl chloride (1.2 mmol, 0.1 mL) was diluted 
with DCM (1 mL) and added dropwise at 0 °C. After stirring at room temperature for 4 h, the 
reaction mixture was evacuated by using a water suction pump. The residue was redissolved 
in DMF (5 mL) and K2CO3 (1.23 mmol, 170 mg) was added. 3-Benzoyl-7-azaindole 
(0.41 mmol, 91 mg) was dissolved in DMF (5 mL), added dropwise and the solution was 
stirred for 1 h at room temperature. After evaporation of the solvent, the crude product was 
redissolved in ethyl acetate and washed with hydrochloric acid (0.1M) and brine. The organic 
layer was dried over Na2SO4, filtered and evacuated. Purification by flash silica gel 
chromatography with a gradient of petroleum ether and ethyl acetate afforded an orange solid 
(0.16 mmol, 73 mg, 39%). Purity (HPLC) 97%; m.p. 70 °C; 1H NMR (300 MHz, DMSO-d6): 
δ 1.43 (d, 3J = 6.1 Hz, 3H), 3.47 (s, 3H), 3.72 (s, 3H), 5.39 (q, 3J = 6.1 Hz, 1H), 5.74 (d, 2J = 
11.1 Hz, 1H), 5.80 (d, 2J = 11.1 Hz, 1H), 6.78 (s, 1H), 7.31 (dd, 3J = 7.9 Hz, 3J = 4.7 Hz, 1H), 
7.32 (s, 1H), 7.54-7.59 (m, 2H), 7.64-7.68 (m, 1H), 8.16 (s, 1H), 8.31 (dd, 3J = 4.7 Hz, 4J = 
1.4 Hz, 1H), 8.38 (dd, 3J = 7.9 Hz, 4J = 1.4 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): δ 23.7, 
55.4, 56.0, 73.3, 107.0, 108.1, 113.3, 118.8, 118.9, 128.3, 128.5, 130.1, 131.6, 134.3, 138.0, 
139.0, 139.2, 144.6, 147.1, 147.7, 152.9, 189.42; LC-MS (ESI): m/z 462 [MH]+. 
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2-(3-Benzoyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-1-(4-hydroxyphenyl)ethanone (82) 
RH_039 
C22H16N2O3 (Mr 356.37) 
3-Benzoyl-7-azaindole (0.45 mmol, 100 mg) and K2CO3 (1.35 mmol, 187 mg) were dissolved 
in DMF (10 mL) and stirred for 15 min at room temperature. 4-Hydroxyphenacylbromide 
(0.4 mmol, 97 mg) was dissolved in DMF (10 mL) and added dropwise at 0 °C. Afterwards, 
the reaction mixture was stirred for another 30 min at room temperature. After evaporation of 
the solvent, the remainder was redissolved in ethyl acetate, washed with hydrochloric acid 
(1M) and brine and subsequently dried over Na2SO4. The crude product was purified by flash 
silica gel chromatography with a gradient of petroleum ether and ethyl acetate to give grey 
needles (0.16 mmol, 58 mg, 36%). Purity (HPLC) 96%; m.p. 215 °C; 1H NMR (300 MHz, 
CDCl3): δ 5.93 (s, 2H), 6.94 (d, 
3J = 8.8 Hz, 2H), 7.36 (dd, 3J = 7.9 Hz, 3J = 4.7 Hz, 1H), 
7.54-7.60 (m, 2H), 7.60-7.67 (m, 1H), 7.81-7.85 (m, 2H), 7.99 (d, 3J = 8.8 Hz, 2H), 8.29 (s, 
1H), 8.35 (dd, 3J = 4.7 Hz, 4J = 1.6 Hz, 1H), 8.59 (dd, 3J = 7.9 Hz, 4J = 1.6 Hz, 1H), 10.57 
(bs, 1H); 13C NMR (75 MHz, CDCl3): δ 50.6, 112.8, 115.6, 118.7, 118. 9, 125.8, 128.4, 128.6, 
130.2, 130.7, 131.5, 139.6, 140.1, 144.3, 148.2, 162.9, 189.6, 191.0; LC-MS (ESI): 
m/z 357 [MH]+. 
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2-(3-Benzoyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-1-(4-(dimethylamino)phenyl)ethanone (83) 
RH_040 
C24H21N3O2 (Mr 383.44) 
3-Benzoyl-7-azaindole (0.45 mmol, 100 mg) and K2CO3 (1.35 mmol, 187 mg) were dissolved 
in DMF (10 mL) and stirred for 15 min at room temperature. 4-(Dimethylamino)phenacyl 
bromide (0.4 mmol, 109 mg) was dissolved in DMF (10 mL) and was added dropwise at 0 °C. 
Afterwards, the reaction mixture was stirred for 1 h at room temperature. After evaporation of 
the solvent, the crude product was redissolved in ethyl acetate, washed with hydrochloric acid 
(1M) and brine and dried over Na2SO4. Subsequently, the solvent was removed under reduced 
pressure and the residue washed with diethyl ether to afford a white powder (0.26 mmol, 
101 mg, 59%). Purity (HPLC) > 98%; m.p. 147 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.05 
(s, 6H), 5.88 (s, 2H), 6.78 (d, 3J = 9.1 Hz, 2H), 7.35 (dd, 3J = 7.8 Hz, 3J = 4.7 Hz, 1H), 7.54-
7.62 (m, 2H), 7.62-7.66 (m, 1H), 7.81-7.84 (m, 2H), 7.93 (d, 3J = 9.1 Hz, 2H), 8.28 (s, 1H), 
8.35 (dd, 3J = 4.7 Hz, 4J = 1.6 Hz, 1H), 8.60 (dd, 3J = 7.8 Hz, 4J = 1.6 Hz, 1H); 13C NMR 
(75 MHz, DMSO-d6): δ 39.6, 50.3, 110.8, 112.7, 118.6, 118.9, 121.6, 128.4, 128.6, 130.1, 
130.1, 131.5, 139.7, 140.3, 144.3, 148.2, 153.8, 189.6, 189.97; LC-MS (ESI): m/z 384 [MH]+. 
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4-((3-Benz yl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-7-methoxy-2H-chromen-2-one (84) 
RH_042 
C25H18N2O4 (Mr 410.42) 
Synthesis was performed by Dr. Melanie Zindler.142 
3-Benzoyl-7-azaindole (0.5 mmol, 111 mg) and Li2CO3 (2.0 mmol, 148 mg) were dissolved 
in DMF (5 mL) and stirred for 15 min at room temperature. 4-Bromomethyl-7-
methoxycoumarin (0.5 mmol, 134 mg) was dissolved in DMF (5 mL) and added dropwise. 
Afterwards, the reaction mixture was stirred for 18 h at room temperature. After evaporation 
of the solvent, the remainder was redissolved in ethyl acetate, washed with hydrochloric acid 
(1M) and brine and dried over Na2SO4. The crude product was purified by flash silica gel 
chromatography with a gradient of petroleum ether and ethyl acetate to afford a white powder 
(0.23 mmol, 94 mg, 46%). Purity (HPLC) 96%; m.p. 214 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 3.88 (s, 3H), 5.34 (s, 1H), 5.87 (s, 2H), 7.05 (s, 1H), 7.02-7.06 (m, 1H), 7.41 
(dd, 3J = 7.9 Hz, 3J = 4.7 Hz, 1H), 7.53-7.59 (m, 2H), 7.61-7.67 (m, 1H), 7.84-7.88 (m, 2H), 
7.93-7.97 (m, 1H), 8.42 (s, 1H), 8.43 (dd, 3J = 4.7 Hz, 4J = 1.6 Hz, 1H), 8.63 (dd, 3J = 7.9 Hz, 
4J = 1.6 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): δ 44.6, 56.1, 101.2, 108.5, 110.6, 112.5, 
113.5, 119.0, 119.1, 125.7, 128.6, 130.6, 131.7, 138.8, 139.4, 144.9, 147.7, 151.9, 154.9, 
159.8, 162.7, 189.6; LC-MS (ESI): m/z 411 [MH]+. 
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4-((3-Benzoyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-6,7-dimethoxy-2H-chromen-2-one 
(85) 
RH_041 
C26H20N2O5 (Mr 440.45) 
3-Benzoyl-7-azaindole (0.45 mmol, 100 mg) and K2CO3 (1.35 mmol, 187 mg) were dissolved 
in DMF (10 mL) and stirred for 15 min at room temperature. 4-Bromomethyl-6,7-
dimethoxycoumarin (0.4 mmol, 135 mg) was dissolved in DMF (10 mL) and added dropwise. 
Afterwards, the reaction mixture was stirred for 1 h at room temperature. After evaporation of 
the solvent, the remainder was redissolved in ethyl acetate, washed with hydrochloric acid 
(1M) and brine and dried over Na2SO4. Purification of the crude product by flash silica gel 
chromatography with a gradient of petroleum ether and ethyl acetate gave a white powder 
(0.31 mmol, 135 mg, 68%). Purity (HPLC) > 98%; m.p. 226 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 3.81 (s, 3H), 3.87 (s, 3H), 5.50 (s, 1H), 5.89 (s, 2H), 7.11 (s, 1H), 7.42 (dd, 
3J = 
7.9 Hz, 3J = 4.7 Hz, 1H), 7.43 (s, 1H), 7.53-7.63 (m, 2H), 7.61-7.67 (m, 1H), 7.83-7.87 (m, 
2H), 8.42 (s, 1H), 8.45 (dd, 3J = 4.7 Hz, 4J = 1.6 Hz, 1H), 8.63 (dd, 3J = 7.9 Hz, 4J = 1.6 Hz, 
1H); 13C NMR (75 MHz, DMSO-d6): δ 44.7, 56.1, 56.2, 100.4, 105.4, 109.2, 109.5, 113.6, 
119.0, 119.1, 128.5, 130.7, 131.7, 138.6, 139.3, 144.9, 146.0, 147.7, 149.0, 151.7, 152.8, 
160.1, 189.6; LC-MS (ESI): m/z 441 [MH]+. 
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2-(3-Benzoyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-1,2-diphenylethanone (86) 
RH_046 
C28H20N2O2 (Mr 416.47) 
3-Benzoyl-7-azaindole (0.45 mmol, 100 mg) and K2CO3 (1.35 mmol, 187 mg) were dissolved 
in DMF (10 mL) and stirred for 15 min at room temperature. Subsequently, desyl bromide 
(0.4 mmol, 124 mg) was dissolved in DMF (10 mL) and added dropwise at room temperature, 
where upon the color changed to orange. After stirring for 1 h at room temperature, the 
solvent was removed in vacuo. In the next step, the remainder was redissolved in ethyl acetate 
and washed with hydrochloric acid (0.1M) and brine. Afterwards, the organic layer was dried 
over Na2SO4, filtered and concentrated to afford a brown oil. The crude product was purified 
by flash silica gel chromatography with a gradient of petroleum ether and ethyl acetate to give 
an orange solid (0.22 mmol, 90 mg, 48%). Purity (HPLC) 97%; m.p. 152 °C; 1H NMR 
(300 MHz, DMSO-d6): δ 7.37-7.69 (m, 14H), 7.59 (s, 1H), 8.00 (s, 1H), 8.09-8.12 (m, 2H), 
8.42 (dd, 3J = 4.7 Hz, 4J = 1.6 Hz, 1H), 8.53 (dd, 3J = 7.9 Hz, 4J = 1.6 Hz, 1H); 13C NMR 
(75 MHz, DMSO-d6): δ 62.9, 113.2, 119.1, 119.3, 128.2, 128.6, 128.9, 129.1, 129.6, 129.6, 
129.7, 130.4, 131.7, 133.1, 134.2, 134.2, 136.2, 139.3, 144.6, 147.6, 189.4, 193.8; LC-MS 
(ESI): m/z 417 [MH]+. 
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N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-
difluorophenyl)propane-1-sulfonamide (44), INN: vemurafenib 
RH_007 
C23H18ClF2N3O3S (Mr 489.92) 
One tablet of Zelboraf (vemurafenib content 0.49 mmol, 240 mg) was pestle, absorbed onto 
silica gel and eluted with DCM and ethyl acetate to afford white needles (0.46 mmol, 228 mg, 
95%). Purity (HPLC) > 98%; m.p. 271 °C; 1H NMR (300 MHz, DMSO-d6): δ 0.97 (t, 
3J = 
7.4 Hz, 3H), 1.75 (tq , 3J = 7.7 Hz, 3J = 7.4 Hz, 2H), 3.13 (t, 3J = 7.7 Hz, 2H), 7.28 (ddd, 3J = 
8.8 Hz, 3JHF = 8.8 Hz, 
5JHF = 1.4 Hz, 1H), 7.56 (d, 
3J = 8.6 Hz, 2H), 7.56-7.63 (m, 1H), 7.79 
(d, 3J = 8.6 Hz, 2H), 8.24 (s, 1H), 8.64 (d, 4J = 1.7 Hz, 1H), 8.71 (d, 4J = 2.3 Hz, 1H), 9.75 
(bs, 1H), 13.01 (bs, 1H); 13C NMR (75 MHz, DMSO-d6): δ 12.6, 16.8, 53.5, 112.3 (dd, 
2JCF = 
22.5 Hz, 4JCF = 3.7 Hz), 115.7, 117.5, 118.2 (dd, 
2JCF = 24.6 Hz, 
2JCF = 22.4 Hz), 122.0 (dd, 
2JCF = 13.6 Hz, 
4JCF = 3.7 Hz), 127.1, 128.8 (dd, 
3JCF = 10.0 Hz, 
3JCF = 1.6 Hz), 128.9, 129.1, 
130.3, 132.5, 137.0, 138.9, 143.9, 149.0, 152.4 (dd, 1JCF = 249.5 Hz, 
3JCF = 8.5 Hz), 156.0 
(dd, 1JCF = 246.5 Hz, 
3JCF = 7.0 Hz), 180.6; 
19F NMR (282 MHz, DMSO-d6): δ -122.0, -116.7; 
LC-MS (ESI): m/z 490, 492 [MH]+.  
   
 
Molecular structure determined by X-ray crystallography: CCDC 1044606 
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N-(3-(5-(4-Chlorophenyl)-1-(4,5-dimethoxy-2-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridine-3-
carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (58) 
RH_015 
C32H27ClF2N4O7S (Mr 685.09) 
Vemurafenib (0.25 mmol, 122 mg), 4,5-dimethoxy-2-nitrobenzyl bromide (0.25 mmol, 
69 mg) and K2CO3 (1.25 mmol, 173 mg) were dissolved in DMF (10 mL). The reaction 
mixture was stirred for 1 h at room temperature. After evaporation of the solvent, the 
yellowish oil was redissolved in ethyl acetate, washed with brine and dried over Na2SO4. The 
crude product was purified by flash silica gel chromatography with a gradient of petroleum 
ether and ethyl acetate to give a yellowish solid (0.026 mmol, 18 mg, 11%). Purity (HPLC) 
> 98%; m.p. 200 °C; 1H NMR (300 MHz, DMSO-d6): δ 0.90 (t, 
3J = 7.4 Hz, 3H), 1.71 (tq, 
3J = 7.5 Hz, 3J = 7.4 Hz, 2H), 3.08 (t, 3J = 7.5 Hz, 2H), 3.59 (s, 3H), 3.85 (s, 3H), 5.89 (s, 
2H), 6.45 (s, 1H), 7.31 (ddd, 3JHF = 9.0 Hz, 
3J = 8.7 Hz, 5JHF = 1.6 Hz, 1H), 7.57 (d, 
3J = 
8.5 Hz, 2H), 7.60 (dd, 3J = 8.7 Hz, 4JHF = 6.1 Hz, 1H), 7.70 (s, 1H), 7.81 (d, 
3J = 8.5 Hz, 2H), 
8.45 (s, 1H), 8.69 (bs, 1H), 8.73 (d, 4J = 2.0 Hz, 1H), 9.78 (bs, 1H); 13C NMR (75 MHz, 
DMSO-d6): δ 12.5, 16.9, 45.6, 53.5, 55.8, 56.2, 108.4, 110.7, 112.3 (d, 
2JCF = 22.7 Hz), 115.1, 
117.7, 117.8 (t, 2JCF = 23.5 Hz), 122.9 (d, 
2JCF = 15.5 Hz), 126.4, 127.6, 128.7 (d, 
3JCF = 
8.1 Hz), 129.0, 129.1, 131.0, 132.7, 136.6, 140.0, 141.3, 144.2, 147.8, 147.9, 152.2 (dd, 1JCF = 
252.6 Hz, 3JCF = 8.4 Hz), 153.1, 155.5 (dd, 
1JCF = 251.1 Hz, 
3JCF = 6.8 Hz), 180.6; 
19F NMR 
(282 MHz, DMSO-d6): δ -122.2, -116.7; LC-MS (ESI): m/z 685, 687 [MH]
+. 
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Molecular structure determined by X-ray crystallography: CCDC 1044607 
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N-(3-(5-(4-Chlorophenyl)-1-(1-(4,5-dimethoxy-2-nitrophenyl)ethyl)-1H-pyrrolo[2,3-
b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide (59) 
RH_032 
C33H29ClF2N4O7S (Mr 699.12) 
1-(4,5-Dimethoxy-2-nitrophenyl)ethanol (1.0 mmol, 230 mg) was dissolved in DCM (8 mL) 
and PBr3 (3.0 mmol, 0.28 mL), diluted with DCM (1 mL), was added dropwise at 0 °C. After 
stirring of the reaction mixture for 30 min at 0 °C and another 15 min at room temperature, 
the reaction mixture was washed with brine, dried over Na2SO4, filtered and concentrated. 
The residue was used in the next step without further purification. The formed 
1-(1-bromoethyl)-4,5-dimethoxy-2-nitrobenzene was dissolved in DMF (15 mL). 
Vemurafenib (0.6 mmol, 295 mg) and K2CO3 (2.4 mmol, 330 mg) were added and stirred for 
18 h at room temperature. After evaporation of the solvent, the yellowish oil was redissolved 
in ethyl acetate, washed with brine and dried over Na2SO4. Purification by flash silica gel 
chromatography with a gradient of petroleum ether and ethyl acetate afforded a yellowish 
solid (0.14 mmol, 98 mg, 23%). Purity (HPLC) > 98%; m.p. 218 °C; 1H NMR (300 MHz, 
DMSO-d6): δ 0.96 (t, 
3J = 7.5 Hz, 3H), 1.71 (tq, 3J = 7.6 Hz, 3J = 7.5 Hz, 2H), 2.02 (d, 3J = 
7.1 Hz, 3H), 3.14 (t, 3J = 7.6 Hz, 2H), 3.71 (s, 3H), 3.82 (s, 3H), 6.77 (q, 3J = 7.1 Hz, 1H), 
6.81 (s, 1H), 7.32 (ddd, 3J = 8.9 Hz, 3JHF = 8.8 Hz, 
5JHF = 1.5 Hz, 1H), 7.53 (d, 
3J = 8.8 Hz, 
2H), 7.58 (s, 1H), 7.63 (ddd, 3J = 8.9 Hz, 4JHF = 5.9 Hz, 
4JHF = 5.9 Hz, 1H), 7.75 (d, 
3J = 
8.8 Hz, 2H), 8.61 (bs, 1H), 8.64 (d, 6J = 2.2 Hz, 1H), 8.74 (s, 1H), 9.80 (bs, 1H); 13C NMR 
(75 MHz, DMSO-d6): δ 12.6, 16.8, 19.7, 49.7, 53.5, 55.6, 56.1, 107.9, 108.8, 112.6 (dd, 
3JCF = 
22.8 Hz, 5JCF = 2.8 Hz), 115.3, 118.0 (dd, 
2JCF = 24.2 Hz, 
2JCF = 21.9 Hz), 118.1, 122.0 (dd, 
2JCF = 13.5 Hz, 
4JCF = 3.4 Hz), 127.5, 129.0, 129.1, 129.2 (d, 
4JCF = 0.2 Hz), 130.5, 131.1, 
132.7, 136.6, 138.2, 140.3, 144.0, 147.4, 147.8, 152.7 (dd, 1JCF = 250.2 Hz, 
3JCF = 8.4 Hz), 
153.1, 156.3 (dd, 1JCF = 247.2 Hz, 
3JCF = 6.6 Hz), 180.6; 
19F NMR (282 MHz, DMSO-d6): 
δ -121.5, -116.5; LC-MS (ESI): m/z 699, 701 [MH]+. 
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Molecular structure determined by X-ray crystallography: CCDC 1044608 
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N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)-N-
(4,5-dimethoxy-2-nitrobenzyl)propane-1-sulfonamide (60) 
RH_015* 
C32H27ClF2N4O7S (Mr 685.09) 
Vemurafenib (0.5 mmol, 245 mg) and 4,5-dimethoxy-2-nitrobenzyl bromide (0.7 mmol, 
179 mg) were dissolved in DMF (15 mL). N,N-Diisopropylethylamine (2.0 mmol, 0.34 mL, 
Hunig’s base) was diluted with DMF (5 mL) and added dropwise over 30 min. The mixture 
was stirred for 18 h at room temperature. After evaporation of the solvent, the yellowish oil 
was redissolved in ethyl acetate, washed with brine and dried over Na2SO4. Purification by 
flash silica gel chromatography with a gradient of petroleum ether and ethyl acetate afforded a 
pale yellow solid (0.1 mmol, 67 mg, 20%). Purity (HPLC) > 98%; m.p. 237 °C; 1H NMR 
(300 MHz, DMSO-d6): δ 1.00 (t, 
3J = 7.4 Hz, 3H), 1.77 (tq, 3J = 7.5 Hz, 3J = 7.4 Hz, 2H), 
3.35 (t, 3J = 7.5 Hz, 2H), 3.83 (s, 6H), 5.19 (s, 2H), 7.28 (dd, 3J = 8.4 Hz, 3JHF = 8.1 Hz, 1H), 
7.29 (s, 1H), 7.55 (d, 3J = 8.5 Hz, 2H), 7.56 (s, 1H), 7.73 (ddd, 3J = 8.4 Hz, 4JHF = 6.0 Hz, 
4JHF = 6.0 Hz, 1H), 7.77 (d, 
3J = 8.5 Hz, 2H), 8.05 (d, 3J = 2.7, 1H), 8.59 (bs, 1H), 8.72 (d, 
4J = 2.3 Hz, 1H), 13.07 (d, 3J = 2.7, 1H); 13C NMR (75 MHz, DMSO-d6): δ 12.6, 16.6, 50.7, 
52.3, 56.0, 56.1, 108.1, 112.4, 112.8 (dd, 2JCF = 22.9 Hz, 
4JCF = 2.6 Hz), 115.6, 117.4, 118.4 
(dd, 2JCF = 23.6 Hz, 
2JCF = 22.8 Hz), 123.6 (dd, 
2JCF = 12.9 Hz, 
4JCF = 3.5 Hz), 125.7, 127.0, 
128.9, 129.0, 130.3, 132.5, 133.6 (d, 3JCF = 10.1 Hz), 136.9, 138.3, 140.6, 144.0, 147.9, 149.0, 
152.7, 156.0 (dd, 1JCF = 252.4 Hz, 
3JCF = 8.8 Hz), 158.0 (dd, 
1JCF = 250.3 Hz, 
3JCF = 7.7 Hz), 
180.0; 19F NMR (282 MHz, DMSO-d6): δ -116.3, -112.2; LC-MS (ESI): m/z 685, 687 [MH]
+; 
HRMS (EI): m/z calculated 684.1257, found 684.1264. 
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N-(3-(5-(4-Chlorophenyl)-1-(4,5-dimethoxy-2-nitrobenzyl)-1H-pyrrolo[2,3-b]pyridine-3-
carbonyl)-2,4-difluorophenyl)-N-(4,5-dimethoxy-2-nitrobenzyl)propane-1-sulfonamide 
(87) 
RH_016 
C41H36ClF2N5O11S (Mr 880.27) 
Vemurafenib (0.5 mmol, 245 mg) and 4,5-dimethoxy-2-nitrobenzyl bromide (0.7 mmol, 
179 mg) were dissolved in DMF (15 mL). N,N-Diisopropylethylamine (2.0 mmol, 0.34 mL, 
Hunig’s base) was diluted with DMF (5 mL) and added dropwise over 30 min. The mixture 
was stirred for 18 h at room temperature. After evaporation of the solvent, the yellow oil was 
redissolved in ethyl acetate, washed with brine and dried over Na2SO4. The crude product was 
purified by flash silica gel chromatography with a gradient of petroleum ether and ethyl 
acetate to give a yellow solid (0.1 mmol, 100 mg, 23%). Purity (HPLC) > 98%; m.p. 254 °C; 
1H NMR (300 MHz, DMSO-d6): δ 0.95 (t, 
3J = 7.4 Hz, 3H), 1.73 (tq, 3J = 7.5 Hz, 3J = 7.4 Hz, 
2H), 3.30 (t, 3J = 7.5 Hz, 2H), 3.63 (s, 3H), 3.81 (s, 6H), 3.84 (s, 3H), 5.15 (s, 2H), 5.87 (s, 
2H), 6.63 (s, 1H), 7.24 (s, 1H), 7.28 (dd, 3J = 8.4 Hz, 3JHF = 8.4 Hz, 1H), 7.51 (s, 1H), 7.56 (d, 
3J = 8.5 Hz, 2H), 7.72-7.64 (m, 1H), 7.69 (s, 1H), 7.79 (d, 3J = 8.5 Hz, 2H), 8.21 (s, 1H), 8.62 
(bs, 1H), 8.75 (d, 4J = 2.2 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): δ 12.6, 16.6, 45.8, 50.5, 
52.4, 55.8, 56.0, 56.0, 56.1, 108.1, 108.4, 111.6, 112.4, 112.8 (dd, 2JCF = 22.1 Hz, 
4JCF = 
3.3 Hz), 114.9, 117.7, 118.1 (dd, 2JCF = 26.1 Hz, 
2JCF = 23.2 Hz), 123.6 (dd, 
2JCF = 11.9 Hz, 
4JCF = 3.0 Hz), 125.5, 125.7, 127.5, 129.0, 129.1, 131.0, 132.7, 133.9 (d, 
3JCF = 10.2 Hz), 
136.6, 140.2, 140.5, 140.6, 144.2, 147.7, 147.9, 148.1, 152.7, 153.1, 156.0 (dd, 1JCF = 
251.7 Hz, 3JCF = 7.3 Hz), 157.9 (dd, 
1JCF = 250.7 Hz, 
3JCF = 7.0 Hz), 179.8; 
19F NMR 
(282 MHz, DMSO-d6): δ -112.0, -112.2; LC-MS (ESI): m/z 880, 882 [MH]
+. 
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Caged diarylmaleimides and carbazole 
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3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (55) 
RH_003 
C21H18N2O2 (Mr 378.38) 
2-(3,4,5-Trimethoxyphenyl)acetamide (10 mmol, 2.25 g) was dissolved in dry THF (30 mL) 
under nitrogen atmosphere and the reaction mixture was cooled to 0 °C. Ethyl 2-(1H-indol-3-
yl)-2-oxoacetate (13 mmol, 2.82 g) dissolved in dry THF (40 mL) was added dropwise. 
Afterwards, potassium tert-butoxide solution (1M in THF, 40 mmol, 40 mL) was added. 
Subsequently, the deep purple reaction mixture was stirred for 6 h at room temperature. 
Quenching of the reaction with saturated ammonium chloride solution (40 mL) changed the 
color to orange. After addition of ethyl acetate (50 mL), the solution was stirred for another 
15 min. After filtration, the organic layer was washed with brine, dried over Na2SO4 and 
evacuated. The crude product was purified by flash silica gel chromatography with a gradient 
of petroleum ether and ethyl acetate to give an orange solid (5.9 mmol, 2.25 g, 59%). Purity 
(HPLC) > 98%; m.p. 243 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.38 (s, 6H), 3.67 (s, 3H), 
6.37 (d, 3J = 8.0 Hz, 1H), 6.74 (s, 2H), 6.76 (t, 3J = 7.9 Hz, 1H), 7.09 (t, 3J = 7.6 Hz, 1H), 7.45 
(d, 3J = 8.0 Hz, 1H), 7.98 (d, 3J = 1.7 Hz, 1H), 11.03 (s, 1H), 11.89 (bs, 1H); 13C NMR 
(75 MHz, DMSO-d6): δ 55.5, 60.1, 104.2, 107.6, 112.1, 119.6, 121.5, 122.0, 123.7, 125.5, 
128.2, 131.2, 131.8, 136.4, 138.1, 152.2, 172.2, 172.5; LC-MS (ESI): m/z 379 [MH]+. 
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5,6,7-Trimethoxybenzo[a]pyrrolo[3,4-c]carbazole-1,3(2H,8H)-dione (57) 
RH_004 
C21H16N2O5 (Mr 376.36) 
3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (0.3 mmol, 114 mg) was 
dissolved in DMSO (20 mL) and irradiated with an LED reactor at 365 nm (5.4 W) for 
30 min. Ethyl acetate (100 mL) was added and washed thoroughly with water, dried over 
Na2SO4 and concentrated. Purification by flash silica gel chromatography with a gradient of 
petroleum ether and ethyl acetate afforded an orange solid (0.03 mmol, 12 mg, 11%). Purity 
(HPLC) > 98%; m.p. 275 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.95 (s, 3H), 3.97 (s, 3H), 
4.19 (s, 3H), 7.32 (t, 3J = 7.6, 1H), 7.50 (t, 3J = 7.6, 1H), 7.88 (d, 3J = 8.1, 1H), 8.23 (s, 1H), 
8.89 (d, 3J = 7.8, 1H), 11.03 (s, 1H), 11.84 (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 55.8, 
60.9, 61.6, 100.0, 111.6, 112.5, 113.2, 116.9, 120.4, 120.4, 123.5, 123.9, 126.0, 127.7, 138.4, 
139.9, 141.3, 148.5, 154.5, 170.4, 171.6; LC-MS (ESI): m/z 377 [MH]+. 
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3-(1H-Indol-3-yl)-1-(2-nitrobenzyl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione 
(98) 
RH_005 
C28H23N3O7 (Mr 513.15) 
3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (0.5 mmol, 189 mg), 
K2CO3 (1 mmol, 138 mg) and 2-nitrobenzyl bromide (0.6 mmol, 130 mg) were dissolved in 
dry DMF (8 mL). The reaction mixture was stirred at 70 °C for 3 h. After evaporation of the 
solvent, the crude product was redissolved in ethyl acetate (10 mL), washed with brine, dried 
over Na2SO4 and concentrated. Purification by flash silica gel chromatography with a gradient 
of petroleum ether and ethyl acetate afforded an orange solid (0.26 mmol, 132 mg, 51%). 
Purity (HPLC) > 98%; m.p. 209 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.39 (s, 6H), 3.68 (s, 
3H), 5.09 (s, 2H), 6.40 (d, 3J = 8.1 Hz, 1H), 6.79 (s, 2H), 6.80 (dd, 3J = 7.5 Hz, 4J = 0.8 Hz, 
1H), 7.10 (dd, 3J = 7.6 Hz, 4J = 0.9 Hz, 1H), 7.47 (d, 3J = 8.1 Hz, 1 H), 7.53 (dd, 3J = 7.8 Hz, 
4J = 0.9 Hz, 1H), 7.58 (dd, 3J = 7.8 Hz, 4J = 1.3 Hz, 1H), 7.73 (dd, 3J = 7.6 Hz, 4J = 1.3 Hz, 
1H), 8.06 (d, 3J = 2.9 Hz, 1H), 8.11 (dd, 3J = 8.2 Hz, 4J = 1.2 Hz, 1H), 11.98 (d, 3J = 2.1 Hz, 
1H); 13C NMR (75 MHz, DMSO-d6): δ 38.2, 55.5, 60.1, 104.4, 107.7, 112.3, 119.8, 121.7, 
122.3, 123.6, 124.9, 125.3, 127.3, 128.8, 131.5, 131.6, 131.7, 134.2, 136.5, 138.2, 147.8, 
152.3, 170.7, 170.9; LC-MS (ESI): m/z 514 [MH]+. 
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1-(4,5-Dimethoxy-2-nitrobenzyl)-3-(1H-indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-
pyrrole-2,5-dione (99) 
RH_013 
C30H27N3O9 (Mr 573.55) 
3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (0.5 mmol, 189 mg) and 
K2CO3 (1 mmol, 138 mg) were dissolved in dry DMF (15 mL). 4,5-dimethoxy-2-nitrobenzyl 
bromide (0.5 mmol, 138 mg) was dissolved in dry DMF (2 mL) and added dropwise to the 
reaction mixture. After stirring at room temperature for 2 h, the solvent was evaporated and 
the crude product was redissolved in ethyl acetate, washed with brine, dried over Na2SO4 and 
concentrated. Purification by flash silica gel chromatography with a gradient of petroleum 
ether and ethyl acetate afforded an orange solid (0.27 mmol, 155 mg, 54%). Purity (HPLC) 
> 98%; m.p. 205 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.38 (s, 6H), 3.68 (s, 3H), 3.84 (s, 
3H), 3.87 (s, 3H), 5.08 (s, 2H), 6.38 (d, 3J = 8.1 Hz, 1H), 6.77 (s, 2H), 6.78 (t, 3J = 7.3 Hz, 
1H), 6.95 (s, 1H), 7.11 (t, 3J = 7.5 Hz, 1H), 7.46 (d, 3J = 8.0 Hz, 1H), 7.66 (s, 1H), 8.04 (d, 
3J = 2.6 Hz, 1H), 11.96 (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 38.5, 55.5, 56.1, 56.2, 60.1, 
104.3, 107.6, 108.2, 111.3, 112.2, 119.8, 121.7, 122.2, 123.6, 125.3, 126.2, 127.3, 131.5, 
131.7, 136.5, 138.2, 140.5, 147.8, 152.2, 153.0, 170.8, 170.9; LC-MS (ESI): m/z 574 [MH]+. 
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2-(4,5-Dimethoxy-2-nitrobenzyl)-5,6,7-trimethoxybenzo[a]pyrrolo[3,4-c]carbazole-
1,3(2H,8H)-dione (100) 
RH_049 
C30H25N3O9 (Mr 571.53) 
5,6,7-Trimethoxybenzo[a]pyrrolo[3,4-c]carbazole-1,3(2H,8H)-dione (0.13 mmol, 28 mg) and 
K2CO3 (0.38 mmol, 52 mg) were dissolved in dry DMF (5 mL). 4,5-Dimethoxy-2-nitrobenzyl 
bromide (0.13 mmol, 33 mg) was dissolved in dry DMF (2 mL) and added dropwise to the 
reaction mixture. After stirring at room temperature for 2 h, the solvent was evaporated and 
the crude product redissolved in ethyl acetate, washed with brine, dried over Na2SO4 and 
concentrated. Recrystallization from ethyl acetate gave an orange solid (0.03 mmol, 19 mg, 
26%). Purity (HPLC) > 98%; m.p. 283 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.71 (s, 3H), 
3.86 (s, 3H), 3.97 (s, 3H), 3.99 (s, 3H), 4.21 (s, 3H), 5.15 (s, 2H), 6.96 (s, 1H), 7.33 (t, 3J = 
7.4 Hz, 1H), 7.52 (t, 3J = 7.4 Hz, 1H), 7.68 (s, 1H), 7.90 (d, 3J = 7.6 Hz, 1H), 8.23 (s, 1H), 
8.87 (d, 3J = 7.6 Hz, 1H), 11.88 (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 38.0, 55.8, 56.1, 
60.9, 61.6, 100.0, 108.3, 111.0, 111.8, 112.6, 113.1, 115.9, 120.2, 120.6, 123.4, 123.9, 126.2, 
126.5, 126.7, 138.5, 139.9, 140.4, 141.5, 147.7, 148.5, 153.1, 154.8, 168.8, 169.8; LC-MS 
(ESI): m/z 571 [MH]+. 
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2-(3,4,5-Trimethoxyphenyl)acetamide (102) 
RH_001 
C11H15NO4
 (Mr 225.24) 
2-(3,4,5-Trimethoxyphenyl)acetic acid (20 mmol, 4.6 g) was dissolved in anhydrous THF 
(30 mL). After addition of thionyl chloride (40 mmol, 3 mL) and a catalytic amount of DMF, 
the reaction mixture was heated to 40 °C until gas formation was completed (30 min). 
Subsequently, the solvent and excessive thionyl chloride were removed under reduced 
pressure. This step was repeated after addition of THF (10 mL). The remaining brown oil was 
dissolved in DCM (50 mL) and cooled to 0 °C. Next, ammonia solution (25%, 10 mL) was 
added to the mixture and stirred for 1 h at room temperature. After addition of hydrochloric 
acid (1M, 20 mL), the organic layer was washed with brine and dried over Na2SO4. 
Evacuation and recrystallization from ethanol afforded grey needles (16.8 mmol, 3.86 g, 
84%). Purity (HPLC) > 98%; m.p. 124 °C; 1H NMR (300 MHz, CDCl3): δ 3.50 (s, 2H), 3.82 
(s, 3H), 3.84 (s, 6H), 5.53 (bs, 1H), 5.79 (bs, 1H), 6.47 (s, 2H); 13C NMR (75 MHz, CDCl3): δ 
43.8, 56.3, 61.0, 106.5, 130.6, 137.4, 153.7, 173.6; LC-MS (ESI): m/z 226 [MH]+. 
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Ethyl 2-(1H-indol-3-yl)-2-oxoacetate (104) 
RH_002 
C12H11NO3 (Mr 217.22) 
Indole (40 mmol, 4.8 g) was dissolved in dry DCM (70 mL) under nitrogen atmosphere and 
stirred at 0 °C. After dropwise addition of diethylaluminium chloride solution (1M in hexane, 
60 mmol, 60 mL), the reaction mixture was stirred for 30 min at 0 °C. Subsequently, ethyl 
oxalyl chloride (60 mmol, 6.8 mL) was added dropwise followed by stirring for further 3 h. In 
the next step, ice was carefully added to the reaction mixture for hydrolysis. The organic layer 
was washed with saturated ammonium chloride solution and brine, dried over Na2SO4 and 
concentrated. Purification by flash silica gel chromatography with a gradient of petroleum 
ether and ethyl acetate afforded light-pink needles (21.9 mmol, 4.75 g, 55%). Purity (HPLC) 
> 98%; m.p. 186 °C; 1H NMR (300 MHz, CDCl3): δ 1.34 (t, 
3J = 7.1 Hz, 3H), 4.36 (q, 3J = 
7.1, 2H), 7.24-7.33 (m, 2H), 7.53-7.58 (m, 1H), 8.14-8.19 (m, 1H), 8.42 (d, 3J = 3.3, 1H), 
12.38 (bs, 1H); 13C NMR (75 MHz, CDCl3): δ 13.9, 61.6, 112.4, 112.7, 121.1, 122.8, 123.8, 
125.5, 136.7, 138.2, 163.6, 179.1; LC-MS (ESI): m/z 218 [MH]+. 
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1-(2-Nitrobenzyl)-3-(1-(2-nitrobenzyl)-1H-indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-
pyrrole-2,5-dione (105) 
RH_006 
C35H28N4O9 (Mr 648.62) 
3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (0.5 mmol, 189 mg), 
K2CO3 (1 mmol, 138 mg) and 2-nitrobenzyl bromide (0.6 mmol, 130 mg) were dissolved in 
dry DMF (8 mL). The reaction mixture was stirred at 70 °C for 3 h. After evaporation of the 
solvent, the crude product was redissolved in ethyl acetate (10 mL), washed with brine, dried 
over Na2SO4 and concentrated. Purification by flash silica gel chromatography with a gradient 
of petroleum ether and ethyl acetate afforded an orange solid (0.12 mmol, 94 mg, 24%). 
Purity (HPLC) > 98%; m.p. 127 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.41 (s, 6H), 3.68 (s, 
3H), 5.09 (s, 2H), 5.99 (s, 2H), 6.50 (d, 3J = 8.0 Hz, 1H), 6.53-6.56 (m, 1H), 6.84 (s, 2H), 6.86 
(ddd, 3J = 7.9 Hz, 3J = 7.1 Hz, 4J = 0.8 Hz, 1H), 7.12 (ddd, 3J = 8.2 Hz, 3J = 7.2 Hz, 4J = 
1.0 Hz, 1H), 7.48 (d, 3J = 8.3 Hz, 1H), 7.52-7.61 (m, 4H), 7.73 (td, 3J = 7.6 Hz, 4J = 1.3 Hz, 
1H), 8.10 (dd, 3J = 8.1 Hz, 4J = 1.2 Hz, 1H), 8.16 (s, 1H), 8.15-8.19 (m, 1H); 13C NMR 
(75 MHz, DMSO-d6): δ 38.3, 47.1, 55.4, 60.1, 104.5, 107.5, 111.1, 120.4, 122.0, 122.7, 124.2, 
124.9, 125.0, 125.1, 127.5, 128.5, 128.8, 128.8, 128.9, 130.8, 131.5, 133.3, 134.1, 134.1, 
134.7, 136.6, 138.3, 147.3, 147.8, 152.3, 170.4, 170.7; LC-MS (ESI): m/z 649 [MH]+. 
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1-(4,5-Dimethoxy-2-nitrobenzyl)-3-(1-(4,5-dimethoxy-2-nitrobenzyl)-1H-indol-3-yl)-4-
(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (106) 
RH_014 
C39H36N4O13 (Mr 768.72) 
3-(1H-Indol-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5-dione (0.5 mmol, 189 mg) and 
K2CO3 (1 mmol, 138 mg) were dissolved in dry DMF (15 mL). 4,5-Dimethoxy-2-nitrobenzyl 
bromide (0.5 mmol, 138 mg) was dissolved in dry DMF (2 mL) and added dropwise to the 
reaction mixture. After stirring at room temperature for 2 h, the solvent was evaporated and 
the crude product redissolved in ethyl acetate, washed with brine, dried over Na2SO4 and 
evacuated. Purification by flash silica gel chromatography with a gradient of petroleum ether 
and ethyl acetate afforded an orange solid (0.10 mmol, 73 mg, 19%). Purity (HPLC) > 98%; 
m.p. 228 °C; 1H NMR (300 MHz, DMSO-d6): δ 3.39 (s, 6H), 3.55 (s, 3H), 3.68 (s, 3H), 3.82 
(s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 5.06 (s, 2H), 5.89 (s, 2H), 6.46 (d, 3J = 8.0 Hz, 1H), 6.51 (s, 
1H), 6.79 (s, 2H), 6.85 (t, 3J = 7.4 Hz, 1H), 6.96 (s, 1H), 7.14 (t, 3J = 7.7 Hz, 1H), 7.51 (d, 
3J = 8.3 Hz, 1 H), 7.65 (s, 1H), 7.73 (s, 1H), 8.06 (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 
38.5, 47.4, 55.5, 55.9, 56.1, 56.2, 60.1, 104.3, 107.8, 108.2, 108.6, 111.0, 111.3, 111.5, 120.4, 
121.9, 122.7, 124.2, 125.2, 126.0, 126.9, 128.4, 130.8, 134.5, 136.7, 138.5, 140.0, 140.6, 
147.8, 147.9, 152.3, 153.0, 153.1, 170.6, 170.8; LC-MS (ESI): m/z 769 [MH]+. 
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Photoswitchable axitinib 
  
  
 
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
Chemical Synthesis and Characterization 138 
(E)-axitinib, (E)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide 
(19), INN: axitinib 
JW_01 
C22H18N4OS (Mr 386.47) 
Analytical characterization was partially performed by Jantje Weber.89 
The pale yellow compound was purchased from LC Laboratories, Woburn, MA, USA. Purity 
(HPLC) > 98%; m.p. 219 °C; 1H NMR (300 MHz, DMSO-d6): δ 2.78 (d, 
3J = 4.5 Hz, 3H), 
7.06 (dd, 3J = 7.3 Hz, 4J = 1.7 Hz, 1H), 7.19 (dd, 3J = 8.5 Hz, 4J = 1.4 Hz, 1H), 7.25-7.29 (m, 
1H), 7.31 (dd, 3J = 7.3 Hz, 4J = 1.7 Hz, 1H), 7.33 (dd, 3J = 7.3 Hz, 4J = 1.9 Hz, 1H), 7.49 (dd, 
3J = 7.3 Hz, 4J = 1.9 Hz, 1H), 7.58 (d, 3J = 16.4 Hz, 1H), 7.61 (s, 1H), 7.66 (d, 3J = 7.8 Hz, 
1H), 7.79 (ddd, 3J = 7.8 Hz, 3J = 7.6 Hz, 4J = 1.8 Hz, 1H), 7.96 (d, 3J = 16.4 Hz, 1H), 8.21 (d, 
3J = 8.5 Hz, 1H), 8.39 (q, 3J = 4.5 Hz, 1H), 8.60 (ddd, 3J = 4.7 Hz, 4J = 1.8 Hz, 5J = 0.9 Hz, 
1H), 13.36 (s, 1H); 13C NMR (75 MHz, DMSO-d6): δ 26.1, 114.7, 120.3, 121.8, 122.5, 122.6, 
123.6, 125.5, 126.2, 127.8, 129.3, 130.0, 130.3, 132.6, 135.6, 136.9, 137.0, 141.9, 142.0, 
149.6, 154.9, 167.9; 15N NMR (30 MHz, DMSO-d6): δ -275.7, -275.2, -196.6, -65.7; LC-MS 
(ESI): m/z 387 [MH]+. 
 
   
 
Molecular structure determined by X-ray crystallography: CCDC 1419084 
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(Z)-axitinib (19a/b), (Z)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-
yl)thio)benzamide (19a) and (Z)-N-methyl-2-((3-(2-(pyridin-2-yl)vinyl)-2H-indazol-6-
yl)thio)benzamide  
JW_02 
C22H18N4OS (Mr 386.47) 
Synthesis and analytical characterization was partially performed by Jantje Weber.89 
(E)-Axitinib (100 mg, 0.26 mmol) was dissolved in DMSO (10 mL) and the solution was 
stirred and irradiated (365 nm, 5.4 W) for 15 min. Subsequently, ethyl acetate (100 mL) was 
added. DMSO was removed by washing the organic phase thoroughly with water. Next, the 
organic layer was dried over Na2SO4, filtered and concentrated. Flash silica gel 
chromatography with a gradient of petroleum ether and ethyl acetate afforded a yellow solid 
(21 mg, 0.05 mmol, 21%). Purity (HPLC) 97%; m.p. 174 °C; LC-MS (ESI): m/z 387 [MH]+. 
1H-tautomer 
 
2H-tautomer 
 
 
Molecular structure determined by X-ray crystallography: CCDC 1419085   
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5.4 BIOLOGICAL EVALUATION 
5.4.1 Kinase Assays (Kd values) 
Caged vemurafenib: BRAF
V600E
 
Binding affinities of 44, 58, 59, and 60 toward BRAFV600E were measured in the KdELECTSM 
assay.143 KINOMEscanTM is a competition binding assay that quantitatively measures the 
ability of a compound to compete with an immobilized active-site directed ligand. Binding 
constants (Kd values) were calculated from duplicate 11-point dose-response curves. The 
highest tested compound concentration was 30 µM. The 3-fold serial dilution of each tested 
inhibitor was prepared in 100% DMSO. The final DMSO concentration in the assay was 1%. 
Analyses were performed by DiscoveRx (San Diego, CA, USA). 
5.4.2 Kinase Assays (IC50 values) 
Caged diarylmaleimides resp. carbazole and photoswitchable axitinib: VEGFR2 
The VEGFR2 IC50 profile for 55, 57, 99, 100, 19, and 19a/b was determined using VEGFR2 
protein kinase by a radiometric 33PanQinase® assay122 and a luminescent ADP-Glo™ assay 
(Promega)144. IC50 values were measured by testing 10 semi-log concentrations of each 
compound in the range from 1 x 10-04 M to 3 x 10-09 M, in singlicate. Prior to testing, the 
compounds were dissolved to 1 x 10-02 M stock solutions in 100% DMSO. The final DMSO 
concentration in the reaction cocktails was 1% in all cases. 
Analyses were performed by ProQinase (Freiburg, Germany). 
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Photoswitchable axitinib: PDGFRβ 
PDGFRβ inhibition curves of 19 and 19a/b were determined by a luminescent PDGFRβ 
kinase assay using an ADP-Glo™ assay kit (Promega).144 The compounds were dissolved in 
100% DMSO and tested in a range of 1 x 10-11 M to 1 x 10-06 M, in duplicate. The reaction 
cocktails were incubated at 20 °C for 60 min. ATP concentration was 10 µM and the final 
DMSO concentration was 1%. 
Analyses were performed by Boris Pinchuk123 and Christian Renn132. 
5.4.3 Kinase Profiling 
Caged vemurafenib 
Compounds 44, 58, and 60 were screened against 140 kinases in the Premier Screen.145 The 
used method was a radioactive filter binding assay using 33P ATP, for details see references 
146,147. The substances were dissolved in DMSO at a tested concentration of 10 µM. The mean 
percentage residual kinase activity and standard deviations of assay duplicates were 
determined. 
Analyses were performed by the International Center for Kinase Profiling at the University of 
Dundee, UK. 
Caged diarylmaleimides resp. carbazole 
Compounds 55 and 57 were screened against 79 kinases. The used method was a radioactive 
filter binding assay using 33P ATP, for details see references 146,147. The substances were 
dissolved in DMSO at tested concentrations of 0.1 µM and 1 µM. The mean percentage 
residual kinase activity and standard deviations of assay duplicates were determined. 
Analyses were performed by the International Center for Kinase Profiling at the University of 
Dundee, UK. 
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Photoswitchable axitinib 
Kinase inhibition profiles of 19 and 19a/b were determined by measuring residual activity 
values in duplicate in 300 wild-type protein kinase assays. A radiometric 33PanQinase® assay 
was used for measuring the kinase activity.122 The substances were dissolved in 100% DMSO. 
The reaction cocktails were incubated at 30 °C for 60 min at a concentration of 1 µM. The 
final DMSO concentration was 1%. 
Analyses were performed by ProQinase (Freiburg, Germany). 
5.4.4 Cell Culture 
Caged vemurafenib: SKMel13 cells 
SKMel13 cells were kindly provided by Dr. Kumara Dissanayake from the MRC Protein 
Phosphorylation Unit, College of Life Sciences, Dundee, UK. Cells were grown in RPMI 
1640 Glutamax with 10% FCS. All cells were incubated in a 5% CO2 humidified atmosphere 
at 37 °C. 
Cell culture was performed by Boris Pinchuk.115 
Caged diarylmaleimides resp. carbazole and photoswitchable axitinib: NIH/3T3 and 
PC-3 cells 
NIH/3T3 cells were kindly provided by Dr. Athena Chalaris-Rissmann from the Biochemistry 
Institute, University of Kiel, Germany. PC-3 cells were purchased from CLS Cell Lines 
Service GmbH, Germany. NIH/3T3 cells were grown in DMEM medium with 2 mM 
L-Glutamine, 1 mM Sodium Pyruvate and 10% FCS. PC-3 cells were grown in DMEM:Hams 
F12 (1:1) medium with 5% FCS. Both cell lines were incubated in a 5% CO2 humidified 
atmosphere at 37 °C. 
Cell culture was performed by Boris Pinchuk123 and Christian Renn132. 
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5.4.5 Proliferative Assays 
Caged vemurafenib, caged diarylmaleimides and carbazole resp. photoswitchable 
axitinib 
The cells were grown in cell flasks until approximately 90% confluence and then seeded to 
give 7000 resp. 15000 cells in 100 μL per well into 96-well CulturePlatesTM (PerkinElmer, 
US). In addition to the test plates, one plate was prepared for reference measurement at day 
zero. All plates were incubated for 24 h at 37 °C in a humidified atmosphere with 5% CO2. 
Compounds 44, 58, 59, 60, 55, 57, 99, 100, 19, and 19a/b were dissolved in 100% DMSO 
(v/v) and added to the test plates. The final DMSO concentration in the assay was 0.5% (v/v). 
Viability of the cells in the day zero control plates were determined on the same day without 
adding any compounds. For viability measurement the resazurin assay was used. The shift in 
the fluorescence signal was measured at the LS55 Fluorescence spectrometer (PerkinElmer, 
Waltham, US). For the photoactivation experiments the test plates were irradiated at 365 nm 
for 5 min (LED source: 8x Nichia NCSU033B, Sahlmann Photochemical Solutions, 50%, 
1.8 W). Test plates were incubated for further 48 h and cell viability was defined as described 
above. Measured raw data was converted into percent of cell growth by using the high control 
(0.5% DMSO (v/v) without compound) and the day zero control. For dose-response studies, 
11 different concentrations of compounds were tested in duplicates. IC50 values were 
calculated using the 4-parameter logistic fit option of GraphPad Prism 5. 
Proliferation assays were performed by Boris Pinchuk115,123 and Christian Renn132. 
5.4.6 Stability in Cellular Medium 
Caged vemurafenib 
A vemurafenib (44) solution (0.01 mM) was prepared in Dulbecco’s Modified Eagle Medium 
(DMEM) with 2 mM L-glutamine, 1 mM sodium pyruvate and 10% DMSO. The probe was 
incubated in a 5% CO2 humidified atmosphere at 37 °C for 48 h. At different time points 
aliquots were taken, diluted with methanol (1:2), and analyzed by HPLC. Proteins were 
removed prior to HPLC analysis by centrifugation at 9500g for 5 min (Mikro 200, Hettich). 
Analyses were performed by Boris Pinchuk.115 
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Photoswitchable axitinib 
A (Z)-axitinib solution (19, 1 mM) was prepared in minimum essential medium (MEM) with 
and without fetal bovine serum (FBS). For that purpose (Z)-axitinib was dissolved in DMSO 
and diluted with MEM. The final DMSO concentration was 0.5%. The solutions were 
incubated at 37 °C for up to 180 h. At different time points aliquots were taken, diluted with 
methanol (1:2) and analyzed by HPLC. In the FBS samples, proteins were removed prior to 
HPLC analysis by centrifugation at 9500g for 5 min (Mikro 200, Hettich). 
Analyses were performed by Christian Renn.132 
5.4.7 Western Blot Analyses 
Caged vemurafenib 
Cells were treated with the indicated concentrations for 1 h at 37 °C. The same experiments 
were repeated with irradiation. 30 min after addition to the cells, the compound solutions of 
44, 58, and 60 were irradiated at 365 nm (1.8 W) for 5 min. Cells were lysed and lysates 
immunoblotted with the indicated antibodies. The lysis buffer contained both phosphatase and 
protease inhibitors. Similar results were obtained in duplicate experiments. 
Primary antibodies 
- p44/42 MAPK (Erk1/2) (137F5) rabbit m-ab (t-Erk) Ref: #4695S Cell signaling 
technology (CST) 
- P-p44/42 MAPK (T202/Y204) (197G2) rabbit m-ab (p-Erk) Ref: #4377S CST 
- P-Akt (T308) (244F9) rabbit mAb Ref: #4056S CST 
- Anti-PKB alpha S742B 1st Bleed (t-Akt), 1 x 0,05 mg; 0,28 mg/mL (courtesy by the 
lab of Prof. Dario Alessi, MRC, Dundee, Scotland) 
Secondary antibodies 
- Anti-rabbit IgG, HRP-linked Antibody Ref: #7074P2 CST 
- Rabbit anti-sheep, HRP-linked Antibody (courtesy by the lab of Prof. Dario Alessi, 
MRC, Dundee, Scotland) 
Western blot analyses were performed by Boris Pinchuk.115 
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Photoswitchable axitinib 
Cells were treated with the indicated concentrations of test compounds 19 and 19a/b for 1 h at 
37 °C. Cells were lysed and lysates immunoblotted with the indicated antibodies. The lysis 
buffer contained both phosphatase and protease inhibitors. Similar results were obtained in 
duplicate experiments. 
Primary antibodies 
- p44/42 MAPK (Erk1/2) (137F5) rabbit mAb (t-Erk), Ref: #4695S, CST 
- P-p44/42 MAPK (T202/Y204) (197G2) rabbit mAb (p-Erk), Ref: #4370P, CST 
- P-Akt (Thr308) (D25E6) XP® Rabbit mAb (p-Akt), Ref: #13038S, CST 
- Anti-PKB alpha S742B 1st Bleed (t-Akt), 1 x 0,05 mg; 0,28 mg/mL (courtesy by the 
lab of Prof. Dario Alessi, MRC, Dundee, Scotland) 
- PDGF Receptor β (28E1) Rabbit mAb (t-PDGFR), Ref #3169P, CST 
- Phospho-PDGF Receptor β (Tyr751) (C63G6) Rabbit mAb (p-PDGFR), Ref #4549P, 
CST 
 
Secondary antibodies 
- Anti-rabbit IgG, HRP-linked Antibody, Ref: #7074P2, CST 
- Rabbit anti-sheep, HRP-linked Antibody, (courtesy by the lab of Prof. Dario Alessi, 
MRC, Dundee, Scotland)  
Western blot analyses were performed by Christian Renn.132 
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7. APPENDIX 
Supplementary Table 1. Kinase profiling of vemurafenib and caged prodrugs 58 and 60. The inhibitory 
effect was tested on a panel of 140 kinases. The residual activity (RA) of kinases was measured after incubation 
with 10 µM of each compound. The data is portrayed as mean percentage activity and standard deviation (SD) of 
assay duplicates. 
# Kinase Name 
vemurafenib 
DMNB-vemurafenib 
(sulfonamide) 
DMNB-vemurafenib 
(azaindole) 
44 60 58 
RA (%) SD RA (%) SD RA (%) SD 
1 MAP4K5 1 0 2 1 7 1 
2 RIPK2 11 9 9 1 26 13 
3 GCK 7 3 6 3 36 21 
4 DDR2 1 0 6 1 45 2 
5 BRK 1 0 2 1 46 4 
6 TrkA 21 7 7 3 51 8 
7 MST2 15 12 16 0 54 14 
8 MLK1 8 8 10 0 68 2 
9 MAP4K3 3 0 20 0 79 4 
10 BRSK2 67 17 73 2 79 5 
11 BTK 14 1 50 1 79 6 
12 DYRK2 57 8 58 12 80 4 
13 Aurora B 5 1 36 8 82 10 
14 CSK 20 15 22 1 82 1 
15 PLK1 74 6 77 10 85 0 
16 MKK2 26 8 67 2 86 5 
17 TTK 57 6 60 5 86 1 
18 MKK1 49 7 71 5 86 8 
19 EIF2AK3 9 1 48 0 87 4 
20 MKK6 74 5 98 16 88 17 
21 CAMK1 20 0 15 2 88 6 
22 MINK1 27 7 61 21 89 1 
23 TSSK1 63 14 53 4 89 4 
24 p38a MAPK 70 27 85 13 90 0 
25 PDGFRA 7 2 34 1 90 3 
26 ROCK 2 49 3 72 6 90 10 
27 AMPK (hum) 77 5 54 9 90 10 
28 DYRK3 53 1 77 2 91 5 
29 JNK3 68 7 83 13 91 1 
30 TESK1 8 1 51 2 91 17 
31 ERK5 70 2 81 16 92 5 
32 MST4 43 4 90 13 92 5 
33 PINK 80 10 96 6 92 3 
34 MARK4 74 10 66 10 93 1 
35 LKB1 82 1 88 17 93 7 
36 IKKe 32 1 57 2 93 3 
37 OSR1 50 0 90 4 94 2 
38 MAPKAP-K3 70 14 73 3 94 2 
39 PDK1 83 14 98 30 94 6 
40 SGK1 73 4 83 0 94 11 
41 JNK2 61 24 85 1 94 15 
42 MARK2 80 1 93 17 95 0 
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43 MAPKAP-K2 86 7 86 6 95 3 
44 PRK2 73 11 75 3 96 2 
45 VEG-FR 7 3 19 5 96 6 
46 HER4 25 2 78 3 96 2 
47 STK33 83 5 93 6 96 7 
48 BRSK1 84 0 78 12 97 8 
49 CK2 104 1 104 7 97 1 
50 MEKK1 73 11 84 1 97 2 
51 SmMLCK 69 15 70 1 97 4 
52 PKBa 96 7 84 5 97 9 
53 WNK1 78 13 85 8 98 7 
54 RSK1 88 0 70 5 98 6 
55 Aurora A 46 9 68 12 98 14 
56 MNK2 39 3 67 7 98 4 
57 PKA 102 1 106 9 98 12 
58 SIK3 30 1 90 8 98 22 
59 PIM3 75 2 55 4 99 4 
60 MARK1 74 5 84 5 99 20 
61 ERK8 15 1 53 4 99 2 
62 MNK1 48 7 50 11 99 7 
63 EPH-B4 72 5 115 18 99 6 
64 YES1 3 0 18 6 99 14 
65 PIM1 65 4 89 1 100 15 
66 PIM2 87 3 89 6 100 11 
67 ASK1 89 17 88 5 100 24 
68 MSK1 61 3 61 0 100 0 
69 IKKb 88 1 83 4 100 13 
70 ERK2 84 8 95 19 101 9 
71 DYRK1A 61 7 84 6 101 4 
72 HIPK3 95 9 100 1 101 1 
73 SIK2 20 2 66 15 101 21 
74 TTBK1 89 6 92 9 101 0 
75 ERK1 103 13 102 19 102 5 
76 NEK2a 22 5 67 2 102 2 
77 ULK2 56 3 87 6 102 15 
78 EPH-A4 93 19 98 13 102 1 
79 PRAK 90 14 80 7 102 10 
80 PAK4 53 16 97 7 103 5 
81 IGF-1R 16 1 68 5 103 6 
82 HIPK1 95 13 101 0 103 13 
83 TLK1 81 0 89 9 103 4 
84 DAPK1 95 11 95 11 104 6 
85 IR 22 5 36 2 104 4 
86 IRR 36 7 60 8 104 12 
87 MLK3 6 1 60 16 104 2 
88 CAMKKb 93 2 101 3 105 2 
89 SRPK1 81 3 91 0 105 5 
90 CK1δ 100 7 95 7 106 13 
91 Src 3 1 45 9 106 8 
92 CHK2 87 6 66 11 106 8 
93 IRAK1 63 2 90 7 107 2 
94 MST3 62 1 87 2 107 2 
95 TBK1 96 3 90 5 107 3 
96 MPSK1 48 9 76 8 107 5 
97 TAK1 25 0 74 4 107 1 
98 TGFBR1 45 2 96 28 107 8 
99 HIPK2 66 4 71 4 107 2 
100 TAO1 45 7 92 10 107 7 
101 ULK1 69 5 98 10 108 5 
102 GSK3b 32 4 41 8 108 3 
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103 p38g MAPK 121 3 104 12 108 6 
104 EF2K 90 10 108 14 108 1 
105 FGF-R1 29 5 72 9 108 4 
106 SYK 43 4 93 0 108 23 
107 MELK 103 1 80 28 108 11 
108 p38d MAPK 99 13 120 36 109 4 
109 PKCa 101 2 98 5 109 12 
110 PHK 90 7 101 3 110 5 
111 NUAK1 30 5 89 5 111 6 
112 CDK9-Cyclin T1 80 8 96 8 111 1 
113 PKBb 99 12 102 6 111 3 
114 S6K1 80 13 83 2 111 13 
115 CK1γ2 109 10 107 14 111 20 
116 JNK1 62 43 77 3 111 8 
117 RSK2 79 3 82 20 111 1 
118 EPH-A2 91 3 101 9 112 10 
119 MARK3 86 7 98 3 112 5 
120 TIE2 77 2 95 11 112 6 
121 EPH-B3 96 8 73 5 112 0 
122 CDK2-Cyclin A 63 3 57 4 113 6 
123 JAK2 32 11 36 2 113 2 
124 PAK2 32 6 101 15 114 11 
125 ABL 35 9 70 5 114 15 
126 NEK6 117 7 97 2 115 11 
127 PKCγ 104 15 94 16 115 6 
128 p38b MAPK 32 1 86 7 117 6 
129 ZAP70 84 6 98 0 118 5 
130 CLK2 22 1 65 13 118 7 
131 TTBK2 108 13 136 30 121 4 
132 Lck 6 0 41 4 123 1 
133 PKD1 70 8 84 5 124 8 
134 PAK6 87 2 117 21 124 5 
135 IRAK4 88 2 125 11 125 3 
136 PAK5 78 3 137 2 130 14 
137 EPH-B2 57 2 102 6 134 2 
138 PKCz 101 1 128 27 139 6 
139 CHK1 123 3 160 18 139 1 
140 EPH-B1 133 9 170 18 177 32 
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Supplementary Table 2. Kinase profiling of diarylmaleimide 55 and carbazole 57. The inhibitory effect of 
the compounds was tested on the panel of 79 kinases in duplicates. The residual activity (RA) of kinases was 
measured after incubation with 0.1 µm resp. 1 µm of each compound. The data is portrayed as mean percentage 
activity and standard deviation (SD) of assay duplicates. 
# Kinase Name 
diarylmaleimide 
55 
carbazole 
57 
0.1 µM 1 µM 0.1 µM 1 µM 
RA (%) SD RA (%) SD RA (%) SD RA (%) SD 
1 MKK1 54 27 44 5 67 5 9 0 
2 ERK1 100 5 88 8 91 25 40 12 
3 ERK2 94 5 86 10 93 0 81 4 
4 JNK1 96 13 92 3 96 5 69 0 
5 JNK2 78 14 46 2 93 16 62 3 
6 p38a MAPK 89 0 87 19 78 12 79 4 
7 P38b MAPK 86 8 85 4 89 17 79 5 
8 p38g MAPK 91 2 81 8 86 7 53 7 
9 p38s MAPK 108 0 103 6 90 17 88 3 
10 ERK8 46 5 10 2 11 1 4 0 
11 RSK1 96 7 50 3 51 6 20 0 
12 RSK2 91 1 54 5 62 6 20 3 
13 PDK1 68 4 38 3 39 1 18 1 
14 PKBa 66 4 81 12 81 16 83 2 
15 PKBb 98 2 91 8 91 9 86 6 
16 SGK1 75 5 51 13 52 15 36 3 
17 S6K1 65 4 22 0 28 1 6 2 
18 PKA 93 13 88 6 90 5 72 4 
19 ROCK 2 97 2 88 3 88 6 55 3 
20 PRK2 84 4 51 3 52 2 22 3 
21 PKCa 113 5 95 3 90 14 90 2 
22 PKC zeta 102 6 97 6 98 2 97 5 
23 PKD1 100 12 64 22 60 9 35 4 
24 MSK1 69 1 44 4 55 10 21 0 
25 MNK1 80 0 72 3 79 4 67 18 
26 MNK2 90 15 78 3 81 1 46 3 
27 MAPKAP-K2 94 2 90 3 95 4 83 0 
28 PRAK 91 7 90 2 85 2 71 1 
29 CAMKKb 81 3 44 5 49 3 15 0 
30 CAMK1 107 1 74 12 94 18 58 3 
31 SmMLCK 60 17 28 2 30 5 10 0 
32 PHK 73 8 41 3 41 6 7 0 
33 CHK1 72 0 36 2 34 3 10 2 
34 CHK2 64 9 54 5 63 2 20 1 
35 GSK3b 21 2 4 1 5 1 2 1 
36 CDK2-Cyclin A 59 5 28 8 28 4 6 1 
37 PLK1 79 9 58 2 49 5 31 4 
38 PLK1 (Okadaic Acid) 85 2 72 2 83 0 47 12 
39 Aurora B 84 12 40 3 47 14 26 6 
40 AMPK 78 8 69 13 75 13 38 4 
41 MARK3 90 5 71 19 73 3 33 6 
42 BRSK2 94 8 61 2 66 2 44 6 
43 MELK 74 13 45 3 55 7 15 0 
44 CK1 86 5 76 4 78 2 59 12 
45 CK2 94 9 101 2 91 10 73 15 
46 DYRK1A 73 2 29 2 26 0 13 3 
47 DYRK2 57 15 18 4 17 0 5 1 
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48 DYRK3 85 6 53 5 46 5 16 3 
49 NEK2a 87 1 97 4 91 6 67 4 
50 NEK6 96 2 97 20 104 9 92 2 
51 IKKb 102 7 104 2 113 25 94 2 
52 PIM1 14 1 3 0 5 1 1 0 
53 PIM2 115 5 102 1 115 12 100 7 
54 PIM3 5 1 2 1 4 2 2 1 
55 SRPK1 85 1 85 16 83 5 67 5 
56 MST2 53 0 19 4 24 2 10 4 
57 EFK2 104 3 102 10 109 15 91 5 
58 HIPK2 23 2 4 1 7 1 3 1 
59 PAK4 75 3 48 3 55 6 29 3 
60 PAK5 105 1 79 3 84 4 49 2 
61 PAK6 97 5 91 7 99 2 70 2 
62 Src 81 0 78 12 86 1 88 5 
63 Lck 91 2 67 16 91 4 60 13 
64 CSK 138 8 102 9 99 1 97 8 
65 FGF-R1 69 9 15 4 92 1 44 1 
66 IRR 58 1 35 2 41 0 19 3 
67 EPH A2 104 6 89 1 109 4 110 26 
68 MST4 94 7 59 1 69 3 42 6 
69 SYK 85 5 87 7 86 16 61 6 
70 YES1 84 14 68 10 88 5 43 9 
71 IKKe 80 3 58 5 63 8 31 1 
72 TBK1 87 1 72 4 85 7 79 3 
73 IGF1-R 90 24 54 1 65 4 23 9 
74 VEG-FR 10 0 3 0 37 2 10 1 
75 BTK 93 14 79 19 90 1 68 4 
76 IR-HIS 101 11 73 3 88 15 30 2 
77 EPH-B3 104 14 131 26 133 4 115 28 
78 TBK1 (DU12569) 88 5 69 1 73 2 39 3 
79 IKK epsilon (14231) 85 7 83 2 94 5 58 8 
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Supplementary Table 3. Kinase profiling of (E)- and (Z)-axitinib. The inhibitory effect of both axitinib 
isomers was tested on the panel of 300 kinases in duplicates. The residual activity of kinases was measured after 
incubation with 1 µM of each compound. 
# 
Kinase 
Name 
Kinase 
Family* 
(E)-axitinib 
19 
Mean 
(Z)-axitinib 
19a/b 
Mean 
1 ABL1 TK 5 5 5 20 19 20 
2 ABL2 TK 6 7 6 12 16 14 
3 ACK1 TK 63 62 63 89 77 83 
4 ACV-R1 TKL 90 94 92 98 90 94 
5 ACV-R1B TKL 71 63 67 73 69 71 
6 ACV-R2A TKL 86 100 93 95 99 97 
7 ACV-R2B TKL 75 76 76 83 72 78 
8 ACV-RL1 TKL 84 77 80 85 91 88 
9 AKT1 AGC 106 102 104 103 104 104 
10 AKT2 AGC 102 89 96 113 106 109 
11 AKT3 AGC 99 97 98 103 94 99 
12 ALK (GST-HIS-tag) TK 84 80 82 95 94 94 
13 AMPK-alpha1 aa1-550 CAMK 71 68 70 83 86 85 
14 ARK5 CAMK 52 48 50 72 65 69 
15 ASK1 STE 81 88 84 98 97 98 
16 Aurora-A OTHER 8 11 10 24 22 23 
17 Aurora-B OTHER 7 8 8 13 11 12 
18 Aurora-C OTHER 7 6 6 9 12 11 
19 AXL TK 54 58 56 63 59 61 
20 BLK TK 65 71 68 90 81 86 
21 BMPR1A TKL 91 81 86 104 89 97 
22 BMX TK 97 100 99 100 101 100 
23 B-RAF TKL 95 101 98 94 108 101 
24 BRK TK 93 97 95 110 116 113 
25 BRSK1 CAMK 87 84 85 95 100 98 
26 BTK TK 89 95 92 103 104 104 
27 CAMK1D CAMK 97 99 98 96 91 93 
28 CAMK2A CAMK 89 86 87 88 81 85 
29 CAMK2B CAMK 91 90 90 79 88 83 
30 CAMK2D CAMK 94 94 94 99 97 98 
31 CAMK4 CAMK 99 126 112 120 106 113 
32 CAMKK1 OTHER 95 93 94 101 102 101 
33 CAMKK2 OTHER 68 73 70 91 89 90 
34 CDC42BPA AGC 90 86 88 92 95 94 
35 CDC42BPB AGC 97 108 102 112 106 109 
36 CDK1/CycA2 CMGC 99 95 97 98 100 99 
37 CDK1/CycB1 CMGC 94 89 91 102 102 102 
38 CDK1/CycE1 CMGC 73 82 78 86 87 87 
39 CDK2/CycA2 CMGC 97 101 99 107 105 106 
40 CDK2/CycE1 CMGC 95 94 95 107 105 106 
41 CDK3/CycE1 CMGC 96 99 98 99 106 103 
42 CDK4/CycD1 CMGC 99 91 95 95 93 94 
43 CDK4/CycD3 CMGC 102 103 103 116 115 116 
44 CDK5/p25NCK CMGC 100 99 99 102 101 102 
45 CDK5/p35NCK CMGC 93 94 94 99 99 99 
46 CDK6/CycD1 CMGC 87 91 89 99 95 97 
47 CDK7/CycH/MAT1 CMGC 107 106 107 104 97 100 
48 CDK8/CycC CMGC 98 101 100 113 107 110 
49 CDK9/CycK CMGC 106 96 101 117 97 107 
50 CDK9/CycT1 CMGC 100 96 98 105 112 109 
51 CHK1 CAMK 94 94 94 110 108 109 
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52 CHK2 CAMK 92 96 94 99 93 96 
53 CK1-alpha1 CK1 99 99 99 104 97 100 
54 CK1-delta CK1 98 95 97 108 104 106 
55 CK1-epsilon CK1 83 85 84 86 80 83 
56 CK1-gamma1 CK1 91 97 94 87 93 90 
57 CK1-gamma2 CK1 92 89 91 98 96 97 
58 CK1-gamma3 CK1 93 91 92 99 93 96 
59 CK2-alpha1 OTHER 99 103 101 102 100 101 
60 CK2-alpha2 OTHER 102 114 108 96 103 100 
61 CLK1 CMGC 91 84 88 100 94 97 
62 CLK2 CMGC 104 92 98 102 100 101 
63 CLK3 CMGC 87 97 92 93 93 93 
64 CLK4 CMGC 96 81 88 96 86 91 
65 COT STE 104 102 103 101 133 117 
66 CSF1-R TK 51 46 49 60 59 60 
67 CSK TK 92 88 90 104 101 103 
68 DAPK1 CAMK 90 85 87 85 81 83 
69 DAPK2 CAMK 94 92 93 103 87 95 
70 DAPK3 CAMK 96 91 94 94 95 94 
71 DCAMKL2 CAMK 90 90 90 91 93 92 
72 DDR2 TK 67 64 66 85 79 82 
73 DMPK AGC 88 94 91 103 97 100 
74 DANN-PK ATYP 99 97 98 99 95 97 
75 DYRK1A CMGC 105 96 101 100 97 98 
76 DYRK1B CMGC 100 112 106 103 113 108 
77 DYRK2 CMGC 90 93 91 98 95 97 
78 DYRK3 CMGC 82 81 81 86 80 83 
79 DYRK4 CMGC 102 101 102 98 100 99 
80 EEF2K ATYPICAL 104 104 104 111 111 111 
81 EGF-R TK 101 96 98 109 99 104 
82 EIF2AK2 OTHER 113 106 110 109 107 108 
83 EIF2AK3 OTHER 87 99 93 99 98 99 
84 EPHA1 TK 88 103 95 104 110 107 
85 EPHA2 TK 103 104 104 107 107 107 
86 EPHA3 TK 96 93 95 92 100 96 
87 EPHA4 TK 93 91 92 101 104 102 
88 EPHA5 TK 87 91 89 116 94 105 
89 EPHA7 TK 101 86 94 105 106 105 
90 EPHA8 TK 94 100 97 111 104 107 
91 EPHB1 TK 94 93 94 107 103 105 
92 EPHB2 TK 50 48 49 70 67 69 
93 EPHB3 TK 100 95 98 107 105 106 
94 EPHB4 TK 104 111 108 113 112 112 
95 ERBB2 TK 93 95 94 116 112 114 
96 ERBB4 TK 109 103 106 104 98 101 
97 ERK1 CMGC 103 103 103 105 97 101 
98 ERK2 CMGC 102 97 99 103 94 98 
99 ERK7 CMGC 90 84 87 87 81 84 
100 FAK aa2-1052 TK 111 97 104 111 97 104 
101 FER TK 93 88 90 104 100 102 
102 FES TK 84 88 86 98 95 97 
103 FGF-R1 TK 3 3 3 6 4 5 
104 FGF-R2 TK 6 5 6 9 10 9 
105 FGF-R3 TK 45 34 39 65 49 57 
106 FGF-R4 TK 85 89 87 96 96 96 
107 FGR TK 16 17 16 25 27 26 
108 FLT3 TK 93 96 94 93 98 95 
109 FRK TK 95 91 93 106 91 99 
110 FYN TK 58 55 56 102 85 94 
111 GRK2 AGC 95 88 92 92 91 91 
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112 GRK3 AGC 90 86 88 89 77 83 
113 GRK4 AGC 84 76 80 83 74 78 
114 GRK5 AGC 91 87 89 85 92 88 
115 GRK6 AGC 80 80 80 83 87 85 
116 GRK7 AGC 89 91 90 95 93 94 
117 GSG2 OTHER 95 95 95 106 102 104 
118 GSK3-alpha CMGC 96 89 92 92 89 90 
119 GSK3-beta CMGC 93 94 93 101 107 104 
120 HCK TK 91 94 92 98 107 103 
121 HIPK1 CMGC 103 105 104 101 103 102 
122 HIPK2 CMGC 102 98 100 111 102 106 
123 HIPK3 CMGC 109 97 103 103 105 104 
124 HIPK4 CMGC 90 91 90 90 90 90 
125 HRI OTHER 93 104 98 86 104 95 
126 IGF1-R TK 113 101 107 109 97 103 
127 IKK-alpha OTHER 84 93 88 92 93 93 
128 IKK-beta OTHER 101 106 104 110 105 107 
129 IKK-epsilon OTHER 87 85 86 100 95 97 
130 INS-R TK 100 89 94 96 109 102 
131 INSR-R TK 98 98 98 100 105 103 
132 IRAK1 TKL 77 77 77 86 83 84 
133 IRAK4 (untagged) TKL 86 95 91 89 102 95 
134 ITK TK 85 79 82 93 97 95 
135 JAK1 TK 96 92 94 89 96 93 
136 JAK2 TK 70 73 71 90 92 91 
137 JAK3 TK 79 81 80 85 97 91 
138 JNK1 CMGC 91 84 88 84 95 89 
139 JNK2 CMGC 90 97 94 102 105 104 
140 JNK3 CMGC 85 91 88 105 112 108 
141 KIT TK 6 6 6 9 8 9 
142 LCK TK 68 67 67 70 69 70 
143 LIMK1 TKL 95 92 94 104 104 104 
144 LIMK2 TKL 114 87 100 101 90 96 
145 LRRK2 TKL 26 28 27 32 34 33 
146 LTK TK 97 96 97 99 101 100 
147 LYN TK 62 54 58 80 78 79 
148 MAP3K1 STE 106 106 106 110 109 109 
149 MAP3K10 STE 80 82 81 92 92 92 
150 MAP3K11 STE 33 35 34 53 59 56 
151 MAP3K7/MAP3K7IP1 STE 81 84 82 94 87 90 
152 MAP3K9 STE 69 62 65 85 77 81 
153 MAP4K2 STE 21 21 21 62 57 59 
154 MAP4K4 STE 7 6 6 9 12 10 
155 MAP4K5 STE 18 18 18 35 32 34 
156 MAPKAPK2 CAMK 79 72 76 69 74 71 
157 MAPKAPK3 CAMK 98 101 100 101 100 100 
158 MAPKAPK5 CAMK 89 82 85 83 81 82 
159 MARK1 CAMK 87 95 91 98 91 94 
160 MARK2 CAMK 94 76 85 94 90 92 
161 MARK3 CAMK 90 88 89 96 89 93 
162 MARK4 CAMK 103 99 101 108 106 107 
163 MATK TK 107 118 113 116 122 119 
164 MEK1 STE 66 65 66 77 74 76 
165 MEK2 STE 104 94 99 98 98 98 
166 MEKK2 STE 85 82 83 86 89 87 
167 MEKK3 STE 87 77 82 89 81 85 
168 MELK CAMK 91 89 90 94 102 98 
169 MERTK TK 48 48 48 78 66 72 
170 MET TK 77 76 76 85 90 87 
171 MINK1 STE 7 7 7 13 13 13 
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172 MKK6 S207D/T211D** STE 97 106 102 99 115 107 
173 MKNK1 CAMK 98 90 94 100 107 103 
174 MKNK2 CAMK 91 90 90 93 90 91 
175 MST1 STE 61 59 60 68 73 71 
176 MST2 STE 53 57 55 93 73 83 
177 MST3 STE 100 102 101 102 101 102 
178 MST4 STE 89 92 91 90 103 96 
179 mTOR ATYPICAL 92 92 92 97 103 100 
180 MUSK TK 24 13 18 60 49 55 
181 MYLK CAMK 93 86 89 92 88 90 
182 MYLK2 CAMK 92 102 97 105 103 104 
183 MYLK3 CAMK 87 85 86 90 102 96 
184 NEK1 OTHER 100 103 101 105 107 106 
185 NEK11 OTHER 89 90 89 101 98 100 
186 NEK2 OTHER 100 90 95 98 110 104 
187 NEK3 OTHER 99 95 97 87 96 92 
188 NEK4 OTHER 100 93 96 103 100 102 
189 NEK6 OTHER 107 97 102 111 111 111 
190 NEK7 OTHER 90 83 86 88 85 86 
191 NEK9 OTHER 89 94 91 97 95 96 
192 NIK STE 112 90 101 110 103 106 
193 NLK CMGC 95 109 102 102 118 110 
194 p38-alpha CMGC 98 92 95 99 100 99 
195 p38-beta CMGC 98 97 98 95 106 100 
196 p38-delta CMGC 91 99 95 84 86 85 
197 p38-gamma CMGC 99 94 97 96 97 96 
198 PAK1 STE 92 92 92 90 90 90 
199 PAK2 STE 93 87 90 94 88 91 
200 PAK3 STE 95 100 97 100 95 98 
201 PAK4 STE 73 82 77 85 84 84 
202 PAK6 STE 74 70 72 88 88 88 
203 PAK7 STE 81 76 78 82 83 82 
204 PASK CAMK 101 101 101 106 99 102 
205 PBK OTHER 115 110 112 126 103 115 
206 PCTAIRE1/CycY CMGC 94 98 96 101 102 101 
207 PDGFR-alpha TK -5 -3 -4 3 0 2 
208 PDGFR-beta TK 1 1 1 4 5 4 
209 PDK1 AGC 75 74 74 83 74 79 
210 PHKG1 CAMK 113 104 109 113 118 116 
211 PHKG2 CAMK 95 100 97 102 103 102 
212 PIM1 CAMK 101 93 97 99 104 101 
213 PIM2 CAMK 91 90 90 77 75 76 
214 PIM3 CAMK 98 93 95 101 103 102 
215 PKA AGC 89 103 96 105 103 104 
216 PKC-alpha AGC 102 101 101 96 90 93 
217 PKC-beta1 AGC 94 88 91 100 95 98 
218 PKC-beta2 AGC 99 98 99 102 97 100 
219 PKC-delta AGC 104 113 109 108 109 108 
220 PKC-epsilon AGC 96 94 95 105 107 106 
221 PKC-eta AGC 95 94 95 95 106 101 
222 PKC-gamma AGC 102 105 103 105 93 99 
223 PKC-iota AGC 87 98 93 101 101 101 
224 PKC-mu AGC 92 95 93 95 96 96 
225 PKC-nu AGC 94 93 93 91 92 91 
226 PKC-theta AGC 99 94 97 86 92 89 
227 PKC-zeta AGC 100 104 102 105 99 102 
228 PLK1 OTHER 94 95 94 92 88 90 
229 PLK3 OTHER 115 113 114 114 110 112 
230 PRK1 AGC 99 92 96 103 105 104 
231 PRK2 AGC 77 78 77 86 86 86 
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232 PRKD2 CAMK 94 96 95 89 104 97 
233 PRKG1 AGC 101 107 104 104 105 105 
234 PRKG2 AGC 99 85 92 95 85 90 
235 PRKX AGC 77 74 75 68 71 69 
236 PYK2 TK 82 83 83 91 98 94 
237 
RAF1 Y340D/Y341D 
(untagged)** 
TKL 103 104 104 105 109 107 
238 RET TK 16 17 17 49 44 47 
239 RIPK2 TKL 75 68 71 76 79 78 
240 RIPK5 TKL 102 102 102 108 110 109 
241 ROCK1 AGC 83 93 88 88 91 89 
242 ROCK2 AGC 83 80 82 92 90 91 
243 RON TK 89 94 91 95 97 96 
244 ROS TK 32 32 32 45 45 45 
245 RPS6KA1 AGC 94 84 89 104 82 93 
246 RPS6KA2 AGC 80 79 79 84 90 87 
247 RPS6KA3 AGC 68 70 69 90 87 88 
248 RPS6KA4 AGC 98 94 96 103 109 106 
249 RPS6KA5 AGC 91 101 96 97 104 100 
250 RPS6KA6 AGC 74 68 71 85 89 87 
251 S6K AGC 87 108 97 99 91 95 
252 S6K-beta AGC 95 100 98 99 106 103 
253 SAK OTHER 3 6 4 7 4 5 
254 SGK1 AGC 83 79 81 93 85 89 
255 SGK2 AGC 96 93 95 99 103 101 
256 SGK3 AGC 96 99 98 100 97 99 
257 SLK STE 36 32 34 65 61 63 
258 SNARK CAMK 23 23 23 36 33 35 
259 SNF1LK2 CAMK 98 93 96 107 102 105 
260 SNK OTHER 98 93 96 99 100 99 
261 SRC (GST-HIS-tag) TK 90 91 91 94 94 94 
262 SRMS TK 99 89 94 97 99 98 
263 SRPK1 CMGC 103 94 98 100 107 103 
264 SRPK2 CMGC 109 94 102 107 102 104 
265 STK17A CAMK 22 26 24 36 35 35 
266 STK23 CAMK 90 82 86 91 88 89 
267 STK25 STE 99 94 97 91 92 91 
268 STK33 CAMK 91 86 89 93 94 93 
269 STK39 STE 90 93 91 88 99 93 
270 SYK aa1-635 TK 98 91 95 104 96 100 
271 TAOK2 STE 77 72 74 86 84 85 
272 TAOK3 STE 91 92 92 106 98 102 
273 TBK1 OTHER 74 77 75 82 71 76 
274 TEC TK 109 106 108 109 104 106 
275 TGFB-R1 TKL 93 100 96 110 101 105 
276 TGFB-R2 TKL 78 80 79 87 83 85 
277 TIE2 TK 39 38 39 60 55 57 
278 TLK1 AGC 93 99 96 90 87 89 
279 TLK2 AGC 98 92 95 99 99 99 
280 TRK-A TK 22 20 21 34 32 33 
281 TRK-B TK 49 45 47 51 51 51 
282 TRK-C TK 32 30 31 44 42 43 
283 TSF1 OTHER 50 50 50 63 65 64 
284 TSK2 CAMK 95 99 97 108 100 104 
285 TSSK1 CAMK 81 74 78 86 93 90 
286 TTK OTHER 98 100 99 101 98 100 
287 TXK TK 94 87 90 93 101 97 
288 TYK2 TK 64 69 66 76 91 84 
289 TYRO3 TK 96 93 95 88 107 97 
290 VEGF-R1 TK 3 4 4 8 7 8 
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291 VEGF-R2 TK 0 1 0 1 1 1 
292 VEGF-R3 TK 13 16 14 19 17 18 
293 VRK1 CK1 103 103 103 114 105 110 
294 WEE1 OTHER 88 97 93 102 106 104 
295 WNK1 OTHER 94 102 98 91 98 94 
296 WNK2 OTHER 95 93 94 95 91 93 
297 WNK3 OTHER 96 109 102 105 96 100 
298 YES TK 59 61 60 78 72 75 
299 ZAK TKL 61 56 58 69 72 71 
300 ZAP70 TK 104 101 102 109 104 106 
Selectivity Score (< 50 % residual activity):   0.117   0.083 
 
 
*Classification of protein kinase families
148
: 
AGC: containing PKA, PKG and PKC families 
CAMK: Calcium/Calmoduline-dependent protein kinases 
CK1: Casein kinase 1 –like 
CMGC: containing CDK, MAPK ,GSK3 and CLK families 
TK: Tyrosine Kinase 
TKL: Tyrosine Kinase-like 
STE: Homologs of Yeast Sterile 7, Sterile 11, Sterile 20 Kinases 
** Constitutively active kinase 
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TABLE OF ABBREVIATIONS 
°C degrees Celsius 
µ micro 
2D / 3D two-dimensional / three-dimensional 
8-MOP 8-methoxypsoralen 
ALL acute lymphoblastic leukemia 
A-loop activation loop 
ATP adenosine triphosphate 
b (NMR) broad 
BOC tert-butyloxycarbonyl 
Bu butyl 
C, Cys cysteine (amino acid one-letter code) 
cat. catalytic 
CCDC Cambridge Crystallographic Data Centre 
CLL chronic lymphocytic leukemia 
C-lobe C-terminal lobe 
CML chronic myeloid leukemia 
CO2 carbon dioxide 
COSY (NMR) correlation spectroscopy 
CRC colorectal cancer 
CST Cell signaling technology 
d (NMR) doublet 
DCM dichloromethane 
DDR2 discoidin domain-containing receptor 2 
DFG, Asp-Phe-Gly aspartic acid, phenylalanine, glycine (amino acid one-letter code) 
DMEM Dulbecco’s modiﬁed Eagle’s medium 
DMF dimethylformamide 
DMNB 4,5-dimethoxy-2-nitrobenzyl 
DMNPE 1-(4,5-dimethoxy-2-nitrophenyl)ethyl 
DMSO dimethyl sulfoxide 
E, Glu glutamic acid (amino acid one-letter code) 
e.g. exemplī grātiā (lat. for example) 
EMA European Medicine Agency 
Erk extracellular signal-regulated kinase 
ESI electrospray ionization 
Et ethyl 
FBS fetal bovine serum 
FDA Food and Drug Administration 
FL follicular lymphoma 
g gram 
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g gravitational force 
GF growth factor 
GI50 50% growth inhibition 
GIST gastrointestinal stromal tumor 
h hour(s) 
HCC hepatocellular cancer 
HMBC (NMR) heteronuclear multiple-bond correlation spectroscopy 
HP I/II hydrophobic pocket I/II 
HPLC high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HSQC (NMR) heteronuclear single-quantum correlation spectroscopy 
Hz hertz 
IC50 half maximal inhibitory concentration 
INN international nonproprietary name 
J (NMR) coupling constant 
K Kelvin 
L liter 
LC50 50% lethal concentration 
LC-MS liquid chromatography–mass spectrometry 
LED light-emitting diode 
LG leaving group 
m meter 
m milli 
M molar 
m (NMR) unresolved multiplet 
m.p. melting point 
m/z mass-to-charge ratio 
MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 
MAPK mitogen-activated protein kinase 
MCL mantle cell lymphoma 
MEK mitogen-activated protein kinase kinase 
MEM minimum essential medium 
MeOH methanol 
MHz megahertz 
min minute(s) 
mol mole 
Mr relative molecular mass 
MS mass spectrometry 
n nano 
n/a not applicable 
NB o-nitrobenzyl 
N-lobe N-terminal lobe 
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nm nanometer 
NMR nuclear magnetic resonance spectroscopy 
NSCLC non-small cell lung cancer 
NVOC 6-nitroveratryloxycarbonyl 
NVOM 6-nitroveratryloxymethyl  
PBS phosphate-buffered saline 
pdb protein data bank (RCSB) 
PDGFR platelet-derived growth factor receptor 
p-Erk phosphorylated Erk 
pHP 4-hydroxy-phenacyl 
PPG photoremovable protection group 
ppm parts per million 
prep. preparation 
psi pounds per square inch 
PUVA psoralen plus UV-A 
RA residual activity 
RCC renal cell carcinoma 
RCT receptor tyrosine kinase 
resp. respectively 
RIPK2 receptor-interacting serine/threonine-protein kinase 2 
RP reversed phase 
rt room temperature 
s second(s) 
s (NMR) singlet 
SD standard deviation 
SLL small lymphocytic leukemia 
smKI small-molecule kinase inhibitor 
SN nucleophilic substitution 
t (NMR) triplet 
t-Erk total Erk 
TGI  total growth inhibition 
THF tetrahydrofuran 
TKI tyrosine kinase inhibitor 
TLC thin-layer chromatography 
UV ultraviolet 
V volt 
v/v volume fraction 
VEGFR vascular endothelian growth factor receptor 
VHL Von Hippel-Lindau 
vis visible 
vs. versus 
W watt 
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TABLE OF COMPOUNDS 
# Code Formula Nomenclature Pages Prep. 
19 JW_01 
 
(E)-axitinib, 
 
 (E)-N-methyl-2-((3-(2-(pyridin-2-
yl)vinyl)-1H-indazol-6-yl)thio)-
benzamide, 
 
INN: axitinib 
6, 13, 
28, 82 
138 
19a/b JW_02 
 
(Z)-axitinib, mixture of 
 
1H-tautomer (a), 
(Z)-N-methyl-2-((3-(2-(pyridin-2-
yl)vinyl)-1H-indazol-6-yl)thio)-
benzamide 
 
and 
 
2H-tautomer (b), 
(Z)-N-Methyl-2-((3-(2-(pyridin-2-
yl)vinyl)-2H-indazol-6-yl)thio)-
benzamide 
82 139 
44 RH_007 
 
N-(3-(5-(4-chlorophenyl)-1H-
pyrrolo[2,3-b]pyridine-3-carbonyl)-
2,4-difluorophenyl)propane-1-
sulfonamide,  
 
INN: vemurafenib 
13, 31, 
46 
119 
55 RH_003 
 
3-(1H-indol-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrrole-2,5-
dione 
27, 67, 
68, 69, 
74 
128 
56 n/a 
 
(7aR,7bR)-5,6,7-trimethoxy-7b,8-
dihydrobenzo[a]pyrrolo[3,4-
c]carbazole-1,3(2H,7aH)-dione 
27, 69 n/a 
57 RH_004 
 
5,6,7-
trimethoxybenzo[a]pyrrolo[3,4-
c]carbazole-1,3(2H,8H)-dione 
27, 74 129 
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58 RH_015 
 
N-(3-(5-(4-chlorophenyl)-1-(4,5-
dimethoxy-2-nitrobenzyl)-1H-
pyrrolo[2,3-b]pyridine-3-carbonyl)-
2,4-difluorophenyl)propane-1-
sulfonamide
 
37, 46, 
55 
120 
59 RH_032 
 
N-(3-(5-(4-chlorophenyl)-1-(1-(4,5-
dimethoxy-2-nitrophenyl)ethyl)-1H-
pyrrolo[2,3-b]pyridine-3-carbonyl)-
2,4-difluorophenyl)propane-1-
sulfonamide 
37, 46, 
55 
122 
60 RH_015* 
 
N-(3-(5-(4-chlorophenyl)-1H-
pyrrolo[2,3-b]pyridine-3-carbonyl)-
2,4-difluorophenyl)-N-(4,5-
dimethoxy-2-nitrobenzyl)propane-
1-sulfonamide 
37, 46, 
55 
124 
67 RH_038 
 
phenyl-(1H-pyrrolo[2,3-b]pyridin-3-
yl)-methanone 
40, 48, 
49 
103 
69 RH_035 
 
1-(4,5-dimethoxy-2-nitrobenzyl)-
1H-pyrrolo[2,3-b]pyridine 
40, 48, 
49 
104 
70 RH_036 
 
1-(1-(4,5-dimethoxy-2-nitrobenzyl)-
1H-pyrrolo[2,3-b]pyridin-3-yl)-
ethanone 
40, 48, 
49 
105 
71 RH_037 
 
(1-(4,5-dimethoxy-2-nitrobenzyl)-
1H-pyrrolo[2,3-b]pyridin-3-
yl)(phenyl)-methanone
 
40, 48, 
49 
106 
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73 RH_021 
 
1-(4,5-dimethoxy-2-nitrophenyl)-
ethanone 42 107 
74 RH_022 
 
1-(4,5-dimethoxy-2-nitrophenyl)-
ethanol 42 108 
75 RH_029 
 
1-(1-bromoethyl)-4,5-dimethoxy-2-
nitrobenzene 42 109 
76 RH_044 
 
(1-(1-(4,5-dimethoxy-2-
nitrophenyl)-ethyl)-1H-pyrrolo[2,3-
b]pyridin-3-yl)-(phenyl)methanone 
42, 51 110 
77 RH_023 
 
(1-(4,5-dimethoxy-2-nitrophenyl)-
ethoxy)methyl)(methyl)-sulfane 42 111 
78 RH_024 
 
1-(1-(chloromethoxy)ethyl)-4,5-
dimethoxy-2-nitrobenzene 42 112 
79 RH_043 
 
(1-((1-(4,5-dimethoxy-2-
nitrophenyl)-ethoxy)methyl)-1H-
pyrrolo[2,3-b]pyridin-3-
yl)(phenyl)methanone
 
42, 51 113 
82 RH_039 
 
2-(3-benzoyl-1H-pyrrolo[2,3-
b]pyridin-1-yl)-1-(4-
hydroxyphenyl)ethanone 
44, 52 114 
83 RH_040 
 
2-(3-benzoyl-1H-pyrrolo[2,3-
b]pyridin-1-yl)-1-(4-
(dimethylamino)phenyl)-ethanone 
44, 51 115 
  
 
Table of Compounds 
176 Table of Compounds 
84 RH_042 
 
4-((3-benzoyl-1H-pyrrolo[2,3-
b]pyridin-1-yl)methyl)-7-methoxy-
2H-chromen-2-one 
44, 51 116 
85 RH_041 
 
4-((3-benzoyl-1H-pyrrolo[2,3-
b]pyridin-1-yl)methyl)-6,7-
dimethoxy-2H-chromen-2-one 
44, 51 117 
86 RH_046 
 
2-(3-benzoyl-1H-pyrrolo[2,3-
b]pyridin-1-yl)-1,2-
diphenylethanone 
44, 51 118 
87 RH_016 
 
N-(3-(5-(4-chlorophenyl)-1-(4,5-
dimethoxy-2-nitrobenzyl)-1H-
pyrrolo[2,3-b]pyridine-3-carbonyl)-
2,4-difluorophenyl)-N-(4,5-
dimethoxy-2-nitrobenzyl)propane-
1-sulfonamide 
46 125 
93 n/a 
 
n/a 
 
LG = leaving group 
56 n/a 
95 n/a 
 
1-(4,5-dimethoxy-2-
nitrosophenyl)ethanone 56 n/a 
96 n/a 
 
(S)-2-((tert-butoxycarbonyl)-
amino)propanoic acid 61 n/a 
97 n/a 
 
(S)-4,5-dimethoxy-2-nitrobenzyl 2-
((tert-butoxycarbonyl)amino)-
propanoate 
61 n/a 
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98 RH_005 
 
3-(1H-indol-3-yl)-1-(2-nitrobenzyl)-
4-(3,4,5-trimethoxyphenyl)-1H-
pyrrole-2,5-dione 
65, 68, 
71 
130 
99 RH_013 
 
1-(4,5-dimethoxy-2-nitrobenzyl)-3-
(1H-indol-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrrole-2,5-
dione 
65, 69, 
71, 74 
131 
100 RH_049 
 
2-(4,5-dimethoxy-2-nitrobenzyl)-
5,6,7-
trimethoxybenzo[a]pyrrolo[3,4-c]-
carbazole-1,3(2H,8H)-dione 
65, 69, 
71, 74 
132 
102 RH_001 
 
2-(3,4,5-
trimethoxyphenyl)acetamide 67 133 
104 RH_002 
 
ethyl 2-(1H-indol-3-yl)-2-
oxoacetate 67 134 
105 RH_006 
 
1-(2-nitrobenzyl)-3-(1-(2-
nitrobenzyl)-1H-indol-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrrole-2,5-
dione 
68 135 
106 RH_014 
 
1-(4,5-dimethoxy-2-nitrobenzyl)-3-
(1-(4,5-dimethoxy-2-nitrobenzyl)-
1H-indol-3-yl)-4-(3,4,5-
trimethoxyphenyl)-1H-pyrrole-2,5-
dione 
69 136 
  
 
Lebenslauf 
Lebenslauf 178 
LEBENSLAUF 
Persönliche Daten 
Name Rebecca Marisa Horbert 
Geburtsdatum 18. August 1986 
Geburtsort Simmern/Hunsrück 
Staatsangehörigkeit deutsch 
Schulausbildung und Studium 
1993 - 1997 Grundschule Kirchberg/Hunsrück 
1997 - 2005  Herzog-Johann-Gymnasium Simmern/Hunsrück 
03/2005 Abitur 
10/2006 - 09/2010 Studium der Pharmazie an der MLU Halle-Wittenberg 
Weitere Ausbildung und beruflicher Werdegang 
11/2010 - 04/2011 Pharmaziepraktikantin bei Beiersdorf in Hamburg 
05/2011 - 10/2011 Pharmaziepraktikantin in der Hirsch-Apotheke in Kiel 
11/2011 Approbation als Apothekerin 
Seit 01/2012 Wissenschaftliche Mitarbeiterin und Doktorandin am 
Pharmazeutischen Institut der Universität zu Kiel 
Seit 02/2012 Weiterbildung zur Fachapothekerin für pharmazeutische Analytik 
 
  
  
 
Fehler! Verwenden Sie die Registerkarte 'Start', um  dem Text zuzuweisen, der hier angezeigt 
werden soll. 
179 Erklärung 
ERKLÄRUNG  
Die vorliegende Arbeit wurde unter Anleitung von Herrn Prof. Dr. Christian Peifer an der 
Christian-Albrechts-Universität zu Kiel, Pharmazeutisches Institut, Abteilung 
Pharmazeutische Chemie, im Zeitraum von Januar 2012 bis Oktober 2015 angefertigt. 
Der Inhalt wurde, abgesehen von der Beratung durch meinen Betreuer, selbstständig von mir 
erarbeitet und in dieser Form zusammengestellt. Die Arbeit hat an keiner Stelle im Rahmen 
eines anderen Prüfungsverfahrens vorgelegen und ist unter Einhaltung der Regeln guter 
wissenschaftlicher Praxis entstanden. 
 
Kiel, Oktober 2015 
Rebecca Horbert  
  
 
Erklärung 
Erklärung 180 
 
Teile dieser Arbeit wurden bereits an folgenden Stellen veröffentlicht: 
 
Fachzeitschriften 
1.  R. Horbert, B. Pinchuk, P. Davies, D. Alessi, C. Peifer: 
Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib, 
ACS Chemical Biology, 2015, 10 (9), pp 2099–2107. 
Posterbeiträge 
1.  J. Weber, R. Horbert, C. Peifer: 
Photoschaltbare Kinaseinhibitoren, 
Life Science Studierendentagung, 2014, Kiel, Deutschland. 
 
2.  R. Horbert, B. Pinchuk, P. Davies, D. Alessi, C. Peifer: 
Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib, 
Drug Discovery Chemistry, 2015, San Diego (CA), USA. 
 
2.  B. Pinchuk, R. Horbert, P. Davies, D. Alessi, C. Peifer: 
Photoactivatable Prodrugs of Approved Kinase Inhibitor Vemurafenib, 
250th ACS National Meeting, 2015, Boston (MA), USA. 
 
 
  
  
181 Danksagung 
DANKSAGUNG 
An erster Stelle möchte ich meinem Doktorvater, Herrn Prof. Dr. Christian Peifer, für seine 
engagierte und motivierende Unterstützung sowie fortwährende Förderung besonders herzlich 
danken. Die Aufnahme in seinen sich über die Zeit stets wandelnden und weiter 
entwickelnden Arbeitskreis ermöglichte mir die Mitwirkung an vielseitigen und spannenden 
Projekten und Fragestellungen. Ich danke ihm für das entgegengebrachte Vertrauen und seine 
stete Bereitschaft zur wissenschaftlichen Diskussion. 
Ein besonderer Dank gilt Boris Pinchuk für die fruchtbare Zusammenarbeit in diversen 
Projekten und das reibungslose Abstimmen von Arbeitsabläufen. Herzlich danke ich Jantje 
Weber, die mit ihrer Bachelorarbeit einen wesentlichen Beitrag im Axitinib-Projekt geleistet 
hat. Ein großes Dankeschön geht an Dr. Melanie Zindler und Alexander Döbber, mit denen 
sich weitere Schnittpunkte in den Photoprojekten ergeben haben. 
Herzlicher Dank geht an Eugen Johannes, der meine Zeit am Institut von Anfang an begleitet 
hat und mir mit zahlreichen Hilfestellungen und Ratschlägen zur Seite stand. Ich danke Jakob 
Halekotte für seinen unerschütterlichen Humor und seine wunderbare Art. Eine fabelhaftere 
Bürogemeinschaft als mit euch beiden hätte ich mir nicht vorstellen können. 
Miriam Schehr danke ich für die eine oder andere auswärtige Messung. Bei Lydia Kuhl und 
Dorian Schmidt möchte ich mich für den chemischen Input bedanken. Ich danke meinem 
ganzen Arbeitskreis für die angenehme und produktive Zusammenarbeit, das fröhliche 
Miteinander und den humorvollen Umgangston. Danke, dass durch euch Kaffee und Kuchen 
solch eine Bedeutung erzielen konnten. Vielen Dank an alle für das gründliche 
Korrekturlesen. 
Martin Schütt danke ich für seine stete und kompetente Hilfsbereitschaft. Bei Dr. Ulrich 
Girreser möchte ich mich für die Beratung in zahlreichen analytischen Fragestellungen 
bedanken. Sven Wichmann gilt besonderer Dank für die zahlreichen und schnellen 
Rettungsaktionen bei HPLC-Problemen. Karl Willi Bock war unverzichtbar für den 
reibungslosen Betrieb diverser Geräte, ob im Praktikum oder Forschungslabor - ein großes 
Dankeschön für all die unverzüglichen Reparaturen. Dr. Dieter Schollmeyer danke ich für die 
Kristallstrukturanalysen. 
  
  
182 Danksagung 
Für die stets unkomplizierte und heitere Atmosphäre bei der Betreuung des 2. Semesters 
danke ich André Golldack, Eugen Johannes, Christopher Meier, Janis Rambow und Tamara 
Steinhauer. Ohne euch wäre die Zeit im Praktikum, bei der Aufsicht und beim Korrigieren nur 
halb so lustig gewesen. 
Großer Dank gilt Carmen Krischkowski, die mir eine gute Freundin ist und mit der ich tolle 
Erinnerungen verbinde. Danke Birte Plitzko, für deine direkte Art und die Einführung in den 
Klettersport. Ich danke Julia Gudd, auf die man jederzeit zählen kann, für ihr tolles 
Engagement in jeder Hinsicht. Für die großartige Atmosphäre am Institut, sowie zahlreiche 
Ausflüge zum Strand, sonnige Stunden auf dem Mensarasen, gemeinsame Urlaube und so 
manche Feierlichkeit danke ich darüber hinaus: Björn Cohrs, Swetlana Gabel, Franziska 
Gersonde, Lena Knudsen, Jennifer Schneider, Laura Schwarz sowie zahlreichen bereits 
genannten Personen. Danke euch allen von ganzem Herzen für die unvergessliche Zeit. 
Mein allergrößter Dank gilt meinen tollen Eltern und meiner unersetzlichen Schwester, die in 
jeder Lebenslage für mich da sind und auf die immer Verlass ist. Danke für eure 
uneingeschränkte Liebe und Unterstützung, ohne die ich nie so weit gekommen wäre.  
 
 
 
 
 
